**Australian Government**

**Department of Health and Aged Care**

**Medicare Benefits Schedule Book**

**Category 6**

**Operating from 1 July 2024**

Title: Medicare Benefits Schedule Book

**Copyright**

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care.

This work is copyright. You may copy, print, download, display and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation:

      (a) do not use the copy or reproduction for any commercial purpose; and

      (b) retain this copyright notice and all disclaimer notices as part of that copy or reproduction.

Apart from rights as permitted by the *Copyright Act 1968* (Cth) or allowed by this copyright notice*,* all other rights are reserved, including (but not limited to) all commercial rights.

Requests and inquiries concerning reproduction and other rights to use are to be sent to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to [corporatecomms@health.gov.au](mailto:corporatecomms@health.gov.au)

|  |
| --- |
| **At the time of printing, the relevant legislation giving authority for the changes included in this edition of the book may still be subject to the approval of Executive Council and the usual Parliamentary scrutiny.  This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment of Medicare benefits.** |

|  |
| --- |
| **The latest Medicare Benefits Schedule information  is available from *MBS Online* at**  [**https://www.health.gov.au/mbsonline**](https://www.health.gov.au/mbsonline) |

**TABLE OF CONTENTS**

[GENERAL EXPLANATORY NOTES 5](#_Toc169795590)

[GENERAL EXPLANATORY NOTES 6](#_Toc169795591)

[CATEGORY 6: PATHOLOGY SERVICES 33](#_Toc169795592)

[SUMMARY OF CHANGES FROM 01/07/2024 34](#_Toc169795593)

[PATHOLOGY SERVICES NOTES 35](#_Toc169795594)

[Group P1. Haematology 81](#_Toc169795595)

[Group P2. Chemical 87](#_Toc169795596)

[Group P3. Microbiology 104](#_Toc169795597)

[Group P4. Immunology 114](#_Toc169795598)

[Group P5. Tissue Pathology 122](#_Toc169795599)

[Group P6. Cytology 126](#_Toc169795600)

[Group P7. Genetics 130](#_Toc169795601)

[Group P8. Infertility And Pregnancy Tests 172](#_Toc169795602)

[Group P9. Simple Basic Pathology Tests 173](#_Toc169795603)

[Group P10. Patient Episode Initiation 175](#_Toc169795604)

[Group P11. Specimen Referred 178](#_Toc169795605)

[Group P12. Management Of Bulk-Billed Services 178](#_Toc169795606)

[Group P13. Bulk-Billing Incentive 181](#_Toc169795607)

[COMPLEXITY LEVELS FOR HISTOPATHOLOGY ITEMS 182](#_Toc169795608)

# GENERAL EXPLANATORY NOTES

## GENERAL EXPLANATORY NOTES

**GN.0.1 AskMBS Email Advice Service**

If you are a patient seeking advice about Medicare services, benefits or your Medicare claims, please contact Services Australia on the Medicare general enquiry line - 132 011.

AskMBS responds to enquiries from providers of services listed on the Medicare Benefits Schedule (MBS) seeking advice on interpretation of MBS items (including those for dental, pathology and diagnostic imaging), explanatory notes and associated legislation. This advice is intended primarily to assist health professionals, practice managers and others to understand and comply with MBS billing requirements. AskMBS works closely with policy areas within the Department of Health and Aged Care, and with Services Australia, to ensure enquirers receive accurate, authoritative and up-to-date information.

If you have a query relating exclusively to interpretation of the Schedule, you should email [askMBS@health.gov.au](http://mailto:askMBS@health.gov.au).

If you are seeking advice in relation to Medicare billing, claiming, payments or obtaining a provider number, please contact Services Australia on the Provider Enquiry Line on 13 21 50.

AskMBS issues advisories summarising responses to frequently asked questions on specific subject areas.  
[AskMBS Email Advice Service](https://www.health.gov.au/resources/collections/askmbs-advisories)

**GN.1.1 The Medicare Benefits Schedule - Introduction**

**Schedules of Services**

Each professional service contained in the Schedule has been allocated a unique item number.  Located with the item number and description for each service is the Schedule fee and Medicare benefit, together with a reference to an explanatory note relating to the item (if applicable).

If the service attracts an anaesthetic, the word (Anaes.) appears following the description. Where an operation qualifies for the payment of benefits for an assistant, the relevant items are identified by the inclusion of the word (Assist.) in the item description. Medicare benefits are not payable for surgical assistance associated with procedures which have not been so identified.

Higher rates of benefits are provided for consultations by a recognised consultant physician where the patient has been referred by another medical practitioner or an approved dental practitioner (oral surgeons).

Differential fees and benefits also apply to services listed in Category 5 (Diagnostic Imaging Services). The conditions relating to these services are set out in Category 5.

**Explanatory Notes**

Explanatory notes relating to the Medicare benefit arrangements and notes that have general application to services are located at the beginning of the schedule, while notes relating to specific items are located at the beginning of each Category. While there may be a reference following the description of an item to specific notes relating to that item, there may also be general notes relating to each Group of items.

**GN.1.2 Medicare - an outline**

The Medicare Program ('Medicare') provides access to medical and hospital services for all Australian residents and certain categories of visitors to Australia. Services Australia administers Medicare and the payment of Medicare benefits. The major elements of Medicare are contained in the *Health Insurance Act 1973*, as amended, and include the following:

1. Free treatment for public patients in public hospitals.
2. The payment of 'benefits', or rebates, for professional services listed in the Medicare Benefits Schedule (MBS). The relevant benefit rates are:
   1. 100% of the Schedule fee for services provided by a general practitioner to non-referred, non-admitted patients, or for general practitioner attendances specified as not being hospital treatments - see note below;
   2. 100% of the Schedule fee for services provided on behalf of a general practitioner by a practice nurse or Aboriginal and Torres Strait Islander health practitioner\*;
   3. 75% of the Schedule fee for professional services rendered to a patient as part of an episode of hospital treatment (other than services provided to public patients), including services provided in hospital outpatient settings but not generally including services set out in the note below. Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing an asterisk '\*' or the letter 'H' directly after an item number where used; or a description of the professional service and an indication the service was rendered as an episode of hospital treatment (for example, 'in hospital', 'hospital outpatient service', 'admitted' or 'in patient');
   4. 75% of the Schedule fee for professional services rendered as part of a privately insured episode of hospital-substitute treatment such as ‘hospital in the home’, but generally not including certain services listed below. Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing the words 'hospital-substitute treatment' directly after an item number where used; or a description of the professional service, preceded by the words 'hospital-substitute treatment';
   5. 85% of the Schedule fee for all other services.

Note: while hospital treatments and hospital-substitute treatments attract a 75% rebate, most attendances, services provided to private patients in emergency departments, pathology services and diagnostic imaging services do not generally require hospital treatment and therefore do not attract a rebate of 75% of the Schedule fee unless certified as a 'Type C' treatment. A list of most MBS items in scope of this exception, and the requirements around certifying a treatment as 'Type C' can be found in the Private Health Insurance (Benefit Requirement) Rules 2011. Services provided to a private patient in an emergency department are exempted under the Private Health Insurance (Health Insurance Business) Rules 2018.

Medicare benefits are claimable only for 'clinically relevant' services rendered by an appropriate health practitioner. A 'clinically relevant' service is one which is generally accepted by the relevant profession as necessary for the appropriate treatment of the patient.

When a service is not clinically relevant, the fee and payment arrangements are a private matter between the practitioner and the patient.

Services listed in the MBS must be rendered according to the provisions of the relevant Commonwealth, State and Territory laws. For example, medical practitioners must ensure that the medicines and medical devices they use have been supplied to them in strict accordance with the provisions of the Therapeutic Goods Act 1989.

Where a Medicare benefit has been inappropriately paid, Services Australia may request its return from the practitioner concerned.

\* MBS items 10988 and 10989 generally attract a 100% rebate but can be specified as 'Type C' treatments and attract a 75% rebate.

**GN.1.3 Medicare benefits and billing practices**

**Key information on Medicare benefits and billing practices**

The *Health Insurance Act 1973* stipulates that Medicare benefits are payable for professional services.  A professional service is a clinically relevant service which is listed in the MBS.  A medical service is clinically relevant if it is generally accepted in the medical profession as necessary for the appropriate treatment of the patient.

Medical practitioners are free to set their fees for their professional service.  However, the amount specified in the patient's account must be the amount charged for the service specified.  The fee may not include a cost of goods or services which are not part of the MBS service specified on the account.

**Billing practices contrary to the Act**

A *non-clinically relevant service* must not be included in the charge for a Medicare item.  The non-clinically relevant service must be separately listed on the account and not billed to Medicare.

Goods supplied for the patient's home use (such as wheelchairs, oxygen tanks, continence pads) must not be included in the consultation charge.  Medicare benefits are limited to services which the medical practitioner provides at the time of the consultation - any other services must be separately listed on the account and must not be billed to Medicare.

Charging part of all of an episode of hospital treatment or a hospital substitute treatment to a non-admitted consultation is prohibited.  This would constitute a false or misleading statement on behalf of the medical practitioner and no Medicare benefits would be payable.

An account may not be re-issued to include charges and out-of-pocket expenses excluded in the original account.  The account can only be reissued to correct a genuine error.

**Potential consequence of improperly issuing an account**

The potential consequences for improperly issuing an account are

(a)        No Medicare benefits will be paid for the service;

(b)        The medical practitioner who issued the account, or authorised its issue, may face charges under sections 128A or 128B of the *Health Insurance Act 1973*.

(c)        Medicare benefits paid as a result of a false or misleading statement will be recoverable from the doctor under section 129AC of the *Health Insurance Act 1973*.

Providers should be aware that Services Australia is legally obliged to investigate doctors suspected of making false or misleading statements, and may refer them for prosecution if the evidence indicates fraudulent charging to Medicare.  If Medicare benefits have been paid inappropriately or incorrectly, Services Australia will take recovery action.

Services Australia (SA), in consultation with the Department of Health and Aged Care, has developed a [Health Practitioner Guideline for responding to a request to substantiate that a patient attended a service](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation).  There is also a [Health Practitioner Guideline for substantiating that a specific treatment was performed](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation). These guidelines are located on the Department of Health and Aged Care's website.

**GN.2.4 Provider eligibility for Medicare**

To be eligible to provide medical service which will attract Medicare benefits, or to provide services for or on behalf of another practitioner, practitioners must meet one of the following criteria:

(a) be a recognised specialist, consultant physician or general practitioner; or

(b) be in an approved placement under section 3GA of the *Health Insurance Act 1973*; or

(c) be a temporary resident doctor with an exemption under section 19AB of the *Health Insurance Act 1973*, and working in accord with that exemption.

Any practitioner who does not satisfy the requirements outlined above may still practice medicine but their services will not be eligible for Medicare benefits.

**NOTE:** New Zealand citizens entering Australia do so under a special temporary entry visa and are regarded as temporary resident doctors.

**NOTE:**  It is an offence under Section 19CC of the *Health Insurance Act 1973* to provide a service without first informing a patient where a Medicare benefit is not payable for that service (i.e. the service is not listed in the MBS).

**Non-medical practitioners**

To be eligible to provide services which will attract Medicare benefits under MBS items 10950-10977 and MBS items 80000-88000 and 82100-82140 and 82200-82215, allied health professionals, dentists, and dental specialists, participating midwives and participating nurse practitioners must be

(a) registered according to State or Territory law or, absent such law, be members of a professional association with uniform national registration requirements; and

(b) registered with the Services Australia to provide these services.

**GN.2.5 Provider Numbers**

Practitioners eligible to have Medicare benefits payable for their services and/or who for Medicare purposes wish to raise referrals for specialist services and requests for pathology or diagnostic imaging services, may apply ***in writing*** to Services Australia for a Medicare provider number for the locations where these services/referrals/requests will be provided.  The form may be downloaded from the [Services Australia website.](https://www.servicesaustralia.gov.au/)

For Medicare purposes, an account/receipt issued by a practitioner must include the practitioner's name and ***either*** the provider number for the location where the service was provided ***or*** the address where the services were provided.

Medicare provider number information is released in accord with the secrecy provisions of the *Health Insurance Act 1973* (section 130) to authorized external organizations including private health insurers, the Department of Veterans' Affairs and the Department of Health and Aged Care.

When a practitioner ceases to practice at a given location they must inform Medicare promptly.  Failure to do so can lead to the misdirection of Medicare cheques and Medicare information.

**GN.2.6 Locum tenens**

Where a locum tenens will be in a practice for more than two weeks ***or*** in a practice for less than two weeks but on a regular basis, the locum should apply for a provider number for the relevant location.  If the locum will be in a practice for less than two weeks and will not be returning there, they should contact Services Australia (provider liaison - 132 150) to discuss their options (for example, use one of the locum's other provider numbers).

A locum must use the provider number allocated to the location if

(a) they are an approved general practice or specialist trainee with a provider number issued for an approved training placement; or

(b) they are associated with an approved rural placement under Section 3GA of the *Health Insurance Act 1973*; or

(c) they have access to Medicare benefits as a result of the issue of an exemption under section 19AB of the *Health Insurance Act 1973* (i.e. they have access to Medicare benefits at specific practice locations); or

(d) they will be at a practice which is participating in the Practice Incentives Program; or

(e) they are associated with a placement on the MedicarePlus for Other Medical Practitioners (OMPs) program, the After Hours OMPs program, the Rural OMPs program or Outer Metropolitan OMPs program.

**GN.2.7 Overseas trained doctor**

Ten year moratorium

Section 19AB of the *Health Insurance Act 1973* states that services provided by overseas trained doctors (including New Zealand trained doctors) and former overseas medical students trained in Australia, will not attract Medicare benefits for 10 years from either

1. their date of registration as a medical practitioner for the purposes of the *Health Insurance Act 1973*; or
2. their date of permanent residency (the reference date will vary from case to case).

Exclusions - Practitioners who before 1 January 1997 had

1. registered with a State or Territory medical board and retained a continuing right to remain in Australia; or
2. lodged a valid application with the Australian Medical Council (AMC) to undertake examinations whose successful completion would normally entitle the candidate to become a medical practitioner.

The Minister of Health and Ageing may grant an overseas trained doctor (OTD) or occupational trainee (OT) an exemption to the requirements of the ten year moratorium, with or without conditions. When applying for a Medicare provider number, the OTD or OT must

1. demonstrate that they need a provider number and that their employer supports their request; and
2. provide the following documentation:
   1. Australian medical registration papers; and
   2. a copy of their personal details in their passport and all Australian visas and entry stamps; and
   3. a letter from the employer stating why the person requires a Medicare provider number and/or prescriber number is required; and
   4. a copy of the employment contract.

**GN.2.8 Contact details for Services Australia**

The day-to-day administration and payment of benefits under the Medicare arrangements is the responsibility of Services Australia.

**Changes to Provider Contact Details**

It is important that you contact Services Australia promptly of any changes to your preferred contact details.  Your preferred mailing address is used to contact you about Medicare provider matters.  We require requests for changes to your preferred contact details to be made by the provider in writing to Services Australia at:

Medicare

GPO Box 9822

in your capital city

or

the Medicare Provider telephone line on 132 150.

You may also be able to update some provider details through HPOS [http://www.servicesaustralia.gov.au/hpos](https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/hpos)

**GN.3.9 Patient eligibility for Medicare services**

This note sets out who can access Medicare services.

**ELIGIBLE GROUPS**

To be eligible for Medicare, a person must ordinarily live in Australia, be located in Australia at the time of the service, and be:

* an Australian citizen
* an Australian permanent resident
* a New Zealand citizen
* a Resident Return visa holder
* an applicant for permanent residency ([conditions apply](https://www.servicesaustralia.gov.au/enrolling-medicare-if-youre-australian-permanent-resident?context=60092#appliedpermanentresidency)) or
* a temporary visa holder covered by a [Ministerial Order](https://www.servicesaustralia.gov.au/enrolling-medicare-if-youre-temporary-resident-covered-ministerial-order?context=60092).

Ministerial Orders made under Section 6(1) of the [*Health Insurance Act 1973*](https://www.legislation.gov.au/Series/C2004A00101) grant eligibility to groups including Australian citizens who have been absent from Australia for up to five years and holders of particular temporary visa types.

**Note:** access to Medicare by visitors to Australia who are covered by a Reciprocal Health Care Agreement is subject to the specific conditions of each Agreement (see below).

**ENROLLING IN MEDICARE**

The patient must enrol with Medicare before receiving Medicare benefits. Once enrolled, they will receive a Medicare Card. There are three types of Medicare cards, in the following colours:

**Green** – this is the standard Medicare card for Australian citizens, permanent residents and New Zealand citizens living in Australia and Resident Return visa holders.

**Blue** – this is the card for people who have applied for permanent residence or who hold a temporary visa covered by a Ministerial Order.

**Yellow** – this is the card for visitors to Australia from a country with a Reciprocal Health Care Agreement.

More information about enrolling in Medicare and the different Medicare cards is available from [Services Australia](https://www.servicesaustralia.gov.au/your-medicare-card?context=60092).

**RECIPROCAL HEALTH CARE AGREEMENTS**

Under Section 7 of the [*Health Insurance Act 1973*](https://www.legislation.gov.au/Series/C2004A00101), the Australian Government has agreements with 11 other governments to cover the cost of certain medical care when Australians and overseas residents visit each other’s countries.

Eligible overseas visitors from these countries generally receive:

* inpatient/outpatient services as a public patient in a public hospital
* out of hospital care
* Pharmaceutical Benefits Scheme (PBS) prescription medicines

**Exceptions**: Visitors from New Zealand and Ireland are entitled to public hospital care and PBS drugs only (not MBS services).

Reciprocal Health Care Agreements do not cover the cost of treatment as a private patient in a public or private hospital.

People visiting Australia for the specific purpose of receiving medical treatment are not covered.

**Eligible Countries:**

As at 1 February 2024, Australia has Reciprocal Health Care Agreements with the following countries:

* Belgium
* Finland
* Italy (eligibility limited to six months from date of arrival)
* Malta (eligibility limited to six months from date of arrival)
* Netherlands
* New Zealand (public hospital care and PBS medicines only, not MBS services)
* Norway
* Ireland (public hospital care and PBS medicines only, not MBS services)
* Slovenia
* Sweden
* United Kingdom

Eligible patients from these countries need to enrol in Medicare to access MBS services. Once enrolled they will have a yellow Medicare card.

* Visitors from New Zealand and Ireland do not need to enrol in Medicare to access public hospital services and PBS medicines under the Reciprocal Health Care Agreements. They are not eligible for MBS services unless they hold a green Medicare card.

More information about access to medical care under each Reciprocal Health Care Agreement is available from [Services Australia](https://www.servicesaustralia.gov.au/when-reciprocal-health-care-agreements-apply-and-you-visit-australia?context=22481).

**OTHER VISITORS AND TEMPORARY RESIDENTS**

Other visitors and temporary residents are not eligible for Medicare and should arrange private health insurance cover.

**RELEVANT LEGISLATION**

Information about the legislative arrangements applying to Medicare and the Reciprocal Health Care Agreements is set out in the [*Health Insurance Act 1973*](https://www.legislation.gov.au/Series/C2004A00101), which can be found on the [Federal Register of Legislation](https://www.legislation.gov.au/).

**GN.4.13 Who can use the Medicare Benefits Schedule GP items?**

**SUMMARY**

This general note sets out which medical practitioners can use the MBS general practitioner (GP) items.

Medical practitioners that are eligible to provide Medicare services who are not GPs but provide services in a general practice setting can use the medical practitioner and [prescribed medical practitioner](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=note&q=AN.7.1&qt=noteID&criteria=an%2E7%2E1) (explanatory note [AN.7.1](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=note&q=AN.7.1&qt=noteID&criteria=an%2E7%2E1)) MBS items.

**WHO CAN USE THE MBS GP ITEMS?**

The [*Health Insurance Act 1973*](https://www.legislation.gov.au/Series/C2004A00101) (the Act), and legal instruments made under the Act, set out which medical practitioners can claim MBS GP items. The four categories of medical practitioner that can access MBS GP items are those that are:

1. Fellows of a General Practice College
2. On an approved placement in a general practice training program
3. Listed on the Vocational Register of GPs (closed to new participants)
4. Eligible non-VR GPs (closed to new participants)

Before you can claim MBS GP items you must have a Medicare provider number for the location at which you are practising. You can apply for a Medicare provider number through [Services Australia](https://www.servicesaustralia.gov.au/how-to-apply-for-initial-or-additional-medicare-provider-number-or-pbs-prescriber-number?context=34076#applymedicareprovidernumber).

**1. Medical practitioners who are fellows of a General Practice College**

Medical practitioners that are fellows of either the:

* Australian College of Rural and Remote Medicine (ACRRM), or
* Royal Australian College of GPs (RACGP)

are GPs for MBS purposes.

Services Australia uses the Australian Health Practitioner Regulation Agency (Ahpra) [Register of Medical Practitioners](https://www.ahpra.gov.au/Registration/Registers-of-Practitioners.aspx) to determine practitioners’ access to the GP items. Fellows of the RACGP and ACRRM must hold specialist registration as a GP with the [Medical Board of Australia](https://www.medicalboard.gov.au/) to access the GP items. The Ahpra registration for these medical practitioners will indicate that they are a specialist in the field of general practice.

**2. Medical practitioners on an Approved Placement in a general practice training program**

Section 1.1.3 of the [*Health Insurance (General Medical Services Table) Regulations 2021*](https://www.legislation.gov.au/Series/F2021L00678) provides access to the MBS GP items to medical practitioners undertaking an approved training placement. That is, a training placement that will lead to fellowship with the RACGP or ACCRM.

* For more information on approved training placements see the [General Practice Fellowship Program Placement Guidelines](https://www.health.gov.au/resources/publications/general-practice-fellowship-program-placement-guidelines-fourth-edition?language=en).

Your placement organisation must advise [Services Australia](https://www.servicesaustralia.gov.au/gp-medical-specialist-and-consultant-physician-eligibility-requirements?context=34076) of the placement before MBS GP items can be accessed.

**3. Medical practitioners on the Vocational Register of GPs**

The Vocational Register of GPs closed to new participants on 16 June 2021.

Section 16 of the [*Health Insurance Regulation 2018*](https://www.legislation.gov.au/Series/F2018L01365) allows medical practitioners whose names are entered onto the Vocational Register of GPs to access MBS GP items provided they continue to be registered with Ahpra.

**4. Eligible non-vocationally recognised medical practitioners**

The programs below closed to new participants on 1 January 2019.

Section 1.1.2 of the [*Health Insurance (General Medical Services Table) Regulations 2021*](https://www.legislation.gov.au/Series/F2021L00678) specifies which non-vocationally recognised medical practitioners can access MBS GP items:

1. Medical practitioners who have been notified by the Chief Executive of Medicare that they have completed the requirements of the MedicarePlus for Other Medical Practitioners Program before 31 December 2023.
2. Participants in the [Other Medical Practitioners Extension Program](https://www.health.gov.au/our-work/omps) who were enrolled in one of the following programs as at 30 June 2023:
   1. After Hours Other Medical Practitioner Program
   2. Outer Metropolitan Other Medical Practitioner Program
   3. Rural Other Medical Practitioner Program

**RELEVANT LEGISLATION**

Details of the legislative arrangements applying to the categories of medical practitioners able to use the MBS GP items can be found on the [Federal Register of Legislation](https://www.legislation.gov.au/), and are set out in three regulatory instruments:

* [*Health Insurance Act 1973*](https://www.legislation.gov.au/Series/C2004A00101)
* [*Health Insurance (General Medical Services Table) Regulations 2021*](https://www.legislation.gov.au/Series/F2021L00678)
* [*Health Insurance Regulations 2018*](https://www.legislation.gov.au/Series/F2018L01365)

**GN.5.14 Recognition as a Specialist or Consultant Physician**

A medical practitioner who:

· is registered as a specialist under State or Territory law; or

· holds a fellowship of a specified specialist College and has obtained, after successfully completing an appropriate course of study, a relevant qualification from a relevant College

and has formally applied and paid the prescribed fee, may be recognised by the Minister as a specialist or consultant physician for the purposes of the *Health Insurance Act 1973*.

A relevant specialist College may also give Services Australia's Chief Executive Officer a written notice stating that a medical practitioner meets the criteria for recognition.

A medical practitioner who is training for a fellowship of a specified specialist College and is undertaking training placements in a private hospital or in general practice, may provide services which attract Medicare benefits.  Specialist trainees should consult the information available at [Services Australia's Medicare website](https://www.servicesaustralia.gov.au/).

Once the practitioner is recognised as a specialist or consultant physician for the purposes of the *Health Insurance Act 1973*, Medicare benefits will be payable at the appropriate higher rate for services rendered in the relevant speciality, provided the patient has been appropriately referred to them.

Further information about applying for recognition is available at [Services Australia Medicare website](https://www.servicesaustralia.gov.au/).

Services Australia (SA), in consultation with the Department of Health and Aged Care, has developed a [Health Practitioner Guideline to substantiate that a valid referral existed (specialist or consultant physician)](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation) which is located on the Department of Health and Aged Care website.

**GN.5.15 Emergency Medicine**

A practitioner will be acting as an emergency medicine specialist when treating a patient within 30 minutes of  the patient's presentation, and that patient is

(a)        at risk of serious morbidity or mortality requiring urgent assessment and resuscitation; or

(b)        suffering from suspected acute organ or system failure; or

(c)        suffering from an illness or injury where the viability or function of a body part or organ is acutely threatened; or

(d)        suffering from a drug overdose, toxic substance or toxin effect; or

(e)        experiencing severe psychiatric disturbance whereby the health of the patient or other people is at immediate risk; or

(f)        suffering acute severe pain where the viability or function of a body part or organ is suspected to be acutely threatened; or

(g)        suffering acute significant haemorrhage requiring urgent assessment and treatment; and

(h)        treated in, or via, a bona fide emergency department in a hospital.

Benefits are not payable where such services are rendered in the accident and emergency departments or outpatient departments of public hospitals.

**GN.5.16 Conjoint Committee for recognising training in Micro Bypass Glaucoma Surgery (MBGS)**

The Conjoint Committee comprises representatives from the Australian and New Zealand Glaucoma Society (ANZGS) and the Royal Australian and New Zealand College of Ophthalmologists (RANZCO). For the purposes of MBS item 42504, specialists performing this procedure must have certification and training recognised by the Conjoint Committee for the Recognition of Training in Micro-Bypass Glaucoma Surgery, and Services Australia notified of that recognition.

**GN.6.16 Referral Of Patients To Specialists Or Consultant Physicians**

For certain services provided by specialists and consultant physicians, the Medicare benefit payable is dependent on acceptable evidence that the service has been provided following referral from another practitioner.

A reference to a referral in this Section does not refer to written requests made for pathology services or diagnostic imaging services. Information about the form of a diagnostic imaging request can be found in **Note IN.0.6** of the Diagnostic Imaging Services Table (Category 5) and information about the form of a pathology request can be found in **Note PN.2.1** of the Pathology Services Table (Category 6).

**What is a Referral?**

A "referral" is a request to a specialist or a consultant physician for investigation, opinion, treatment and/or management of a condition or problem of a patient or for the performance of a specific examination(s) or test(s).

Subject to the exceptions in the paragraph below, for a valid "referral" to take place

(i)               the referring practitioner must have undertaken a professional attendance with the patient and turned their mind to the patient's need for referral and have communicated relevant information about the patient to the specialist or consultant physician (this need not mean an attendance on the occasion of the referral);

(ii)              the instrument of referral must be in writing as a letter or note to a specialist or to a consultant physician and must be signed and dated by the referring practitioner; and

(iii)             the specialist or consultant physician to whom the patient is referred must have received the instrument of referral on or prior to the occasion of the professional service to which the referral relates.

The exceptions to the requirements in paragraph above are that

(a) sub-paragraphs (i), (ii) and (iii) do not apply to

-     a pre-anaesthesia consultation by a specialist anaesthetist (items 16710-17625);

(b) sub‑paragraphs (ii) and (iii) do not apply to

-     a referral generated during an episode of hospital treatment, for a service provided or arranged by that hospital, where the hospital records provide evidence of a referral (including the referring practitioner's signature); or

-     an emergency where the referring practitioner or the specialist or the consultant physician was of the opinion that the service be rendered as quickly as possible; and

(c) sub‑paragraph (iii) does not apply to instances where a written referral was completed by a referring practitioner but was lost, stolen or destroyed.

**Examination by Specialist Anaesthetists**

A referral  is not required in the case of  pre-anaesthesia consultation items 17610-17625. However, for benefits to be payable at the specialist rate for consultations, other than pre-anaesthesia consultations by specialist anaesthetists (items 17640 -17655) a referral is required.

**Who can Refer?**

The general practitioner is regarded as the primary source of referrals.  Cross-referrals between specialists and/or consultant physicians should usually occur in consultation with the patient's general practitioner.

**Referrals by Dentists or Optometrists or Participating Midwives or Participating Nurse Practitioners**

For Medicare benefit purposes, a referral may be made to

(i)               a recognised specialist:

(a) by a registered dental practitioner, where the referral arises from a dental service; or

(b) by a registered optometrist where the specialist is an ophthalmologist; or

(c) by a participating midwife where the specialist is an obstetrician or a paediatrician, as clinical needs dictate.  A referral given by a participating midwife is valid until 12 months after the first service given in accordance with the referral and for I pregnancy only or

(d) by a participating nurse practitioner to specialists and consultant physicians.  A referral given by a participating nurse practitioner is valid until 12 months after the first service given in accordance with the referral.

(ii)              a consultant physician, by an approved dental practitioner (oral surgeon), where the referral arises out of a dental service.

In any other circumstances (i.e. a referral to a consultant physician by a dentist, other than an approved oral surgeon, or an optometrist, or a referral by an optometrist to a specialist other than a specialist ophthalmologist), it is not a valid referral.  Any resulting consultant physician or specialist attendances will attract Medicare benefits at unreferred rates.

Registered dentists and registered optometrists may refer themselves to specialists in accordance with the criteria above, and Medicare benefits are payable at the levels which apply to their referred patients.

**Billing**

***Routine Referrals***

In addition to providing the usual information required to be shown on accounts, receipts or assignment forms, specialists and consultant physicians must provide the following details (unless there are special circumstances as indicated in paragraph below):-

-                  name and either practice address or provider number of the referring practitioner;

-                  date of referral; and

-                  period of referral (when other than for 12 months) expressed in months, eg "3", "6" or "18" months, or "indefinitely" should be shown.

***Special Circumstances***

*(i) Lost, stolen or destroyed referrals.*

If a referral has been made but the letter or note of referral has been lost, stolen or destroyed, benefits will be payable at the referred rate if the account, receipt or the assignment form shows the name of the referring medical practitioner, the practice address or provider number of the referring practitioner (if either of these are known to the consultant physician or specialist) and the words 'Lost referral'.  This provision only applies to the initial attendance.  For subsequent attendances to attract Medicare benefits at the referred rate a duplicate or replacement letter of referral must be obtained by the specialist or the consultant physician.

*(ii) Emergencies*

If the referral occurred in an emergency, benefit will be payable at the referred rate if the account, receipt or assignment form is endorsed 'Emergency referral'.  This provision only applies to the initial attendance.  For subsequent attendances to attract Medicare benefits at the referred rate the specialist/consultant physician must obtain a letter of referral.

*(iii) Hospital referrals.*

Private Patients - Where a referral is generated during an episode of hospital treatment for a service provided or arranged by that hospital, benefits will be payable at the referred rate if the account, receipt or assignment form is endorsed 'Referral within (name of hospital)' and the patient's hospital records show evidence of the referral (including the referring practitioner's signature). However, in other instances where a medical practitioner within a hospital is involved in referring a patient (e.g. to a specialist or a consultant physician in private rooms) the normal referral arrangements apply, including the requirement for a referral letter or note and its retention by the specialist or the consultant physician billing for the service.

***Public Hospital Patients***

State and Territory Governments are responsible for the provision of public hospital services to eligible persons in accordance with the National Healthcare Agreement.

***Bulk Billing***

Bulk billing assignment forms should show the same information as detailed above.   However, faster processing of the claim will be facilitated where the provider number (rather than the practice address) of the referring practitioner is shown.

**Period for which Referral is Valid**

The referral is valid for the period specified in the referral which is taken to commence on the date of the specialist's or consultant physician's first service covered by that referral.

***Specialist Referrals***

Where a referral originates from a specialist or a consultant physician, the referral is valid for 3 months, except where the referred patient is an admitted patient.  For admitted patients, the referral is valid for 3 months or the duration of the admission and ceases when the patient is discharged.

A referral for a specialist professional service to a patient in a hospital who is not a public patient is valid until the patient ceases to be a patient in the hospital.

As it is expected that the patient's general practitioner will be kept informed of the patient's progress, a referral from a specialist or a consultant physician must include the name of the patient's general practitioners and/or practice. Where a patient is unable or unwilling to nominate a general practitioner or practice this must be stated in the referral.

***Referrals by other Practitioners***

Where the referral originates from a practitioner other than those listed in *Specialist Referrals*, the referral is valid for a period of 12 months, unless the referring practitioner indicates that the referral is for a period more or less than 12 months (eg. 3, 6 or 18 months or valid indefinitely). Referrals for longer than 12 months should only be used where the patient's clinical condition requires continuing care and management of a specialist or a consultant physician for a specific condition or specific conditions.

**Definition of a Single Course of Treatment**

A single course of treatment involves an initial attendance by a specialist or consultant physician and the continuing management/treatment up to the stage where the patient is referred back to the care of the referring practitioner.  It also includes any subsequent review of the patient's condition by the specialist or the consultant physician that may be necessary. Such a review may be initiated by either the referring practitioner or the specialist/consultant physician.

The presentation of an unrelated illness, requiring the referral of the patient to the specialist's or the consultant physician's care would initiate a new course of treatment in which case a new referral would be required.

The receipt by a specialist or consultant physician of a new referral following the expiration of a previous referral for the same condition(s) does not necessarily indicate the commencement of a new course of treatment involving the itemisation of an initial consultation.  In the continuing management/treatment situation the new referral is to facilitate the payment of benefits at the specialist or the consultant physician referred rates rather than the unreferred rates.

However, where the referring practitioner:-

(a)              deems it necessary for the patient's condition to be reviewed; and

(b)              the patient is seen by the specialist or the consultant physician outside the currency of the last referral; and

(c)              the patient was last seen by the specialist or the consultant physician more than 9 months earlier

the attendance following the new referral initiates a new course of treatment for which Medicare benefit would be payable at the initial consultation rates.

**Retention of Referral Letters**

The prima facie evidence that a valid referral exists is the provision of the referral particulars on the specialist's or the consultant physician's account.

A specialist or a consultant physician is required to retain the instrument of referral (and a hospital is required to retain the patient's hospital records which show evidence of a referral) for 2 years from the date the service was rendered.

A specialist or a consultant physician is required, if requested by the Services Australia CEO, to produce to a medical practitioner who is an employee of Services Australia, the instrument of referral within seven days after the request is received. Where the referral originates in an emergency situation or in a hospital, the specialist or consultant physician is required to produce such information as is in his or her possession or control relating to whether the patient was so treated.

**Attendance for Issuing of a Referral**

Medicare benefit is attracted for an attendance on a patient even where the attendance is solely for the purpose of issuing a referral letter or note.  However, if a medical practitioner issues a referral without an attendance on the patient, no benefit is payable for any charge raised for issuing the referral.

**Locum‑tenens Arrangements**

It should be noted that where a non-specialist medical practitioner acts as a locum‑tenens for a specialist or consultant physician, or where a specialist acts as a locum‑tenens for a consultant physician, Medicare benefit is only payable at the level appropriate for the particular locum‑tenens, eg, general practitioner level for a general practitioner locum‑tenens and specialist level for a referred service rendered by a specialist locum tenens.

Medicare benefits are not payable where a practitioner is not eligible to provide services attracting Medicare benefits acts as a locum-tenens for any practitioner who is eligible to provide services attracting Medicare benefits.

Fresh referrals are not required for locum‑tenens acting according to accepted medical practice for the principal of a practice ie referrals to the latter are accepted as applying to the former and benefit is not payable at the initial attendance rate for an attendance by a locum‑tenens if the principal has already performed an initial attendance in respect of the particular instrument of referral.

**Self Referral**

Medical practitioners may refer themselves to consultant physicians and specialists and Medicare benefits are payable at referred rates.

**GN.7.17 Billing procedures**

The Services Australia website contains information on Medicare billing and claiming options.  Please visit the [Services Australia](https://www.servicesaustralia.gov.au/) website for further information.

Bulk billing

Under the *Health Insurance Act 1973*, a bulk billing facility for professional services is available to all persons in Australia who are eligible for a benefit under the Medicare program.  If a practitioner bulk bills for a service the practitioner undertakes to accept the relevant Medicare benefit as full payment for the service.  Additional charges for that service cannot be raised.  This includes but is not limited to:

* any consumables that would be reasonably necessary to perform the service, including bandages and/or dressings;
* record keeping fees;
* a booking fee to be paid before each service, or;
* an annual administration or registration fee.

Where the patient is bulk billed, an additional charge can **only** be raised against the patient by the practitioner where the patient is provided with a vaccine or vaccines from the practitioner's own supply held on the practitioner's premises.  This exemption only applies to general practitioners and other non-specialist practitioners in association with attendance items **3 to 96**, **179 to 212**, **733 to 789** and **5000 to 5267** (inclusive) and only relates to vaccines that are not available to the patient free of charge through Commonwealth or State funding arrangements or available through the Pharmaceutical Benefits Scheme.  The additional charge must only be to cover the supply of the vaccine.

Where a practitioner provides a number of services (excluding operations) on the one occasion, they can choose to bulk bill some or all of those services and privately charge a fee for the other service (or services), in excess of the Medicare rebate. The privately charged fee can only be charged in relation to said service (or services). Where two or more operations are provided on the one occasion, all services must be either bulk billed or privately charged.

It should be noted that, where a service is not bulk billed, a practitioner may privately raise an additional charge against a patient, such as for a consumable.  An additional charge can also be raised where a practitioner does not bulk bill a patient but instead charges a fee that is equal to the rebate for the Medicare service.  For example, where a general practitioner provides a professional service to which item 23 relates the practitioner could, in place of bulk billing the patient, charge the rebate for the service and then also raise an additional charge (such as for a consumable).

**GN.8.18 Provision for review of individual health professionals**

The Professional Services Review (PSR) reviews and investigates service provision by health practitioners to determine if they have engaged in inappropriate practice when rendering or initiating Medicare services, or when prescribing or dispensing under the PBS.

Section 82 of the *Health Insurance Act 1973* defines inappropriate practice as conduct that is such that a PSR Committee could reasonably conclude that it would be unacceptable to the general body of the members of the profession in which the practitioner was practicing when they rendered or initiated the services under review.  It is also an offence under Section 82 for a person or officer of a body corporate to knowingly, recklessly or negligently cause or permit a practitioner employed by the person to engage in such conduct.

Services Australia monitors health practitioners' claiming patterns. Where Services Australia detects an anomaly, it may request the Director of PSR to review the practitioner's service provision.  On receiving the request, the Director must decide whether to a conduct a review and in which manner the review will be conducted.  The Director is authorized to require that documents and information be provided.

Following a review, the Director must:

decide to take no further action; or

enter into an agreement with the person under review (which must then be ratified by an independent Determining Authority); or

refer the matter to a PSR Committee.

A PSR Committee normally comprises three medically qualified members, two of whom must be members of the same profession as the practitioner under review.  However, up to two additional Committee members may be appointed to provide wider range of clinical expertise.

The Committee is authorized to:

investigate any aspect of the provision of the referred services, and without being limited by the reasons given in the review request or by a Director's report following the review;

hold hearings and require the person under review to attend and give evidence;

require the production of documents (including clinical notes).

The methods available to a PSR Committee to investigate and quantify inappropriate practice are specified in legislation:

**(a)        Patterns of Services** - The *Health Insurance (Professional Services Review) Regulations 1999* specify that when a general practitioner or other medical practitioner reaches or exceeds 80 or more attendances on each of 20 or more days in a 12-month period, they are deemed to have practiced inappropriately.

A professional attendance means a service of a kind mentioned in group A1, A2, A5, A6, A7, A9, A11, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22 or A23 of Part 3 of the General Medical Services Table.

If the practitioner can satisfy the PSR Committee that their pattern of service was as a result of exceptional circumstances, the quantum of inappropriate practice is reduce accordingly.  Exceptional circumstances include, but are not limited to, those set out in the *Regulations*.  These include:

an unusual occurrence;

the absence of other medical services for the practitioner's patients (having regard to the practice location); and

the characteristics of the patients.

**(b)        Sampling** - A PSR Committee may use statistically valid methods to sample the clinical or practice records.

**(c)        Generic findings** - If a PSR Committee cannot use patterns of service or sampling (for example, there are insufficient medical records), it can make a 'generic' finding of inappropriate practice.

**Additional Information**

A PSR Committee may not make a finding of inappropriate practice unless it has given the person under review notice of its intention to review them, the reasons for its findings, and an opportunity to respond.  In reaching their decision, a PSR Committee is required to consider whether or not the practitioner has kept adequate and contemporaneous patient records (See general explanatory note G15.1 for more information on adequate and contemporaneous patient records).

The practitioner under review is permitted to make submissions to the PSR Committee before key decisions or a final report is made.

If a PSR Committee finds that the person under review has engaged in inappropriate practice, the findings will be reported to the Determining Authority to decide what action should be taken:

**(i)** a reprimand;

**(ii)** counselling;

**(iii)** repayment of Medicare benefits; and/or

**(iv)** complete or partial disqualification from Medicare benefit arrangements for up to three years.

Further information is available from the PSR website - [www.psr.gov.au](http://www.psr.gov.au/)

**GN.8.19 Medicare Participation Review Committee**

The Medicare Participation Review Committee determines what administrative action should be taken against a practitioner who:

(a) has been successfully prosecuted for relevant criminal offences;

(b) has breached an Approved Pathology Practitioner undertaking;

(c) has engaged in prohibited diagnostic imaging practices; or

(d) has been found to have engaged in inappropriate practice under the Professional Services Review scheme and has received Final Determinations on two (or more) occasions.

The Committee can take no further action, counsel or reprimand the practitioner, or determine that the practitioner be disqualified from Medicare for a particular period or in relation to particular services for up to five years.

Medicare benefits are not payable in respect of services rendered by a practitioner who has been fully disqualified, or partly disqualified in relation to relevant services under the *Health Insurance Act 1973* (Section 19B applies).

**GN.8.20 Referral of professional issues to regulatory and other bodies**

The *Health Insurance Act 1973* provides for the following referral, to an appropriate regulatory body:

1. a significant threat to a person's life or health, when caused or is being caused or is likely to be caused by the conduct of the practitioner under review; or
2. a statement of concerns of non-compliance by a practitioner with 'professional standards'.

**GN.8.21 Comprehensive Management Framework for the MBS**

The Government announced the Comprehensive Management Framework for the MBS in the 2011-12 Budget to improve MBS management and governance into the future.  As part of this framework, the Medical Services Advisory Committee (MSAC) Terms of Reference and membership have been expanded to provide the Government with independent expert advice on all new proposed services to be funded through the MBS, as well as on all proposed amendments to existing MBS items.  Processes developed under the previously funded MBS Quality Framework are now being integrated with MSAC processes under the Comprehensive Management Framework for the MBS.

**GN.8.22 Medical Services Advisory Committee**

The Medical Services Advisory Committee (MSAC) advises the Minister on the strength of evidence relating to the safety, effectiveness and cost effectiveness of new and emerging medical services and technologies and under what circumstances public funding, including listing on the MBS, should be supported.

MSAC members are appointed by the Minister and include specialist practitioners, general practitioners, health economists, a health consumer representative, health planning and administration experts and epidemiologists.

For more information on the MSAC refer to their website - [www.msac.gov.au](http://www.msac.gov.au/) or email on [msac.secretariat@health.gov.au](mailto:msac.secretariat@health.gov.au) or by phoning the MSAC secretariat on (02) 6289 7550.

**GN.8.23 Pathology Services Table Committee**

This Pathology Services Table Committee comprises six representatives from the interested professions and six from the Australian Government.  Its primary role is to advise the Minister on the need for changes to the structure and content of the Pathology Services Table (except new medical services and technologies) including the level of fees.

**GN.9.25 Penalties and Liabilities**

Penalties of up to $10,000 or imprisonment for up to five years, or both, may be imposed on any person who makes a statement (oral or written) or who issues or presents a document that is false or misleading in a material particular and which is capable of being used with a claim for benefits.  In addition, any practitioner who is found guilty of such offences by a court shall be subject to examination by a Medicare Participation Review Committee and may be counselled or reprimanded or may have services wholly or partially disqualified from the Medicare benefit arrangements.

A penalty of up to $1,000 or imprisonment for up to three months, or both, may be imposed on any person who obtains a patient's signature on a direct‑billing form without the obligatory details having been entered on the form before the person signs, or who fails to cause a patient to be given a copy of the completed form.

**GN.10.26 Schedule fees and Medicare benefits**

Medicare benefits are based on fees determined for each medical service. The fee is referred to in these notes as the "Schedule fee". The fee for any item listed in the MBS is that which is regarded as being reasonable on average for that service having regard to usual and reasonable variations in the time involved in performing the service on different occasions and to reasonable ranges of complexity and technical difficulty encountered.

The Schedule fee and Medicare benefit levels for the medical services contained in the MBS are located with the item descriptions. Where appropriate, the calculated benefit has been rounded to the nearest higher 5 cents. However, in no circumstances will the Medicare benefit payable exceed the fee actually charged.

There are presently three levels of Medicare benefit payable:

1. 75% of the Schedule fee:
   1. for professional services rendered to a patient as part of an episode of hospital treatment (other than services provided to public patients). Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing an asterisk '\*' or the letter 'H' directly after an item number where used; or a description of the professional service and an indication the service was rendered as an episode of hospital treatment (for example, 'in hospital', 'hospital outpatient service', 'admitted' or 'in patient'). Certain services are not generally considered hospital treatments – see GN1.2;
   2. for professional services rendered as part of an episode of hospital-substitute treatment, and the patient who receives the treatment chooses to receive a benefit from a private health insurer. Medical practitioners must indicate on their accounts if a medical service is rendered in these circumstances by placing the words 'hospital-substitute treatment' directly after an item number where used; or a description of the professional service, preceded by the words 'hospital-substitute treatment'. Certain services are not generally considered hospital treatments – see GN1.2.
2. 100% of the Schedule fee for non-referred attendances by general practitioners to non-admitted patients and services provided by a practice nurse or Aboriginal and Torres Strait Islander health practitioner on behalf of a general practitioner – see GN1.2 for exceptions.
3. 85% of the Schedule fee, or the Schedule fee less $98.70 (indexed annually in November), whichever is the greater, for all other professional services.

Public hospital services are to be provided free of charge to eligible persons who choose to be treated as public patients in accordance with the 2020-2025 Addendum to the National Health Reform Agreement.

Where a Medicare item with multiple components is provided, and some components are provided in the hospital and the remainder outside of the hospital (e.g. aftercare), the 75% benefit level applies. With regard to obstetric items, benefits would be attracted at the 75% level where the confinement takes place in hospital.

Pathology tests performed after discharge from hospital on bodily specimens taken during hospitalisation also attract the 75% level of benefits if not a type of item specified in GN1.2 as not generally being a hospital treatment.

It should be noted that private health insurers can cover the "patient gap" (that is, the difference between the Medicare rebate and the Schedule fee) for services attracting benefits at the 75% level. Patients may insure with private health insurers for the gap between the 75% Medicare benefits and the Schedule fee or for amounts in excess of the Schedule fee where the doctor has an arrangement with their health insurer.

**GN.10.27 Medicare Safety Nets**

The Medicare Safety Nets provide families and individuals with an additional rebate for out-of-hospital Medicare services, once annual thresholds are reached. There are two safety nets: the Original Medicare Safety Net (OMSN) and the Extended Medicare Safety Net (EMSN).

Original Medicare Safety Net:

Under the OMSN, the Medicare benefit for out-of-hospital services is increased to 100% of the Schedule Fee (up from 85%) once an annual threshold in gap costs is reached. Gap costs refer to the difference between the Medicare benefit (85%) and the Schedule Fee. The threshold from 1 January 2024 is $560.40. This threshold applies to all Medicare-eligible individuals and families.

Extended Medicare Safety Net:

Under the EMSN, once an annual threshold in out-of-pocket costs for out-of-hospital Medicare services is reached, Medicare will pay for up to 80% of any future out-of-pocket costs for out-of-hospital Medicare services for the remainder of the calendar year. However, where the item has an EMSN benefit cap, there is a maximum limit on the EMSN benefit that will be paid for that item. Further explanation about EMSN benefit caps is provided below. Out-of-pocket costs refer to the difference between the Medicare benefit and the fee charged by the practitioner.

In 2024, the threshold for concessional individuals and families, including families that received Family Tax Benefit Part (A), is $811.80. The threshold for all other (non-concessional) individuals and families in 2024 is $2544.30.

The thresholds for both safety nets are indexed on 1 January each year in line with the Consumer Price Index (CPI).

Individuals are automatically registered with Services Australia for the safety nets. Families (including couples) are required to register in order to be recognised as a family for the purposes of the safety nets. In most cases, registered families have their expenses combined to reach the safety net thresholds. This may help to qualify for safety net benefits more quickly. Registration forms can be completed online at https://www.servicesaustralia.gov.au/individuals/services/medicare/medicare-safety-nets.

EMSN Benefit Caps:

The EMSN benefit cap is the maximum EMSN benefit payable for that item and is paid in addition to the standard Medicare rebate. Where there is an EMSN benefit cap in place for the item, the amount of the EMSN cap is displayed in the item descriptor. Once the EMSN threshold is reached, each time the item is claimed the patient is eligible to receive up to the EMSN benefit cap. In other words, once the patient reaches the EMSN threshold, they will receive either 80% of their out-of-pocket costs back or the EMSN cap amount, whichever is the lower amount.

For example: Item A has a Schedule fee of $100, the out-of-hospital benefit is $85 (85% of the Schedule fee). The EMSN benefit cap is $30. Assuming that the patient has reached the EMSN threshold:

o If the fee charged by the doctor for Item A is $125, the standard Medicare rebate is $85, with an out-of-pocket cost of $40. The EMSN benefit is calculated as $40 x 80% = $32. However, as the EMSN benefit cap is $30, only $30 will be paid.

o If the fee charged by the doctor for Item A is $110, the standard Medicare rebate is $85, with an out-of-pocket cost of $25. The EMSN benefit is calculated as $25 x 80% = $20. As this is less than the EMSN benefit cap, the full $20 is paid.

**GN.11.28 Services not listed in the MBS**

Benefits are not generally payable for services not listed in the MBS.  However, there are some procedural services which are not specifically listed because they are regarded as forming part of a consultation or else attract benefits on an attendance basis.  For example, intramuscular injections, aspiration needle biopsy, treatment of sebhorreic keratoses and less than 10 solar keratoses by ablative techniques and closed reduction of the toe (other than the great toe).

If you are seeking advice in relation to Medicare billing, claiming, payments or obtaining a provider number, please contact Services Australia on the Provider Enquiry Line - 13 21 50.

If you have a query relating exclusively to interpretation of the Schedule, you should email [mailto:askmbs@health.gov.au](http://mailto:askmbs@health.gov.au)

**GN.11.29 Ministerial Determinations**

Section 3C of the *Health Insurance Act* *1973* empowers the Minister to determine an item and Schedule fee (for the purposes of the Medicare benefits arrangements) for a service not included in the health insurance legislation.  This provision may be used to facilitate payment of benefits for new developed procedures or techniques where close monitoring is desirable.  Services which have received section 3C approval are located in their relevant Groups in the MBS with the notation "**(Ministerial Determination)**".

**GN.12.30 Professional services**

Professional services which attract Medicare benefits include medical services rendered by or "on behalf of" a medical practitioner.  The latter include services where a part of the service is performed by a technician employed by or, in accordance with accepted medical practice, acting under the supervision of the medical practitioner.

The following medical services will attract benefits only if they have been personally performed by a medical practitioner on not more than one patient on the one occasion (i.e. two or more patients cannot be attended simultaneously, although patients may be seen consecutively), unless a group session is involved (i.e. Items 170‑172).  The requirement of "personal performance" is met whether or not essential assistance is provided, according to accepted medical practice:-

(a) Category 1 (Professional Attendances) items except 170‑172, 342-346, 820-880, 6029–6042, 6064-6075;

(b) Each of the following items in Group D1 (Miscellaneous Diagnostic):- 11012, 11015, 11018, 11021, 11304, 11600, 11627, 11705, 11724, 11728, 11729, 11730, 11731, 11921, 12000, 12003;

(c) All Group T1 (Miscellaneous Therapeutic) items (except 13020, 13025, 13200-13206, 13212-13221, 13703, 13706, 13750-13760, 13950, 14050, 14221 and 14245);

(d) Item 15600 in Group T2 (Radiation Oncology);

(e) All Group T3 (Therapeutic Nuclear Medicine) items;

(f) All Group T4 (Obstetrics) items (except 16400 and 16514);

(g) All Group T6 (Anaesthetics) items;

(h) All Group T7 (Regional or Field Nerve Block) items;

(i) All Group T8 (Operations) items;

(j) All Group T9 (Assistance at Operations) items;

(k) All Group T10 (Relative Value Guide for Anaesthetics) items.

For the group psychotherapy and family group therapy services covered by Items 170, 171, 172,  342, 344 and 346, benefits are payable only if the services have been conducted personally by the medical practitioner.

Medicare benefits are not payable for these group items or any of the items listed in (a) ‑ (k) above when the service is rendered by a medical practitioner employed by the proprietor of a hospital (not being a private hospital), except where the practitioner is exercising their right of private practice, or is performing a medical service outside the hospital.  For example, benefits are not paid when a hospital intern or registrar performs a service at the request of a staff specialist or visiting medical officer.

Medicare benefits are only payable for items 12306 - 12322 (Bone Densitometry) when the service is performed by a specialist or consultant physician in the practice of the specialist's or consultant physician's specialty where the patient is referred by another medical practitioner.

**GN.12.31 Services rendered on behalf of medical practitioners**

Medical services in Categories 2 and 3 not included in GN.12.30 and Category 5 (Diagnostic Imaging) services continue to attract Medicare benefits if the service is rendered by:‑

(a) the medical practitioner in whose name the service is being claimed;

(b) a person, other than a medical practitioner, who is employed by a medical practitioner or, in accordance with accepted medical practice, acts under the supervision of a medical practitioner.

See Category 6 Notes for Guidance for arrangements relating to Pathology services.

So that a service rendered by an employee or under the supervision of a medical practitioner may attract a Medicare rebate, the service must be billed in the name of the practitioner who must accept full responsibility for the service.  All practitioners should ensure they maintain adequate and contemporaneous records.  All elements of the service must be performed in accordance with accepted medical practice.

Supervision from outside of Australia is not acceptable.

While the supervising medical practitioner need not be present for the entire service, they must have a direct involvement in at least part of the service.  Although the supervision requirements will vary according to the service in question, they will, as a general rule, be satisfied where the medical practitioner has:-

(a) established consistent quality assurance procedures for the data acquisition; and

(b) personally analysed the data and written the report.

Benefits are not payable for these services when a medical practitioner refers patients to self‑employed medical or paramedical personnel, such as radiographers and audiologists, who either bill the patient or the practitioner requesting the service.

**GN.12.32 Medicare benefits and vaccinations**

Where a medical practitioner administers an injection for immunisation purposes on the medical practitioner’s own patient, Medicare benefits for that service would be payable on a consultation basis, that is, for the attendance at which the injection is given. However, the cost of the vaccine itself does not attract a Medicare rebate. The Medicare benefits arrangements cover only the professional component of the medical practitioner's service. There are some circumstances where a Medicare benefit is not payable when a medical practitioner administers an injection for immunisation purposes – please refer to example 3 below for further details.

**Example 1**

A patient presents to a GP to receive the influenza vaccination. The patient is not in the cohort of patients which is covered for the influenza vaccine under the NIP.

After taking a short patient history, the GP administers the vaccine to the patient. The GP has met the requirements of a level A consultation and claims item 3. The GP can bulk bill the patient for the cost of the MBS service and can charge a separate amount for the cost of the vaccine, which is not covered under the NIP.

If a patient presented to a GP to receive a vaccine and to enquire about a medical condition, the GP may claim the appropriate item (such as item 23).

**Example 2**

A patient presents to a GP to receive the influenza vaccination. The patient is in the cohort of patients which is covered for the influenza vaccine under the NIP.

After taking a short patient history, the GP administers the vaccine to the patient. The GP has met the requirements of a level A consultation and claims item 3. The GP can bulk bill the patient but does not need to charge a separate amount for the cost of the vaccine, which is covered under the NIP.

If a patient presented to a GP to receive a vaccine and to enquire about a medical condition, the GP may claim the appropriate item (such as item 23).

**Example 3**

A GP is employed by a State or Territory community health centre to administer vaccines and provides no additional medical services.

A Medicare benefit is not payable as the GP is providing the service under an arrangement with the State or Territory, which is prohibited under subsection 19(2) of the *Health Insurance Act 1973*. The service is also prohibited on the basis that it is a mass immunisation which is prohibited under subsection 19(4).

A mass immunisation is a program to inoculate people that is funded by the Commonwealth or State Government, or through an international or private organisation.

**GN.13.33 Services which do not attract Medicare benefits**

**Medical services that do not attract Medicare benefits**

(a) issue of repeat prescriptions when the patient does not attend the surgery in person;

(b) group attendances (unless otherwise specified in the item, such as items 170, 171, 172, 342, 344 and 346);

(c) non-therapeutic cosmetic surgery;

(d) euthanasia and any service directly related to the procedure. However, services rendered for counselling/assessment about euthanasia will attract benefits.

**Medicare benefits are not payable where the medical expenses for the service**

(a) are paid/payable to a public hospital;

(b) are for a compensable injury or illness for which the patient's insurer or compensation agency has accepted liability. (Please note that if the medical expenses relate to a compensable injury/illness for which the insurer/compensation agency is disputing liability, then Medicare benefits are payable until the liability is accepted.);

(c) are for a medical examination for the purposes of life insurance, superannuation, a provident account scheme, or admission to membership of a friendly society;

(d) are incurred in mass immunisation (see General Explanatory Note 12.3 for further explanation).

**Unless the Minister otherwise directs**

Medicare benefits are not payable where:

(a) the service is rendered by or on behalf of, or under an arrangement with the Australian Government, a State or Territory, a local government body or an authority established under Commonwealth, State or Territory law;

(b) the medical expenses are incurred by the employer of the person to whom the service is rendered;

(c) the person to whom the service is rendered is employed in an industrial undertaking and that service is rendered for the purposes related to the operation of the undertaking; or

(d) the service is a health screening service.

(e) the service is a pre-employment screening service

**Current regulations preclude the payment of Medicare benefits** for professional services rendered in relation to or in association with:

(a) chelation therapy (that is, the intravenous administration of ethylenediamine tetra-acetic acid or any of its salts) other than for the treatment of heavy-metal poisoning;

(b) the injection of human chorionic gonadotrophin in the management of obesity;

(c) the use of hyperbaric oxygen therapy in the treatment of multiple sclerosis;

(d) the removal of tattoos;

(e) the transplantation of a thoracic or abdominal organ, other than a kidney, or of a part of an organ of that kind; or the transplantation of a kidney in conjunction with the transplantation of a thoracic or other abdominal organ, or part of an organ of that kind;

(f) the removal from a cadaver of kidneys for transplantation;

(g) the administration of microwave (UHF radio wave) cancer therapy, including the intravenous injection of drugs used in the therapy.

**Pain pumps for post-operative pain management**

The cannulation and/or catheterisation of surgical sites associated with pain pumps for post-operative pain management cannot be billed under any MBS item.

The filling or re-filling of drug reservoirs of ambulatory pain pumps for post-operative pain management cannot be billed under any MBS items.

**Non Medicare Services**

No MBS item applies to a service mentioned in the item if the service is provided to a patient at the same time as, or in connection with, an injection of blood or a blood product that is autologous.

No MBS item applies to a service mentioned in the item if the service is provided to a patient at the same time as, or in connection with, the harvesting, storage, in vitro processing or injection of non‑haematopoietic stem cells.

An item in the range 1 to 10943 does not apply to the service described in that item if the service is provided at the same time as, or in connection with, any of the services specified below:

(a) endoluminal gastroplication, for the treatment of gastro-oesophageal reflux disease;

(b) gamma knife surgery;

(c) intradiscal electro thermal arthroplasty;

(d) intravascular ultrasound (except where used in conjunction with intravascular brachytherapy);

(e) intro-articular viscosupplementation, for the treatment of osteoarthritis of the knee;

(f) low intensity ultrasound treatment, for the acceleration of bone fracture healing, using a bone growth stimulator;

(g) lung volume reduction surgery, for advanced emphysema;

(h) photodynamic therapy, for skin and mucosal cancer;

(i) placement of artificial bowel sphincters, in the management of faecal incontinence;

(j) selective internal radiation therapy for any condition other than hepatic metastases that are secondary to colorectal cancer;

(k) specific mass measurement of bone alkaline phosphatase;

(l) transmyocardial laser revascularisation;

(m) vertebral axial decompression therapy, for chronic back pain;

(n) autologous chondrocyte implantation and matrix-induced autologous chondrocyte implantation;

(o) extracorporeal magnetic innervation.

**Health Screening Services**

Unless the Minister otherwise directs Medicare benefits are not payable for health screening services. A health screening service is defined as a medical examination or test that is not reasonably required for the management of the medical condition of the patient. Services covered by this proscription include such items as:

(a) multiphasic health screening;

(b) mammography screening (except as provided for in Items 59300/59303);

(c) testing of fitness to undergo physical training program, vocational activities or weight reduction programs;

(d) compulsory examinations and tests to obtain a flying, commercial driving or other licence;

(e) entrance to schools and other educational facilities;

(f) for the purposes of legal proceedings;

(g) compulsory examinations for admission to aged persons' accommodation and pathology services associated with clinical ecology.

The Minister has directed that Medicare benefits be paid for the following categories of health screening:

(a) a medical examination or test on a symptomless patient by that patient's own medical practitioner in the course of normal medical practice, to ensure the patient receives any medical advice or treatment necessary to maintain their state of health. Benefits would be payable for the attendance and tests which are considered reasonably necessary according to patients individual circumstances (such as age, physical condition, past personal and family history). For example, a cervical screening test in a person (see General Explanatory note 12.3 for more information), blood lipid estimation where a person has a family history of lipid disorder. However, such routine check-up should not necessarily be accompanied by an extensive battery of diagnostic investigations;

(b) a pathology service requested by the National Heart Foundation of Australia, Risk Evaluation Service;

(c) age or health related medical examinations to obtain or renew a licence to drive a private motor vehicle;

(d) a medical examination of, and/or blood collection from persons occupationally exposed to sexual transmission of disease, in line with conditions determined by the relevant State or Territory health authority, (one examination or collection per person per week). Benefits are not paid for pathology tests resulting from the examination or collection;

(e) a medical examination for a person as a prerequisite of that person becoming eligible to foster a child or children;

(f) a medical or optometrical examination provided to a person who is an unemployed person (as defined by the Social Security Act 1991), as the request of a prospective employer.

The National Policy for the National Cervical Screening Program (NCSP) is as follows:

(a) Cervical screening should be undertaken every five years in asymptomatic persons, using a primary human papillomavirus (HPV) test with partial genotyping and reflex liquid based cytology (LBC) triage;

(b) Persons who have ever been sexually active should commence cervical screening at 25 years of age;

(c) Persons aged 25 years or older and less than 70 years will receive invitations and reminders to participate in the program;

(d) Persons will be invited to exit the program by having a HPV test between 70 years or older and less than 75 years of age and may cease cervical screening if their test result is low risk;

(e) Persons 75 years of age or older who have either never had a cervical screening test or have not had one in the previous five years, may request a cervical screening test and can be screened;

(f)  All persons, both HPV vaccinated and unvaccinated, are included in the program;

(g) Self collection of a sample for testing is available for persons who are aged 30 years and over and has never participated in the NCSP; or is overdue for cervical screening by two years or longer.

·         Self collection must be facilitated and requested by a healthcare professional who also routinely offers cervical screening services;

·         The self collection device and the HPV test, when used together, must meet the requirements of the National Pathology Accreditation Advisory Council (NPAAC) Requirements for Laboratories Reporting Tests for the NCSP; and

(h)   Persons with intermediate and higher risk screening test results should be followed up in accordance with the cervical screening pathway and the NCSP: Guidelines for the management of screen detected abnormalities, screening women in specific populations and investigation of women with abnormal vaginal bleeding (2016 Guidelines) – endorsed by the Royal Australian College of General Practitioners, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, the Royal College of Pathologists of Australasia, the Australian Society of Gynaecologic Oncologists and the Australian Society for Colposcopy and Cervical Pathology.

Note 1: As separate items exist for routine screening, screening in specific population and investigation of persons with abnormal vaginal bleeding, treating practitioners are asked to clearly identify on the request form, if the sample is collected as part of routine screening or for another purpose (see paragraph PP.16.11 of Pathology Services Explanatory Notes in Category 6).

Note 2: Where reflex cytology is performed following the detection of HPV in routine screening, the HPV test and the LBC test results must be issued as a combined report with the overall risk rating.

Note 3: See items 2501 to 2509, and 2600 to 2616 in Group A18 and A19 of Category 1 ‑ Professional Attendances and the associated explanatory notes for these items in Category 1 - Professional Attendances.

**Services rendered to a doctor's dependants, practice partner, or practice partner's dependants**

Medicare benefits are not paid for professional services rendered by a medical practitioner to dependants or partners or a partner's dependants.

A 'dependant' person is a spouse or a child. The following provides definitions of these dependant persons:

(a) a spouse, in relation to a dependant person means:

a. a person who is legally married to, and is not living, on a permanent basis, separately and apart from, that person; and

b. a de facto spouse of that person.

(b) a child, in relation to a dependant person means:

a. a child under the age of 16 years who is in the custody, care and control of the person or the spouse of the person; and

b. a person who:

(i) has attained the age of 16 years who is in the custody, care and control of the person of the spouse of the person; or

(ii) is receiving full time education at a school, college or university; and

(iii) is not being paid a disability support pension under the Social Security Act 1991; and

(iv) is wholly or substantially dependent on the person or on the spouse of the person.

**GN.14.34 Principles of interpretation of the MBS**

Each professional service listed in the MBS is a complete medical service.  Where a listed service is also a component of a more comprehensive service covered by another item, the benefit for the latter service will cover the former.

Where a service is rendered partly by one medical practitioner and partly by another, only the one amount of benefit is payable. For example, where a radiographic examination is started by one medical practitioner and finalised by another.

**GN.14.35 Services attracting benefits on an attendance basis**

Some services are not listed in the MBS because they are regarded as forming part of a consultation or they attract benefits on an attendance basis.

**GN.14.36 Consultation and procedures rendered at the one attendance**

Where, during a single attendance, a consultation (under Category 1 of the MBS) and another medical service (under any other Category of the Schedule) occur, benefits are payable subject to certain exceptions, for both the consultation and the other service.  Benefits are not payable for the consultation in addition to an item rendered on the same occasion where the item is qualified by words such as "each attendance", "attendance at which", "including associated attendances/consultations", and all items in Group T6 and T9. In the case of radiotherapy treatment (Group T2 of Category 3) benefits are payable for both the radiotherapy and an initial referred consultation.

Where the level of benefit for an attendance depends upon the consultation time (for example, in psychiatry), the time spent in carrying out a procedure which is covered by another item in the MBS, may not be included in the consultation time.

A consultation fee may only be charged if a consultation occurs; that is, it is not expected that consultation fee will be charged on every occasion a procedure is performed.

**GN.14.37 Aggregate items**

The MBS includes a number of items which apply only in conjunction with another specified service listed in the MBS.  These items provide for the application of a fixed loading or factor to the fee and benefit for the service with which they are rendered.

When these particular procedures are rendered in conjunction, the legislation provides for the procedures to be regarded as one service and for a single patient gap to apply.  The Schedule fee for the service will be ascertained in accordance with the particular rules shown in the relevant items.

**GN.14.38 Residential aged care facility**

A residential aged care facility is defined in the *Aged Care Act 1997*; the definition includes facilities formerly known as nursing homes and hostels.

**GN.15.39 Practitioners should maintain adequate and contemporaneous records**

All practitioners who provide, or initiate, a service for which a Medicare benefit is payable, should ensure they maintain **adequate** and **contemporaneous** records.

**Note:** 'Practitioner' is defined in Section 81 of the *Health Insurance Act 1973* and includes: medical practitioners, dentists, optometrists, chiropractors, physiotherapists, podiatrists and osteopaths.

Since 1 November 1999 PSR Committees determining issues of inappropriate practice have been obliged to consider if the practitioner kept adequate and contemporaneous records.  It will be up to the peer judgement of the PSR Committee to decide if a practitioner's records meet the prescribed standards.

The standards which determine if a record is adequate and contemporaneous are prescribed in the *Health Insurance (Professional Services Review) Regulations 1999*.

To be ***adequate***, the patient or clinical record needs to:

­ clearly identify the name of the patient; and

­ contain a separate entry for each attendance by the patient for a service and the date on which the service was rendered or initiated; and

­ each entry needs to provide clinical information adequate to explain the type of service rendered or initiated; and

­ each entry needs to be sufficiently comprehensible that another practitioner, relying on the record, can effectively undertake the patient's ongoing care.

To be ***contemporaneous***, the patient or clinical record should be completed at the time that the service was rendered or initiated or as soon as practicable afterwards.  Records for hospital patients are usually kept by the hospital and the practitioner could rely on these records to document in‑patient care.

Services Australia (SA), in consultation with the Department of Health and Aged Care, has developed a [Health Practitioner Guideline to substantiate that a specific treatment was performed](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation) which is located on the Department of Health and Aged Care's website.

# CATEGORY 6: PATHOLOGY SERVICES

## SUMMARY OF CHANGES FROM 01/07/2024

The 01/07/2024 changes to the MBS are summarised below and are identified in the Schedule pages by one or more of the following words appearing above the item number:

|  |  |
| --- | --- |
| (a) new item | New |
| (b) amended description | Amend |
| (c) fee amended | Fee |
| (d) item number changed | Renum |
| (e) EMSN changed | EMSN |

**Deleted Items**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 69511 | 69512 | 69513 | 69514 | 69515 |

**New Items**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 66586 | 69421 | 69422 | 73313 | 73316 |

**Description Amended**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 73295 | 73410 | 73411 | 73412 | 73413 |

**Fee Amended**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 74990 | 74991 | 75861 | 75862 | 75863 | 75864 |

**Indexation**

From 1 July 2024, annual fee indexation will be applied to pathology items in Group P12. The MBS indexation factor for 1 July 2024 is 3.5 per cent.

**Changes to pathology services**

From 1 July 2024, the following changes will be made to pathology services under the MBS:

* New item 66586 to provide pathology testing for quantifying BNP or NT-proBNP in patients with previously diagnosed pulmonary arterial hypertension;
* Two new items (73313 and 73316) for the detection of measurable residual disease (MRD) in patients with acute lymphoblastic leukaemia (ALL) using quantitative molecular assay (qPCR);
* Amendment of pathology item 73410 to include carrier testing of individuals with normal red cell indices if their reproductive partner has been diagnosed with a heterozygous 2-gene deletional alpha thalassemia; and
* Amendment to items 73410, 73411, 73412 and 73413 to allow for testing of reproductive couples in either order.
* Two new items (69421 and 69422) for nucleic acid testing of respiratory pathogens in patients with suspected respiratory infection.
* Amendment to item 73295 for the detection of germline BRCA1 or BRCA2 gene, to enable medical practitioners to request testing for additional groups of patients.

## PATHOLOGY SERVICES NOTES

**PN.0.1 Changes to the Pathology Services Table**

**Health Insurance Regulations**

The *Health Insurance Act 1973* allows the Minister for Health to determine an appropriate Pathology Services Table which is then prescribed by Regulation.

Pathology submissions relating to new medical services and technologies should be submitted to the Medical Services Advisory Committee (MSAC).  MSAC has been established to advise the Minister on the strength of evidence pertaining to new and emerging medical technologies and procedures in relation to their safety, effectiveness and cost effectiveness, and under what circumstances public funding should be supported. Details of how to submit an application to MSAC and guidelines for applying can be found on MSAC's website - [www.msac.gov.au.](http://www.msac.gov.au/internet/msac/publishing.nsf/Content/Home-1)

**PN.0.2 Explanatory Notes - Definitions**

**Excessive Pathology Service**

This means a pathology service for which a Medicare benefit has become or may become payable and which is not reasonably necessary for the adequate medical or dental care of the patient concerned.

**PN.0.3 Group of Practitioners**

This means:

(i)         a practitioner conducting a medical practice or a dental practice, or a participating nurse practitioner practice, or a participating midwife practice together with another practitioner, or other practitioners, participating (whether as employees or otherwise) in the provision of professional services as part of that practice; or

(ii)        two or more practitioners conducting a medical practice or a dental practice, or a participating nurse practitioner practice, or a participating midwife practice as partners; or

(iii)       those partners together with any other practitioner who participates (whether as an employee or otherwise) in the provision of professional services as part of that practice.

**PN.0.4 Initiate**

In relation to a pathology service this means to request the provision of pathology services for a patient.

**PN.0.5 Patient Episode**

A patient episode comprises a pathology service or services specified in one or more items which are provided for a single patient, the need for which was determined under subsection 16A(1) of the Act on the same day, whether they were provided by one or more approved pathology practitioners on one day or over several days and whether they are requested by one or more treating practitioners.  Even if a treating practitioner writes separate request forms to cover the collection of specimens at different times, where the decision to collect the multiple specimens was made at the same time, the multiple tests are deemed to belong to the same patient episode.  In addition, if more than one request is made, on the same or different days, for tests on the same specimen within 14 days, they are part of the same patient episode.

Rule 4 of the Pathology Services Table provides an exemption to the above and enables services requested on one day which are performed under strictly limited circumstances for seriously or chronically ill patients with certain specified conditions to each be classified as a patient episode.  See PN.0.33 and PN.1.2 for further information on exemptions.

Rule 14.(8) also provides that only a single patient episode initiation fee will be payable for all the specimens collected on one day from one patient in or by one Approved Pathology Authority.

**PN.0.7 Personal Supervision**

This means that an Approved Pathology Practitioner will, to the fullest extent possible, be responsible for exercising an acceptable level of control over the rendering of pathology services. See PN.13.1, PN.13.2 and PN.13.3 for a full description of the responsibilities involved in personal supervision.

**PN.0.8 Prescribed Pathology Service**

These are simple basic pathology services which are included in Group P9 and may be performed by a medical practitioner in the practitioner's surgery without the need to obtain Approved Pathology Authority, Approved Pathology Practitioner or Accredited Pathology Laboratory status.

**PN.0.9 Proprietor of a Laboratory**

This means in relation to a pathology laboratory the person, authority or body of persons having effective control of:

(i)         the laboratory premises, whether or not the holder of an estate or interest in the premises;

(ii)        the use of equipment used in the laboratory; and

(iii)       the employment of staff in the laboratory.

**PN.0.10 Specialist Pathologist**

This means a medical practitioner recognised for the purposes of the *Health Insurance Act 1973* as a specialist in pathology (see GN.5.14).  The principal specialty of pathology includes a number of sectional specialties.  Accordingly, a medical practitioner who is recognised as a specialist in a sectional specialty of pathology is recognised as a specialist pathologist for this purpose.

**PN.0.11 Designated Pathology Service**

This means a pathology service specified in items 65150, 65175 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165.  Where one Approved Pathology Practitioner in an Approved Pathology Authority has performed some but not all the estimations in a coned item and has requested another Approved Pathology Practitioner in another Approved Pathology Authority to do the rest, the service provided by the second practitioner is deemed to be the "designated pathology service".  Thus the first practitioner claims under the appropriate item for the services which he/she provides while the second practitioner claims one of items 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165.  Where one Approved Pathology Practitioner in an Approved Pathology Authority has performed some, but not all estimations and has requested another Approved Pathology Practitioner in another Approved Pathology Authority to do the remainder, the first Approved Pathology Practitioner can raise a "patient episode initiation fee". The second Approved Pathology Practitioner who receives the specimen can raise a "specimen referred fee".

**PN.0.12 Interpretation of The Schedule - Items Referring to 'The Detection Of'**

Items that contain the term 'detection of' should be taken to mean 'testing for the presence of'.

**PN.0.13 Blood Grouping - (Item 65096)**

Where a request includes 'Group and Hold' or 'Group and Save', the appropriate item is 65096.

**PN.0.14 Glycosylated Haemoglobin - (Item 66551)**

The requirement of "established diabetes" in this item may be satisfied by:

(a)              a statement of the diagnosis by the ordering practitioner on the current request form or on a previous request form held in the database of the Approved Pathology Authority; or

(b)              two or more blood glucose levels that are in the diabetic range and is contained in the database of the Approved Pathology Authority; or

(c)              an oral glucose tolerance test result that is in the diabetic range and is contained in the database of the Approved Pathology Authority.

**PN.0.15 Iron Studies - (Item 66596)**

Where a request includes 'Iron Studies', 'IS', 'Fe', '% saturation' or 'Iron', the relevant item is 66596.

**PN.0.17 Antibiotics/Antimicrobial Chemotherapeutic Agents**

A test for the quantitation of antibiotics/antimicrobial chemotherapeutic agents is claimable under item 66800 or 66812 - 'quantitation of a drug being used therapeutically'.

**PN.0.18 Human Immunodeficiency Virus (HIV) Diagnostic Tests - (included in Items 69384, 69387, 69390, 69393, 69396, 69405, 69408, 69411, 69413 and 69415)**

Prior to ordering an HIV diagnostics tests (included in items 69384, 69387, 69390, 69393, 69396, 69405, 69408, 69411, 69413, 69415) the ordering practitioner should ensure that the patient has given informed consent.  Appropriate discussion should be provided to the patient.  Further discussion may be necessary upon receipt of the test results.

**PN.0.19 Hepatitis - (Item 69481)**

Benefits for item 69481 are payable only if the request from the ordering practitioner indicates in writing that the patient is suspected of suffering from acute or chronic hepatitis; either by the use of the provisional diagnosis of hepatitis or by relevant clinical or laboratory information eg "hepatomegaly", "jaundice" or "abnormal liver function tests".

**PN.0.20 Eosinophil Cationic Protein - (Item 71095)**

Item 71095 applies to children aged less than 12 years who cannot be reliably monitored by spirometry or flowmeter readings.

**PN.0.21 Tissue Pathology and Cytology - (Items 72813 to 73061)**

When services described in Group P5 need to be performed upon material which is submitted for cytology items listed in Group P6 only the fee for the P6 item can be claimed.

**PN.0.22 Cervical and Vaginal Screening - (Items 73070 to 73076)**

It is the responsibility of the treating healthcare practitioner to determine if the sample is being collected as part of the routine screening program under 73070 or 73071 or represents a sample falling under 73072 or 73074 or 73075 or 73076, and to indicate this on the request form.  Unless a co-test is specifically requested, requiring the pathology laboratory to perform both a human papillomavirus (HPV) test and a liquid based cytology (LBC) test on the same specimen, for a clinician-collected sample, the pathology laboratory will by default perform an HPV test and then only undertake reflex LBC testing if oncogenic HPV (any type) is detected.  The pathology laboratory will issue the HPV test result, the LBC test result and overall screening risk rating as a combined report as prescribed by the National Pathology Accreditation Advisory Council (NPAAC) Requirements for Laboratories reporting tests for the National Cervical Screening Program (NPAAC Requirements).

The test used for detecting oncogenic HPV must allow partial HPV genotyping to identify HPV16, HPV18 with or without HPV45 as well as meet the criteria for a population based screening test as prescribed by the NPAAC Requirements.

When used together, the self-collection device and the HPV test must meet the NPAAC Requirements, including the HPV test must be a polymerase chain reaction (PCR) test.

73070 applies to an HPV test on a cervical specimen for primary screening purposes and collected by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner). 73071 applies to HPV tests for primary screening purposes requested by a healthcare practitioner (or an accredited test provider under the supervision of a healthcare practitioner) on a self-collected vaginal specimen. Tests for both 73070 and 73071 must be from an asymptomatic patient as part of routine five yearly screening recommended by the National Cervical Screening Program.  The *Health Insurance Act 1973* excludes payment of Medicare Benefits for health screening services except where Ministerial directions have been issued to enable benefits to be paid, this includes HPV testing that is performed in accordance with the policy of the National Cervical Screening Program (available at https://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program).  This policy provides for a screening interval of five years for an asymptomatic patient commencing at 24 years and 9 months of age and for a patient aged between 70 to 74 years of age to cease cervical screening if the last test result is normal (i.e. low risk).  A patient aged 75 years of age or older who has never had a cervical screening test or has not had one in the previous five years, may request a cervical screening test and be screened.

In accordance with the national policy for the National Cervical Screening Program, where oncogenic HPV (any type) is detected from a sample collected by a healthcare practitioner (73070), the pathology laboratory will conduct  reflex LBC automatically under 73076 (a) without requiring an additional request by the treating healthcare professional. Where oncogenic HPV (non 16/18) is detected from a self-collected vaginal sample (73071), the participant will need to return to their healthcare practitioner for the collection of a cervical sample for LBC. The healthcare practitioner collected liquid based sample from the cervix that follows, can be claimed under 73076 (a) with a further request by the treating healthcare practitioner.

73072 applies to HPV tests where the specimen has been collected in accordance with the National Cervical Screening Program: Guidelines for the Management of Screen Detected Abnormalities, Screening in Specific Populations and Investigation of Abnormal Vaginal Bleeding (NCSP Clinical Guidelines) which provides for:

(a)           an HPV test performed on a patient within a specific population suggestive of a higher risk of pre cancerous or cancerous cervical changes. HPV tests carried out in specific populations under Item 73072 should be in accordance with the NCSP Clinical Guidelines including:

(i)            screening with a primary HPV test every 3 years for an immune-deficient patient; or

(ii)           a single HPV test between 20 and 24 years of age could be considered by healthcare practitioners on a case by case basis for a patient who experienced first sexual activity at a young age (less than 14 years of age) and who has not received the HPV vaccine before sexual debut; or

(b)           an HPV test performed for the follow up management of previously detected oncogenic HPV infection; or

(c)           a co-test (HPV+LBC) for the investigation of symptoms of cervical cancer, most commonly abnormal vaginal bleeding; or

(d)           co-test (HPV+LBC) for the management of a patient following treatment of high grade squamous intraepithelial lesions (HSIL) of the cervix as part of a ‘test of cure’ process performed at 12 months after treatment and annually thereafter, until receiving a negative co-test on two separate consecutive occasions, then the patient can return to routine five yearly screening. In accordance with the NCSP Clinical Guidelines this also applies to a patient undergoing follow up or post-treatment for a glandular abnormality as part of annual surveillance performed indefinitely; or

(e)           a co-test (HPV+LBC) for the follow up management of glandular abnormalities; or

(f)            a co-test (HPV+LBC) for screening a patient exposed to diethylstilbestrol (DES) in utero and daughters of patients exposed to DES in utero, if requested; or

(g)           a co-test (HPV+LBC) for a patient previously treated for a genital tract malignancy.

A co-test requires both HPV and LBC tests to be performed irrespective of the HPV test result and so must be performed on a clinician collected cervical sample. In other HPV tests, LBC is only required if oncogenic HPV (any type) is detected; where oncogenic HPV (any type) has been detected in a liquid based sample from the cervix by a healthcare professional, the pathology laboratory will conduct LBC automatically without requiring an additional request. It is the intention of the National Cervical Screening Program where a co-test is requested or oncogenic HPV has previously been detected under this item, the LBC can be claimed under 73076 without requiring an additional request by the treating healthcare professional.

73074 applies to an HPV test on a vaginal vault specimen from a patient with past history of total hysterectomy, in accordance with the NCSP Clinical Guidelines which provides for:

(a)           an HPV test for a patient who has no evidence of cervical pathology and the patient’s screening history is not available, performed at 12 months following a total hysterectomy and annually thereafter until a patient has two negative HPV tests (i.e. oncogenic HPV not detected) on two separate consecutive occasions and can be advised that no further testing is required; or

(b)           a co-test (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months following a total hysterectomy and annually thereafter until two consecutive co-tests are negative:

(i)            if unexpected LSIL or HSIL is identified in the cervix at the time of total hysterectomy after completed ‘test of cure’ process; or

(ii)           if the total hysterectomy was for treatment of high-grade cervical intraepithelial neoplasia in the presence of benign gynaecological disease; or

(iii)          if the total hysterectomy was after histologically confirmed HSIL without Test of Cure and there is no cervical pathology; or

(c)           indefinite co-testing (HPV+LBC) for a patient who has had a total hysterectomy, performed at 12 months after treatment and annually thereafter if the total hysterectomy was after adenocarcinoma in situ (AIS).

73075 applies to HPV tests repeated due to an unsatisfactory HPV test under 73070 or 73071 or 73072 or 73074.

73076 applies to a liquid-based cytology (LBC) test on a cervical or vaginal vault specimen:

(a)           as part of a reflex test following detection of oncogenic HPV described in the national policy and NCSP Clinical Guidelines associated with items 73070 or  73071 or 73072  (a) or (b) or 73074 or 73075; or

(b)           as part of a co-test described in the national policy and NCSP Clinical Guidelines under 73072 (c) or (d) or (e) of (f) or 73074; or

(c)           where the previous specimen collected is unsatisfactory; or

(d)           for the follow up management of a patient with a past history of total hysterectomy for endometrial adenocarcinoma.

**PN.0.23 Informed consent and genetic counselling for genetic tests**

Items 73297, 73300, 73305, 73334, 73339, 73340, 73393, 73394, 73417, 73418, 73440, 73441, 73442, 73443, and 73444

Prior to ordering these tests the ordering practitioner should ensure the patient (or approximate proxy) has given written informed consent. Testing should only be performed after genetic counselling. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral. Further counselling may be necessary upon receipt of the test results.

Items 73295, 73296, 73304, 73333, 73392, 73395, 73416 and 73419

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

**PN.0.24 Additional Bulk Billing Payment for Pathology Services**

Additional Bulk Billing Payment for Pathology Services - (Item 74990, 74991, 75861, 75862, 75863 and 75864)

The Additional Bulk Billing Payment for Pathology Services operates in the same way as the equivalent items for unreferred medical services (see note MN.1.1), apart from the following differences:

* Item 74990 and 74991 can only be used in conjunction with items in the Pathology Services Table of the MBS
* Item 74990 and 74991 applies to unreferred pathology services performed by a medical practitioner which are included in Group P9 of  the Pathology Services Table, and unreferred pathology services provided by category M laboratories
* Item 74990 and item 74991 applies to pathology services self determined by general practitioners and specialists with dual qualifications acting in their capacity as general practitioners.

Specialists and consultant physicians who provide pathology services are not able to claim the Additional Bulk Billing Payment unless, for the purposes of the *Health Insurance Act 1973*, the medical practitioner is also a general practitioner and the service provided by the medical practitioner has not been referred to that practitioner by another medical practitioner or person with referring rights.

The pathology rules (see note PN.0.33) have been amended to exclude the Additional Bulk Billing Payment items from the Multiple Services Rule and the Coning Rule.

Item 74991 can only be used where the service is provided at, or from, a practice location that is in a MMM 2 area under the Modified Monash Model classification system

Item 75861 can only be used where the service is provided at, or from, a practice location that is in a MMM 3 or 4 area under the Modified Monash Model classification system

Item 75862 can only be used where the service is provided at, or from, a practice location that is in a MMM 5 area under the Modified Monash Model classification system

Item 75863 can only be used where the service is provided at, or from, a practice location that is in a MMM 6 area under the Modified Monash Model classification system

Item 75864 can only be used where the service is provided at, or from, a practice location that is in an MMM 7 area under the Modified Monash Model classification system.

**PN.0.25 Transfer of Existing Items from Group P1 (Haematology) to Group P7 Genetics Effective 1 May 2006.**

PN.0.25 has been created to note the transfer of existing items from Group P1 (Haematology) items 65168, 65174, 65200 and item 66794 from Group P2 (Chemistry) to Group P7 (Genetics) as items 73308, 73311, 73314, 73317 and the introduction of the new item in Group P7 (Genetics) item 73320 HLA-B27 typing by nucleic acid amplification (NAA) which was effective as of 1 May 2006.

**PN.0.26 RAS gene mutation status (Item 73338)**

Item 73338 provides for testing of RAS mutations to limit subsidy of anti-EGFR antibodies to only those patients demonstrated to have no RAS mutations.

For a Medicare benefit to be payable, the test must be conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3 and 4, or until a RAS mutation is found.

Enabling the requirements of the item descriptor to be met once any RAS mutation is found means that once the test indicates that the patient is not RAS wild-type and therefore not suitable for access to cetuximab and panitumumab under the PBS, a pathologist is not required to continue testing for other clinically relevant mutations.

**PN.0.27 Germline gene mutation tests (Items 73416 and 73392)**

**Genomic testing methods for future re-analysis**

Items 73416 and 73392

The rapidly expanding field of genomic medicine has resulted in recognition of an increasing number of genetic causes of cardiac diseases. Use of genomic testing methods that permit reanalysis of existing data for variants in newly described clinically relevant genes are recommended/encouraged.

**PN.0.28 Abbreviations, Groups of Tests**

As stated at PN.3.2, details that must be recorded on accounts, receipts or assignment forms of an Approved Pathology Practitioner/Authority include a description of the pathology service that is of sufficient detail to identify the specific service rendered. The lists of abbreviations for group tests are contained in PN.0.31.  The abbreviations are provided to allow users to identify and refer to particular pathology services, or particular groups of pathology services, more accurately and conveniently.

The above requirements may be used for billing purposes but treating practitioners requesting pathology services are encouraged to use the approved abbreviations. In this regard treating practitioners should note that:

-                  pathology services cannot be self determined by a rendering pathologist responding to a request. This places the onus for medical necessity on the treating practitioner who, in normal circumstances would, if he or she was unclear in deciding the appropriate test for a clinical situation, consult a pathologist for assistance; and

-                  Approved Pathology Practitioners/Authorities undertake not to issue accounts etc unless the pathology service was rendered in response to an unambiguous request.

**PN.0.29 Tests not Listed**

Tests which are not listed in the Pathology Services Table do not attract Medicare benefits. As explained in PN.0.1, changes to the Pathology Services Table can only be made by the Minister for Health and Aged Care.

**PN.0.30 Audit of Claims**

Services Australia is undertaking routine audits of claims for pathology benefits against requested services to ensure compliance with the provisions of the *Health Insurance Act 1973*.

**PN.0.31 Groups of Tests**

For the purposes of recording a description of the pathology service on accounts etc, an Approved Pathology Practitioner /Authority may use group abbreviations or group descriptions for the following specified groups of tests. These groups consist of two or more tests within the same item. These groups exclude abbreviations such as MBA and TORCH.

Treating practitioners are encouraged to use these group abbreviations or group descriptions where appropriate.

For ease of identification of group tests, it is recommended that practitioners use the following abbreviations. Tests requested individually may attract Medicare benefits.

| **Group** | **Estimations included in Group** | **Group Abbreviation** | **Item Numbers** |
| --- | --- | --- | --- |
| Cardiac enzymes or cardiac markers | Creatine kinase isoemzymes, Myoglobin, Troponin | CE / CM | 66518, 66519 |
| Coagulation studies | Full blood count, Prothrombin time, Activated partial thromboplastin time and two or more of the following tests - Fibrinogen, Thrombin, Clotting time, Fibrinogen degradation products, Fibrin monomer, D-dimer factor XIII screening tests | COAG | 65129, 65070 |
| Electrolytes | Sodium (NA), Potassium (K), Chloride (CL) and Bicarbonate (HCO3) | E | 66509 |
| Full Blood Examination | Erythrocyte count, Haematocrit, Haemoglobin, Platelet count, Red cell count, Leucocyte count, Manual or instrument generated differential, Morphological assessment of blood film where appropriate | FBE, FBC, CBC | 65070 |
| Lipid studies | Cholesterol (CHOL) and Triglycerides (TRIG) | FATS | 66503 |
| Liver function tests | Alkaline phosphatase (ALP),  Alanine aminotransferase (ALT),  Aspartate aminotransferase (AST),  Albumin (ALB), Bilirubin (BIL),  Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH), and  Protein (PROT) | LFT | 66512 |
| Syphilis serology | Rapid plasma regain test (RPR), or  Venereal disease research laboratory test (VDRL), and Treponema pallidum haemagglutination test (TPHA), or Fluorescent treponemal antibody-absorption test (FTA) | STS | 69387 |
| Urea, Electrolytes, Creatinine | Urea, Electrolytes, Creatinine | U&E | 66512 |

**PN.0.32 Complexity Levels for Histopathology Items**

Only one of these histopathology examination items (72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838) can be claimed in a patient episode.

The remaining items (72844, 72846, 72847, 72848, 72849, 72850, 72851, 72852, 72855, 72856 and 72857) are add-on items, covering enzyme histochemistry and immunohistochemistry, electron microscopy and frozen sections, which can be claimed in addition to the main item.

The list of complexity levels by type of specimen are contained at the back of this Section.

**PN.0.33 Pathology Services Table**

**Rules for the Interpretation of the Pathology Services Table**

Please note that in the Health Insurance (Pathology Services Table) Regulations 2020 rules and sub-rules are referred to as clauses and sub-clauses.  In addition in the Regulations a rule that refers to specific items within a pathology group, for example Group P1 Haemotology, is listed directly above the Schedule of Services for that group.  A table cross referencing the following rules with the clauses in the Regulations is at the end of this section.

**1. (1)**          In this table

***patient episode*** means:

(a) a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:

(i)      on the same day; or

(ii)     if more than 1 test is performed on the 1 specimen within 14 days ‑ on the same or different days;

whether the services:

(iii)       are requested by 1 or more practitioners; or

(iv)       are described in a single item or in more than 1 item; or

(v)        are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or

(vi)       are rendered on the same or different days; or

(b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

***receiving APP*** means an approved pathology practitioner in an approved pathology authority who performs one or more pathology services in respect of a single patient episode following receipt of a request for those services from a referring APP.

***recognised pathologist*** means a medical practitioner recognised as a specialist in pathology by a determination under section 3D, 3DB or 3E of the Act.

***referring APP*** means an approved pathology practitioner in an approved pathology authority who:

(i) has been requested to render 1 or more pathology services, all of which are requested in a single patient episode; and

(ii) is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the pathology services; and

(iii) requests an approved pathology practitioner (the ***receiving APP***) in another approved pathology authority to render the pathology service or services that the referring APP is unable to render; and

(iv) renders each pathology service (if any) included in that patient episode, other than the pathology service or services in respect of which the request mentioned in subparagraph (iii) is made.

***serial examinations*** means a series of examinations requested on 1 occasion whether or not:

(a) the materials are received on different days by the approved pathology practitioner; or

(b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

***the* Act** means the *Health Insurance Act 1973.*

**1. (2)**          In these rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist‑determinable service to which subsection 16A (6) of the Act applies.

**1. (3)**          A reference in this table by number to an item that is not included in this table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.

**1. (4)**          A reference to a **Group** in the table includes every item in the Group and a reference to a **Subgroup** in the table includes every item in the Subgroup.

**Precedence of items**

**2. (1)**          If a service is described:

(a) in an item in general terms; and

(b) in another item in specific terms;

only the item that describes the service in specific terms applies to the service.

**2. (2)**          Subject to subrule (3), if:

(a) subrule (1) does not apply; and

(b) a service is described in 2 or more items;

only the item that provides the lower or lowest fee for the service applies to the service.

**2. (3)**          If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first‑mentioned item, whether or not the services described in the 2 items are requested separately.

**Application of Additional Bulk Billing Payment for Pathology Services (items 74990, 74991, 75861, 75862, 75863 and 75864)**

**2. (4)** Despite subrules (1), (2) and (3):

(a) if an Additional Bulk Billing Payment item applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in the table that applies to the service.

**2. (5)** For the Additional Bulk Billing Payment for Pathology Services:

***bulk-billed***, in relation to a pathology service, means:

(a) a medicare benefit is payable to a person in respect of the service; and

(b) under an agreement entered into under section 20A of the Act:

(i)      the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and

(ii)     the practitioner accepts the assignment in full payment of his or her fee for the service provided.

***Concessional beneficiary*** means a person who is a concessional beneficiary within the meaning given by subsection 84(1) of the *National Health Act 1953*.

***unreferred service*** means a pathology service that:

(a) is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and

(b) has not been referred to the medical practitioner by another medical practitioner or person with referring rights.

**2. (6)**      For items 74991, 75861, 75862, 75863 and 75864:

***practice location***, in relation to the provision of a pathology service, means the place of practice in respect of which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Commission.

**Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request**

**3. (1)**          In subrule 3(2), ***service***  includes assay, estimation and test.

**3. (2)**          Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

(a) the services are listed in the same item; and

(ab)  that item is not item 74990, 74991, 75861, 75862, 75863 or 75864; and

(b)    the patient's need for the services was determined  under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one  day.

**Services to which rule 3 does not apply**

**4. (1)**          Rule 3 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153, 65156, 66500, 66503, 66506, 66509, 66512, 66584 or 66800, if:

(a) the service is rendered in relation to one or more specimens taken on each of not more than 6 separate occasions in a period of 24 hours; and

(b) the service is rendered to an inpatient in a hospital; and

(c)  each service must be rendered as soon as possible after collection and after authorization of the result of the previous specimen; and

(d) the account for the service is endorsed 'Rule 3 Exemption'.

**4. (2)**          Rule 3 does not apply to any of the following pathology services:

(a) estimation of prothrombin time (INR) in respect of a patient undergoing anticoagulant therapy;

(b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;

(c)  a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

(d) a service described in item 65070 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient;

(e)  a service described in item 66500 - 66512 in relation to methotrexate or leflunomide therapy of a patient;

(f)  quantitative estimation of urea, creatinine and electrolytes in relation to:

(i)   cis‑platinum or cyclosporin therapy of a patient; or

(ii)  chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;

(g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;

(h) quantitative estimation of calcium, phosphate, magnesium, urea, creatinine and electrolytes in cancer patients receiving bisphosphonate infusions.

                   if:

(i)   under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and

(ii)  the tests are performed within 6 months of the request; and

(iii) the account for the service is endorsed "Rule 3 Exemption".

**4. (3)** Rule 3 does not apply to a pathology service described in items 65109 or 65110 if:

(a) The service is rendered on not more than 5 separate occasions in the case of item 65109 and 2 separate occasions in the case of item 65110 in a period of 24 hours; and

(b) The service is rendered in response to a written request separated in time from the previous request; and

(c) The account for the service is endorsed "Rule 3 Exemption".

**Item taken to refer only to the first service of a particular kind**

**5. (1)**          For an item in Group P1 (Haematology):

(a) if pathology services of a kind referred to in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

(b) if:

(i)      tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out in relation to a patient episode; and

(ii)     specimen material from the patient episode is stored; and

(iii)    in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 and 65108) are carried out on the stored material; the later tests and the earlier tests are taken to be part of one patient episode.

**5. (2)**          Benefits for items 65102 and 65108 are payable only if a minimum of 6 units are issued for the patient's care in any 1 day.

**5.(3)**           For items 65099 and 65102:

***compatibility tests by crossmatch*** means that, in addition to all the tests described in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by 1 or more accepted crossmatching techniques.

**Certain items not to apply to a service referred by one pathology practitioner to another**

**6. (1)**      In this rule:

***designated pathology service*** means a pathology service in respect of tests relating to a single patient episode that are tests of the kind described in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165.

**6. (2)**      This rule applies in respect of a designated pathology service where:

               (a)          an approved pathology practitioner ***(practitioner A)*** in an approved pathology authority:

(i)                has been requested to render the designated pathology service; and

(ii)               is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the tests included in the service; and

(iii)              requests an approved pathology practitioner ***(practitioner B)*** in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

(iv)              renders each test (if any) included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

(b)            the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 65156, 65179, 66653, 66712, 66734, 66788, 66806, 66815, 66822, 66828,  69496, 71093, 71159 or 71168.

**6. (3)**      If this rule applies in respect of a designated pathology service:

(a)            item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 71165, 71166 or 71167 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

(b)            where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) and:

(i)              practitioner A has rendered one or more of the tests that the service comprises - subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each test that the service comprises; or

                              (ii)          practitioner A has not rendered any of the tests that the service comprises -

(A)  the amount specified in item 65157, 65180, 66651, 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case requires) shall be taken to be the fee for the first test that the service comprises; and

(B)  subject to subrule (4), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case requires) shall be taken to be the fee for each subsequent test that the service comprises.

**6. (4)**      For paragraph (3) (b), the maximum number of tests to which item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 applies is:

(a)         for item 66652, 66715, 66790, 66817, 66821 or 66827:

2 - X; and

               (b)          for item 65158, 66805, 69498 or 71092:

3 - X; and

               (c)          for item 71156 or 71170:

4 - X; and

               (d)          for item 65181 or 66724:

5 - X; and

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

**6. (5)**      Items in Group P10 (Patient episode initiation) do not apply to the second mentioned approved pathology practitioner in subrule (2).

**Items not to be split**

**7.** Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

**Creatinine ratios - Group P2 (chemical)**

**8.** A pathology service mentioned in an item (except item 66500) in Group P2 (chemical) that:

(a) involves the measurement of a substance in urine; and

(b) requires calculation of a substance/creatinine ratio;

                   is taken to include the measurement of creatinine necessary for the calculation.

**Thyroid function testing**

**9. (1)**          For item 66719:

***abnormal level of TSH*** means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

**9. (2)**          Except where paragraph (a) of item 66719 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

**9. (3)** The written statement from the medical practitioner must indicate:

(a) that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66719; or

(b) that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

(c) that the patient is on drugs that interfere with thyroid hormone metabolism or function.

**Meaning of "serial examinations or cultures"**

**10.**             For an item in Group P3 (Microbiology):

(a) ***serial examinations or cultures*** means a series of examinations or cultures requested on 1 occasion whether or not:

(i)   the materials are received on different days by the approved pathology practitioner; or

(ii)  the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

(b)      if:

(i)   tests are carried out in relation to a patient episode; and

(ii)  specimen material from the patient episode is stored; and

(iii)in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

the later tests and the earlier tests are taken to be part of one patient episode.

**Investigation for hepatitis serology**

**11.**             A medicare benefit is not payable in respect of more than one of items 69475, 69478 and 69481 in a patient episode.

**Tests in Group P4 (Immunology) relating to antibodies**

**12.**             For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

(a) tests are carried out in relation to a patient episode; and

(b) specimen material from the patient episode is stored; and

(c)  in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

                   the later tests and the earlier tests are taken to be part of one patient episode.

**Tests on biopsy material ‑ Group P5 (Tissue pathology) and Group P6 (Cytology)**

**13. (1)**       For items in Group P5 (Tissue pathology):

(a) ***biopsy material*** means all tissue received by the Approved Pathology Practitioner:

(i)   from a medical procedure or group of medical procedures performed on a patient at the same time; or

(ii)  after being expelled spontaneously from a patient.

(b) ***cytology*** means microscopic examination of 1 or  more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal,  abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate; and

(c)  ***separately identified specimen*** means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

**13. (2)**       For Groups P5 and P6 of the pathology services table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

**13. (3)** For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

**13.(4)** If more than 1 of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 are performed in a single patient episode, only the fee for  the item performed having the highest specified fee is applicable to the services.

**13.(5)**        If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, a medicare benefit is payable only for the examination that has the highest schedule fee.

**13.(6)** In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 a reference to a ***complexity level*** is a reference to the level given to a specimen type mentioned in Part 4 of this Table.

**13.(7)** If more than 1 of the services mentioned in items 72846, 72847, 72848; 72849 and 72850 or 73059, 73060, 73061, 73064 and 73065 are performed in a single patient episode, a medicare benefit is payable only for the item performed that has the highest scheduled fee.

**13.(8)**        If more than 1 of the services mentioned in items 73049, 73051, 73062, 73063, 73066 and 73067 are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.

**Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances**

**14. (1)** For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

***approved collection centre*** has the same meaning as in Part IIA of the Act.

***institution*** means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

(a) disadvantaged children; or

(b) juvenile offenders; or

(c)  aged persons; or

(d) chronically ill psychiatric patients; or

(e)  homeless persons; or

(f)  unemployed persons; or

(g)  persons suffering from alcoholism; or

(h) persons addicted to drugs; or

(i)   physically or mentally handicapped persons;

but does not include:

(j)  a hospital; or

(k) a residential aged care home; or

(l)   accommodation for aged persons that is attached to a residential aged care home or situated within a residential aged care home.

***prescribed laboratory*** means a laboratory operated by:

(a) the Australian Government; or

(b) an authority of the Commonwealth; or

(c)  a State or internal Territory; or

(d) an authority of a State or internal Territory; or

(e)  an Australian tertiary education institution.

**s*pecimen collection centre*** has the same meaning as in Part IIA of the Act.

***treating practitioner*** has the same meaning as in paragraph 16A(1)(a) of the Act.

**14. (2)**       If a service described in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

(a) the service is rendered upon a request made in the course of a service provided to a public patient in a recognised hospital or when attending an outpatient service of a recognised hospital.

**14. (3)** An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A(7) of the Act applies.

**14. (4)**       An item in Group P10 or P11 does not apply to a pathology service unless at least 1 item in Groups P1 to P8 also applies to the service.

**14. (5)**       Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

**14. (6)** An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

**14. (7)**       If, in respect of the same patient episode:

(a) services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or

(b) services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in the laboratory of another approved pathology authority;

the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

**14. (8)**       If more than one specimen is collected from a person on the same day for the provision of pathology services:

(a) in accordance with more than 1 request; and

(b) in or by a single approved pathology authority;

                   the fee specified in the applicable item in Group P10 applies once only to the services unless an exemption listed in Rule 4 applies or an exemption has been granted under Rule 3 "S4B(3)".

**14. (9)**       The amount specified in item 73940 is payable only once in respect of a single patient episode.

**Application of an item in Group P11 (Specimen referred) to a service excludes certain other items**

**15.**             If item 73940 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73940 in respect of the patient episode.

**Circumstances in which an item in Group P11 (Specimen referred) does not apply**

**16. (1)**          An item in Group P11 does not apply to a referral if:

(a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

(b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

**16. (2)**       An approved pathology authority is ***related to*** another approved pathology authority for subrule (1) if:

(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or

(c)  both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Act; or

(d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities; or

(e)  both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or

(f)  both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.

**16. (3)**       An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are referred in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66536, 66596, 69300, 69303, 69333 or 73527.

**Abbreviations**

**17. (1)**       The abbreviations in Part 4 of this table may be used to identify particular pathology services or groups of pathology services.

**17. (2)**       The names of services or drugs not listed in Part 4 of this table must be written in full.

Certain pathology services to be treated as 1 service

18. (1)       In this rule:

***general practitioner*** means a medical practitioner who:

                     (a)    is not a consultant physician in any specialty; and

                     (b)    is not a specialist in any specialty.

***set of pathology services*** means a group of pathology services:

                     (a)    that consists of services that are described in at least 4 different items; and

                     (b)    all of which are requested in a single patient episode; and

                      (c)    each of which relates to a patient who is not an admitted patient of a hospital; and

                     (d)    excludes services referred to in an item in Group P10, Group P11, Group P12 or

Group P13, items 66900, 69484, 73070, 73071, 73072, 73074, 73075 or 73076; and

                      (e)    excludes services described in the following items:  
  
65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66610, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 66832, 66834, 66837, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69451, 69500, 69484, 69489, 69492, 69497, 69498, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318, 73321 and 73324;  
  
where those services are performed by an approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority following referral by another approved pathology practitioner in an accredited pathology laboratory of an approved pathology authority which is not **related to** the first mentioned approved pathology authority.

          (1A)            An approved pathology authority is **related to** another approved pathology authority for the purposes of paragraph 18(1)(e) if that approved pathology authority would be related to the other approved pathology authority for the purposes of rule 16(2).

**18. (2)**   If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

**18. (3)**   If the fee specified in 1 item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

                     (a)    the pathology service described in the first‑mentioned item is to be treated as 1 pathology service; and

                     (b)    either:

                                   (i)         the pathology service in the set that is described in the item that specifies the second‑highest fee is to be treated as 1 pathology service; or

                                  (ii)         if 2 or more items that describe any of those services specify the second‑highest fee¿ the pathology service described in the item that specifies the second‑highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

                      (c)    the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

**18. (4)**   If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

                     (a)    the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as 1 pathology service; and

                     (b)    the pathology service in the set that is described in the item that specifies the highest fee, and has the second‑lowest item number, is to be treated as 1 pathology service; and

                      (c)    the pathology services in the set, other than the services that are to be treated as 1 pathology service under paragraphs (a) and (b), are to be treated as 1 pathology service.

**18. (5)**   If pathology services are to be treated as 1 pathology service under paragraph (3)(c) or (4)(c), the fee for the 1 pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the 1pathology service.

**Hepatitis C viral RNA testing**

**19.**             For item 69499 and 69500:

***Hepatitis C sero‑positive***, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

***serological status is uncertain*,** for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

**Haemochromatosis testing**

**20.**             For items 73317 and 73318:

***elevated serum ferritin*** for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

**Nutritional and toxicity metals testing**

**22. (1)**       For this rule:

***nutritional metals testing group*** means items 66819, 66820, 66821 and 66822.

***metal toxicity testing group*** means items 66825, 66826, 66827, 66828, 66831 and 66832.

**22. (2)**       An item in the nutritional metals testing group or the metal toxicity testing group does not apply in relation to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:

(a)    that item; or

(b)    the other item in the same group; or

(c)     an item in the other group.

**Antineutrophil Cytoplasmic Antibody**

**23.** A request for Antineutrophil Cytoplasmic Antibody immunofluorescence test (ANCA) shall be deemed to include requests for antineutrophil proteinase 3 antibody test (PR-3 ANCA) and antimyeloperoxidase antibody test (MPO ANCA) where the immunofluorescence test for ANCA is abnormal, or has been abnormal, or those specific antibodies have been previously detected.

**Satisfying Requirements Described in Items**

**24.** Unless stated elsewhere in these rules, where an item contains a requirement, this requirement is satisfied if:

(a) The requirement/s as stipulated in the item descriptor are contained in the request form; or

(b) The requirement/s as stipulated in the item descriptor were supplied previously in writing to the APA and this documentation is retained by the APA; or

(c)  The results of other laboratory tests performed in the same episode meet the requirement/s as stipulated in the item descriptor; or

(d) The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are supplied on the request form; or

                   The results of laboratory tests that meet the requirement/s as stipulated in the item descriptor are contained in the APA's records.

**Limitation on certain items**

**25.**             (a) For any particular patient, items 66539, 66605, 66606, 66607, 66610, 69380, 69488, 69489, 71075, 71127, 71135 or 71137 is applicable not more than twice in a 12 month period.

                   (b) For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.

                   (c)  For any particular patient, items 66655, 66659, 66838, 66841, 69482, 69491, 69499 or 69500 are applicable not more than once in a 12 month period.

                   (d) For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.

                   (e)  For any particular patient, item 69336 is applicable not more than once in each period of 7 days.

                   (f)  For any particular patient, items 66660, 69445, 69451, 69483, 71079 or  73523 are applicable not more than 4 times in a 12 month period.

                   (g)  For any particular patient, items 66554, 66830 and 71077 are applicable not more than 6 times in a 12 month period.

                   (h) For any particular patient, item 66819, 66820, 66821, 66822, 66825, 66826, 66827 or 66828 is applicable not more than 3 times in a 6 month period.

                    (i)  For any particular patient, items 73339 and 73340 are applicable not more than once.

**Antigen Detection - Group P3 (Microbiology)**

**26.**          If the service listed in 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498 is a pathologist determinable service the specialist pathologist is required to record the reasons for determining the need for this service.

**27.** If the service rendered in 71148, 73320 or 73321 is a pathologist determinable service, the specialist pathologist is required to record the reason for determining the need for this service including the result of the service in 71147.

**Second Opinion morphology, limitations on items 72858 and 72859**

**28.1** Items 72858 and 72859 apply:

                                    (a)     only to a service that is covered by:

                         (i)         item 65084 or 65087; or

                         (ii)        item 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 or 72838; or

                         (iii)       an item in Group P6 (other than item 73070, 73071, 73072, 73074, 73075 or 73076); and

(b) only if the treating practitioner and the approved pathology practitioner who provided the original opinion on the patient specimen agree that a second opinion is reasonably necessary for diagnostic purposes.

**28.2**        Items72858 and 72859 do not apply if the accredited pathology laboratory in which the second opinion is provided is the same laboratory in which the original opinion was provided.

**Table for Cross Referencing Rules and Clauses appearing in Regulations**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **1 Nov 2010 MBS Book Rules** | | **Health Insurance (Pathology Services Table) Regulations 2010 Clauses** | | | | | |
| 1 | Dictionary | |  |  |  |  |  |
| 2 | 1.2.1 | | 2.12.1 |  |  |  |  |
| 3 | 1.2.2 | |  |  |  |  |  |
| 4 | 1.2.3 | | 2.1.1 | 2.2.2 |  |  |  |
| 5 | 2.1.2 | |  |  |  |  |  |
| 6 | 1.2.4 | |  |  |  |  |  |
| 7 | 1.2.5 | |  |  |  |  |  |
| 8 | 2.2.1 | |  |  |  |  |  |
| 9 | 2.2.5 | |  |  |  |  |  |
| 10 | 2.3.1 | |  |  |  |  |  |
| 11 | 2.3.3 | |  |  |  |  |  |
| 12 | 2.4.2 | |  |  |  |  |  |
| 13 | 2.5.1 | | 2.6.1 |  |  |  |  |
| 14 | 2.10.1 | | 2.11.1 |  |  |  |  |
| 15 | 2.11.2 | |  |  |  |  |  |
| 16 | 2.11.3 | |  |  |  |  |  |
| 17 | 1.1.1 | |  |  |  |  |  |
| 18 | 1.2.6 | |  |  |  |  |  |
| 18A | 1.2.7 | |  |  |  |  |  |
| 19 | 2.3.5 | |  |  |  |  |  |
| 20 | 2.7.1 | |  |  |  |  |  |
| 21 | 2.2.4 | |  |  |  |  |  |
| 22 | 2.2.7 | |  |  |  |  |  |
| 23 | 2.4.4 | |  |  |  |  |  |
| 24 | 1.2.8 | | 2.4.5 |  |  |  |  |
| 25 | 2.2.3 | | 2.2.6 | 2.2.7 | 2.3.4 | 2.4.1 | 2.8.1 |
| 26 | 2.3.2 | |  |  |  |  |  |
| 27 | 2.4.3 | | 2.7.2 |  |  |  |  |

**PN.0.35 Detection of measurable residual disease in patients with acute lymphoblastic leukaemia (MBS items 71202 and 73310)**

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

**PN.1.1 Pathology Services in Relation to Medicare Benefits - Outline of Arrangements**

**Basic Requirements**

***Determination of Necessity of Service***

The treating practitioner must determine that the pathology service is necessary.

***Request for Service***

The service may only be provided:

(i)               in response to a request from the treating practitioner, including a participating midwife or a participating nurse practitioner, or from another Approved Pathology Practitioner and the request must be in writing (or, if oral, confirmed in writing within fourteen days); or

(ii)              if determined to be necessary by an Approved Pathology Practitioner who is treating the patient.

Services requested by participating midwives and participating nurse practitioners:

(i)            A participating midwife can request the following services:

Items 65060, 65070, 65090 to 65099 (inclusive), 65114, 66500 to 66512 (inclusive), 66545, 66548, 66566, 66743, 66750, 66751, 69303 to 69317 (inclusive), 69324, 69384 to 69415 (inclusive), 73070, 73071, 73075, 73076 and 73529.

(ii)            A participating nurse practitioner can request items in the range 65060 to 73529 (inclusive).

***Provision of Service***

The following conditions relate to provision of services:

(i)               the service has to be provided by or on behalf of an Approved Pathology Practitioner;

(ii)              the service has to be provided in a pathology laboratory accredited for that kind of service;

(iii)             the proprietor of the laboratory where the service is performed must be an Approved Pathology Authority;

(iv)             the Approved Pathology Practitioner providing the service must either be the proprietor of the laboratory or party to an agreement, either by way of contract of employment or otherwise, with the proprietor of the laboratory in which the service is provided; and

(v)              no benefit will be payable for services provided by an Approved Pathology Practitioner on behalf of an Approved Pathology Authority if they are not performed in the laboratories of that particular Approved Pathology Authority.

***Therapeutic Goods Act 1989***

For any service listed in the MBS to be eligible for a Medicare rebate, the service must be rendered in accordance with the provisions of the relevant Commonwealth and State and Territory laws. Approved Pathology Practitioners have the responsibility to ensure that the supply of medicines or medical devices used in the provision of pathology services is strictly in accordance with the provisions of the *Therapeutic Goods Act 1989*.

**PN.1.2 Exemptions to Basic Requirements**

**Satisfying requirements described in pathology service**

Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 2 is satisfied if:

(a)        for a requirement for information - the information:

(i)         is included in the request for the service; or

(ii)        was supplied in writing on an earlier occasion to the approved pathology authority that rendered the service, and has been kept by the approved pathology authority; or

(b)        for a requirement for laboratory test results - the results are:

(i)         included in the request for the service; or

(ii)        obtained from another laboratory test performed in the same patient episode; or

(iii)       included in results from an earlier laboratory test that have been kept by the approved pathology authority.

**Services Where Request Not Required**

A pathologist-determinable service is a pathology service:

(a)        that is rendered by or on behalf of an approved pathology practitioner for a person who is a patient of that approved pathology practitioner who has determined that the service is necessary.

(b)        that is specified in item 73332, 73336, 73337, 73389, 73341, 73342, 73344, 73436, 73429 or only one immunohistochemistry items 72846, 72847, 72848, 72849, 72850 and 72860 or electronmicroscopy items 72851 and 72852 or immunocytochemistry items 73059, 73060 or 73061, and 73364 to 73383 and is considered necessary by the approved pathology practitioner as a consequence of information resulting from a pathology service contained in tissue examination items 72813 - 72838 or cytology items 73045 - 73051 respectively.

Please note: a written request is required for a service contained in items 72813 to 72838 and items 73045 to 73051.

(c)        that is specified in one of the antigen detection items 69494, 69495 or 69496 is considered necessary by the approved pathology practitioner as a consequence of information provided by the requesting practitioner or by the nature or appearance of the specimen or as a consequence of information resulting from a pathology service contained in items 69303, 69306, 69312, 69318, 69321 and 69345.

Please note: a written request is required for a service contained in items 69303, 69306, 69312, 69318, 69321 and 69345.

(d)        that is specified in item 73320, HLA-B27 typing by nucleic acid amplification, and is considered necessary by the approved pathology practitioner because the results of HLA-B27 typing described in item 71147 are unsatisfactory.

(e)         that is specified in item 73305, detection of mutation of the FMRI gene by Southern Blot analysis where the results in item 73300 are inconclusive.

(f)  that is specified in alpha thalassaemia genetic testing items 73411, 73412 or 73413 and is considered necessary by the approved pathology practitioner because the results of testing described in item 73410 were inconclusive.

**PN.1.3 Circumstances Where Medicare Benefits Not Attracted**

***Services Rendered by Disqualified Practitioner***

Medicare benefits are not payable for pathology services if at the time the service is rendered, the person, by or on whose behalf the service is rendered, is a person in relation to whom a determination is in force in relation to that class of services.  That is, where an Approved Pathology Practitioner has breached an undertaking, and a determination has been made that Medicare benefits should not be paid during a specified period (of up to five years) in respect of specified pathology services rendered by the practitioner.

Note: An Approved Pathology Practitioner may be disqualified for reasons other than a breach of undertaking.

***Certain Pathology Tests Do Not Attract Medicare Benefits***

Certain tests of public health significance do not qualify for payment of Medicare benefits.  Examples of services in this category are:

-                  examination by animal inoculation;

-                  Guthrie test for phenylketonuria;

-                  neonatal screening for hypothyroidism (T4/TSH estimation);

-                  neonatal screening for Cystic Fibrosis;

-                  neonatal screening for Galactosemia;

-                  pathology services used with the intention of monitoring the performance enhancing effects of any substance;

-                  pathology tests carried out on specimens collected from persons occupationally exposed to sexual transmission of disease where the purpose of the collection of specimens is for testing in accordance with conditions determined by the health authority of the State or Territory in which the service is performed.

In addition to the above, certain other tests do not qualify for payment of Medicare benefits.  These include:

-                  cytotoxic food testing;

-                  pathology services performed for the purposes of control estimation, repeat tests (eg. for confirmation of earlier tests on the same specimen, etc);

-                  preparation of autogenous vaccines;

-                  tissue banking and preparation procedures;

-                  pathology services performed on stillborn babies or cadavers;

-                  pathology services which are performed routinely in association with the termination of pregnancy without there being any indication for the necessity of the services.

However, benefits will be paid for the following pathology tests:

-     item 65060  ‑  haemoglobin estimation;

-     item 65090  ‑  blood grouping ABO and Rh (D antigen);

-     item 65096  ‑  examination of serum for Rh and other blood group antibodies.

**PN.2.1 Responsibilities of Treating/Requesting Practitioners**

***Form of Request***

A treating practitioner may request a pathology service either orally or in writing but oral requests must be confirmed in writing within fourteen days from the day when the oral request was made.

Pathology request forms and combined pathology request/offer to assign forms which are prepared by the pathologists and distributed to requesting practitioners on or after 1 August 2012 must include the minimum information detailed under PN.2.2.

All written requests for pathology services should contain the following particulars:

(i) a description of the individual pathology services, or recognised groups of pathology tests to be rendered (see PN.0.28 and PN.0.31). The description must be sufficient to enable the item in which the service is specified to be identified;

(ii) the date of request;

(iii) the name of the requesting practitioner and their practice address or provider number;

(iv) the patient's name and address;

(v) details of the hospital status of the patient, as follows (for benefit rate assessment). That is, whether the patient was or will be, at the time of the service and when the specimen is obtained:

(a) a private patient in a private hospital, or approved day hospital facility;

(b) a private patient in a recognised hospital;

(c) a public patient in a recognised hospital;

(d) an outpatient of a recognised hospital;

***Offence Not to Confirm an Oral Request***

A requesting practitioner who, without reasonable excuse, does not confirm in writing an oral request within fourteen days of making the oral request is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding $1,100 (10 Penalty Units in accordance with the *Crimes Act 1914*), and the request is deemed never to have been made.

Services Australia, in consultation with the Department of Health and Aged Care, has developed a [Health Practitioner Guideline to substantiate that a valid request existed (pathology or diagnostic imaging)](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation) which is located on the Department of Health and Aged Care's website.

**PN.2.2 Responsibilities of Approved Pathology Practitioners**

***Form of Request***

There is no official "request in writing" form, and the requesting practitioner's own stationery, or pre-printed forms supplied by Approved Pathology Practitioners/Authorities are acceptable.

For the purposes of Medicare eligible services, the minimum information requirements for a pre-printed pathology request and combined pathology request/offer to assign are detailed within the: *Health Insurance Act 1973*; *Health Insurance Regulations 2018*; and the *Privacy Act 1988*.

The following table presents the minimum details that pre-printed pathology request forms and combined pathology request/offer to assign forms must contain for the purposes of a subsequent Medicare claim:

|  |
| --- |
| Requesting Practitioner |
| a) name |
| b) practice address or provider number |

|  |
| --- |
| Patient Details |
| a) name - surname, first name |
| b) address |
| c) date of birth |
| d) sex |
| e) Medicare card number |
| f) hospital status Two acceptable versions are as follows: State the patient's status at the time of the service or when the specimen was collected: OR cross out the statements that do not apply Was or will the patient be, at the time of the service or when the specimen is obtained: (a) a private patient in a private hospital or approved day hospital facility (b) a private patient in a recognised hospital (c) a public patient in a recognised hospital (d) an outpatient of a recognised hospital |

|  |
| --- |
| Tests Requested |
| a) an area titled "Tests Requested" |

|  |
| --- |
| Self Determined (SD) |
| A tick box is required for SD. This is used when the APP determines that pathologist-determinable tests are necessary. This tick box can be put in the Clinical Notes area. |

|  |
| --- |
| Mandatory patient advisory statement |
| One of the following statements: 'Your doctor has recommended that you use (insert name of pathology provider). You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your doctor.' 'Your treating practitioner has recommended that you use (insert name of pathology provider). You are free to choose your own pathology provider. However, if your treating practitioner has specified a particular pathologist on clinical grounds, a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your treating practitioner.' |

|  |
| --- |
| Privacy Note |
| The wording of the note must be: "Privacy Note:  The information provided will be used to assess any Medicare benefit payable for the services rendered and to facilitate the proper administration of government health programs, and may be used to update enrolment records. Its collection is authorised by the provisions of the *Health Insurance Act 1973*. The information may be disclosed to the Department of Health and Aged Care or to a person in the medical practice associated with this claim, or as authorised/required by law." The placement of the note is only necessary on the patient's copy and could be incorporated into the clinical notes area.  Alternatively, the back of the patient copy could be used if that is more practicable. |

Services Australia, in consultation with the Department of Health and Aged Care, has developed a [Health Practitioner Guideline to substantiate that a valid request existed (pathology or diagnostic imaging)](https://www.health.gov.au/resources/collections/health-professional-guidelines?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation) which is located on the Department of Health and Aged Care's website.

|  |
| --- |
| Combined Request/Assignment form only |
| Offer to Assign and Reference to Section 20A |
| An example of a Section 20A Offer to Assign is as follows: "Medicare Agreement (Section 20A of the *Health Insurance Act 1973*) I offer to assign my right to benefits to the approved pathology practitioner who will render the requested pathology service(s) and any eligible pathologist determinable service(s) established as necessary by the practitioner. Patient signature \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  Date    /   /   / |
| Practitioners Use Only |
| A text box is also required for 'Practitioner's Use Only' this section is used where the patient is unable to sign and an appropriate person endorses on behalf of patient, e.g. Practitioner's Use Only \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (Reason patient cannot sign) |

An Approved Pathology Practitioner or Approved Pathology Authority who, without reasonable excuse, provides to practitioners (directly or indirectly) combined request/assignment forms which are not in accordance with the legislation is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding 10 Penalty Units (in accordance with the *Crimes Act 1914*).

***Patient Copy***

Assignment of benefits requires the patient to receive a copy of the request. The doctor must cause the particulars relating to the professional service (tests requested) to be set out on the assignment form, before the patient signs the form and cause the patient to receive a copy of the form as soon as practicable after the patient signs it.

***Authority to lodge a Patient Claim electronically***

Where an Approved Pathology Practitioner or Approved Pathology Authority renders a service and the patient has not assigned the benefit the Approved Pathology Practitioner or Approved Pathology Authority can lodge a claim electronically to Services Australia on behalf of the patient where consent is provided. This consent can be provided verbally.

***Combined Online Patient Claiming Authority***

*Authority for APP/APA to submit an electronic patient claim on behalf of the claimant*

An example of wording that could be used is:  
'I authorise the approved pathology practitioner who will render the requested pathology services, and any further pathology services which the practitioner determines to be necessary, to submit my unpaid account to Medicare, so that Medicare can assess my claim and issue me a cheque made payable to the practitioner, for the Medicare benefit.'

Patient Signature\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date\_\_\_\_\_\_/\_\_\_\_\_\_/\_\_\_\_\_\_\_

Verbal consent was provided by patient to submit unpaid account to Medicare. No signature available*.*

***Request to Approved Pathology Authority***

It is acceptable for a request to be made to an Approved Pathology Authority who is the proprietor or one of the proprietors of a laboratory instead of making the request to the Approved Pathology Practitioner who renders the service or on whose behalf the service is rendered.

***Holding, Retention, Recording and Production of Request Forms***

Approved Pathology Practitioners must hold a request in writing for all services requested by any other practitioner before billing patients. An Approved Pathology Practitioner is required to retain written requests/confirmation of requests for pathology services for 2 years from the day when the service was rendered. This also applies to requests which an Approved Pathology Practitioner receives of which only some tests are referred to another Approved Pathology Practitioner (the first Approved Pathology Practitioner would retain the request for 2 years). If all tests were referred, the second pathologist would retain the original request.

If the written request or written confirmation has been recorded on film or other magnetic medium approved by the Minister for Health and Aged Care, for the purposes of storage and subsequent retrieval, the record so made shall be deemed to be a retention of the request or confirmation. The production or reproduction of such a record shall be deemed to be a production of the written request or written confirmation.

An Approved Pathology Practitioner or an Approved Pathology Authority is required to produce, on request from the Services Australia CEO, no later than the end of the day following the request from the CEO, a written request or written confirmation retained pursuant to the above paragraphs. An employee of Services Australia is authorised to make and retain copies of or take and retain extracts from written requests or written confirmations.

***Offences in Relation to Retaining and Producing Request Forms***

The following offences are punishable upon conviction by a fine not exceeding 10 penalty units:

1. an Approved Pathology Practitioner who, without reasonable excuse, does not keep request forms for 2 years;
2. an Approved Pathology Practitioner who, without reasonable excuse, does not produce a request form to an employee of Services Australia before the end of the day following the day of Services Australia CEO's request;
3. an Approved Pathology Authority which, without reasonable excuse, does not keep request forms for 2 years;
4. an Approved Pathology Authority which, without reasonable excuse, does not produce a request form to an employee of Services Australia before the end of the day following the day of Services Australia CEO's request.

***Referral From An Approved Pathology Practitioner To Another Approved Pathology Practitioner***

Where an Approved Pathology Practitioner refers some or all services requested to another Approved Pathology Practitioner not associated with the same Approved Pathology Authority the following apply:

1. where all the services are referred, the first Approved Pathology Practitioner should forward the original request to the second Approved Pathology Practitioner, and the document bearing the patient's assignment voucher so that the second Approved Pathology Authority can direct-bill Medicare;
2. where some of the services which are listed in different items in the Schedule are referred, the first Approved Pathology Practitioner must issue his/her own request in writing listing the tests to be performed, and when necessary, forward a photocopy of the patient's assignment voucher so that the second Approved Pathology Authority can direct-bill Medicare  
     
   in addition to the details of the first Approved Pathology Practitioner, the second Approved Pathology Practitioner must show on the account/receipt/assignment form:
   1. name and provider number of the original requesting practitioner; and
   2. date of original request;
3. under the item coning rules (which limit benefits for multiple services) only one Medicare benefit is payable for services included in coned items except for estimations covered by Rule 6 entitled "designated pathology services". The exemption allows payment of more than one Medicare benefit where various components of the one item number from the same request e.g. drug assays (items 66800 and 66812) are performed by two Approved Pathology Authorities.

Although the provisions concerning designated pathology services in Rule 6 permit similar services (e.g. hormone estimations) to be performed by 2 or more laboratories, with different Approved Pathology Authorities, the sum of the Medicare benefit payable for services provided by the laboratories concerned will not exceed the maximum amount payable under the item coning rules when a single laboratory performs all the estimations.

Notes:

1. the patient should be billed by each Approved Pathology Practitioner only for those services rendered by or on his/her behalf;
2. photocopies of requests are not acceptable;
3. in the case of "designated pathology services" 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800,66812, 66819, 66825, 69384, 69494, 71089, 71153 or 71165 a patient episode initiation fee (PEI) is payable for the services provided by the laboratory which receives the original request and performs one or more of the estimations.  However, no PEI is payable for services provided by the other laboratory which performs the remainder of the estimations. A "specimen referred fee" is payable instead. One Approved Pathology Practitioner cannot claim both a PEI and a "specimen referred fee" in relation to the same patient episode.

***Offence Not To Confirm An Oral Request***

An Approved Pathology Practitioner who, without reasonable excuse, does not confirm in writing an oral request to another Approved Pathology Practitioner within fourteen days of making the oral request is guilty of an offence under the *Health Insurance Act 1973* punishable, upon conviction, by a fine not exceeding 10 Penalty Units (in accordance with the *Crimes Act 1914*), and the request is deemed never to have been made.

**PN.2.3 Pathology Tests not Covered by Request**

An Approved Pathology Practitioner, who has been requested to perform one or more pathology services, may consider it necessary, in the interest of the patient, that additional tests to those requested be carried out. The Approved Pathology Practitioner must discuss this need with the requesting practitioner, and if the requesting practitioner determines that additional tests are necessary, the Approved Pathology Practitioner must arrange with the requesting practitioner to forward an amended or second request for those services.  The account will then be issued in the ordinary way and the additional services will attract benefits providing the Approved Pathology Practitioner is a recognised specialist pathologist.

**PN.2.4 Faecal Calprotectin Testing (Items 66522 & 66523)**

A patient previously diagnosed with inflammatory bowel disease is not eligible for this item.

Clinical alarms:

Unexplained weight loss (> 3 kg or 5% bodyweight), iron deficiency ± anaemia, melaena, overt rectal bleeding, positive faecal human haemoglobin, abdominal pain awaking patient from sleep, diarrhoea, disturbing sleep or faecal incontinence, documented unexplained fever, family history of colon cancer, family history of inflammatory bowel disease (IBD) in symptomatic patients, or a family history of coeliac disease in symptomatic patients

**PN.2.5 NT-proBNP testing in patients with systemic sclerosis and pulmonary arterial hypertension - MBS items 66585 and 66586**

**MBS item 66585**

NT-proBNP testing under MBS item 66585 should be performed along with a pulmonary function test (PFT) measuring diffusing capacity for carbon monoxide in accordance with the 2012 Australian Scleroderma Interest Group (ASIG) pulmonary arterial hypertension (PAH) screening algorithm.

Repeat testing within a 12 month period should only be performed for a patient presenting with new symptoms suggestive of PAH since last assessment or a patient that has a borderline NT-proBNP level between 168-209 pg/mL.

**MBS items 66585 and 66586**

Where MBS items 66585 or 66586 are requested by a medical practitioner (other than a specialist or consultant physician), the request should be made in consultation with a specialist or consultant physician who manages the treatment of the patient.

**PN.3.1 Details Required on Accounts, Receipts or Assignment Forms**

**General**

Medicare benefit is not payable in respect of a pathology service unless specified details are provided, by the practitioner rendering the service, on his or her account, receipt or assignment form.

**PN.3.2 Approved Pathology Practitioners**

In addition to holding a request in writing from the treating medical or dental practitioner or from another Approved Pathology Practitioner, the following additional details must be recorded on the account, receipt or assignment form of the Approved Pathology Practitioner providing the service:

(i)         the surname and initials of the Approved Pathology Practitioner who performed the service and either his/her practice address or the provider number for the address;

(ii)        the name of the person to whom the service was rendered;

(iii)       the date on which the service was rendered;

(iv)       the name of the requesting practitioner; or in the case of a referred test, the name of the original requesting practitioner;

(v)        the date on which the request was made; or in the case of a referred test, the date on which the original request was made;

(vi)       the requesting practitioner's provider number;

(vii)      a description of the pathology service in words which are derived from the item description in the Schedule and are of sufficient detail to identify the specific test in the Schedule that was rendered. Instead of such a full description, the abbreviations contained in the group abbreviations listed at PN.0.31 are acceptable alternatives (see PN.0.28);

(viii)     where the Approved Pathology Practitioner determines or provides a pathology service on his/her own patient, the account must be endorsed "sd"; and

(ix)       provide collection centre identification number if the specimen was collected in a licensed collection centre (or approved pathology collection centre).

Where some services are referred from one Approved Pathology Practitioner to another Approved Pathology Practitioner, the request details to be shown on the second Approved Pathology Practitioner's account, receipt or assignment form must be identical to those of the original requesting practitioner including the date of request.

**PN.3.3 Prescribed Pathology Services**

For Prescribed Pathology Services (that is, pathology items in Group P9) the medical practitioner who renders the service must ensure his or her account, receipt or assignment form includes his or her name, address or provider number, the date of the service, and a description to clearly identify the service in the Schedule that was rendered.

If the service was determined necessary by another medical practitioner who is a member of the same group practice as the practitioner who rendered the service, the name of the requesting practitioner, sufficient to identify the practitioner from other practitioners in the same group practice with the same surname, must also be included together with the date on which the request was made.

**PN.3.4 Interferon Gamma Release Assay (IGRA) for detection of latent tuberculosis - (Item 69471)**

Before undertaking testing it is advisable to consult with a medical practitioner experienced in the management of tuberculosis.  Neither IGRA tests or the tuberculin skin test (Mantoux) can absolutely exclude latent tuberculosis and following close contact exposure preventative therapy should always be considered in young children and immunosuppressed patients.

IGRA testing for the diagnosis of latent tuberculosis should be requested in compliance with recommendations made by the National Tuberculosis Advisory Committee in 2016 or later. <https://www.health.gov.au/committees-and-groups/national-tuberculosis-advisory-committee?utm_source=health.gov.au&utm_medium=callout-auto-custom&utm_campaign=digital_transformation> including:

* IGRAs have no place in the initial investigation of active TB disease and cannot and should not be used to exclude suspected TB disease.
* IGRA should not be used for the purpose of screening prior to BCG vaccination.
* While IGRA tests can be used in children less than 5 years of age, there may be a higher proportion of indeterminate test results and tuberculin skin testing is preferred, unless there is a history of BCG.

At least eight weeks should elapse following last possible TB exposure before testing of a contact of a confirmed case of active tuberculosis – testing of contacts should be performed only after discussion with appropriate State or Territory public health authorities.

**PN.4.1 Inbuilt Multiple Services Rule**

The term "Multiple Services Rule" (Rule 3 of the Pathology Services Table) describes an arrangement which places limits on the benefits payable for items in the Pathology Services Table depending on the range of services performed during a single patient episode.  A patient episode is defined in PN.0.5.

**PN.4.2 Exemptions**

Under Rule 4 of the Pathology Services Table, exemptions to the multiple services rule have been granted for certain specified tests.  In some circumstances tests which are repeated up to 6 times over a 24 hour period, or tests which are requested up to 6 times on a single request form and are performed within 6 months of the date of request may be eligible for separate Medicare benefits.  The services to which the exemptions apply are listed under Rule 4.(1 and 2) and cover seriously or chronically ill patients who require particular tests under specified circumstances.  In order to claim the exemptions, accounts should be endorsed "Rule 3 Exemption".

Where a practitioner seeks an exemption to the multiple services rule for a patient whose condition requires a series of pathology investigations at various times throughout any one day or over a longer period of time, and the services required are not exempted under Rule 4, an application for exemption can be made which is endorsed "S4B(3)".  Some factors that the delegate of the Minister may take into consideration in approving an exemption are: the patient is seriously ill; there are distinct and separate collections and performances of tests; and the services involve substantial additional expenses for the Approved Pathology Practitioner.  These, and other clinical details, should be supplied by the practitioner when seeking an S4B(3) exemption.

If Rule 3 exemptions are endorsed "S4B(3)", claim assessment could take longer as all S4B(3) claims are passed to the delegate for assessment.  S4B(3) covers all exemptions to the multiple services rule but, where applicable, specific "Rule 3 exemption" endorsements will speed up the payment of claims.  Rule 3 and S4B(3) exemptions cannot be used to overcome time based restrictions within items e.g. "-. each test to a maximum of 4 tests in a 12 month period".

**PN.5.1 Episode Cone**

**Description of Rule 18**

The term "Episode Cone" describes an arrangement under which Medicare benefits payable in a patient episode for a set of pathology services, containing more than three items, ordered by a general practitioner for a non-hospitalised patient, will be equivalent to the sum of the benefits for the three items with the highest Schedule fees.  Further information on the episode coning arrangements is provided in PR.6.1.

**PN.5.2 Exemptions**

Some items are not included in the count of the items performed when applying episode coning.  The items which have been exempted from the cone include all the items identified in Rule 18.(1)(d) and (e).

**PN.6.1 Bulk Billing Incentives for Episodes Consisting of a P10 Service**

The Fees for items in Group P13 are additional payments for bulk billing a patient episode consisting of a pathology service to which a Group P10 item (Pathology Episode Initiation fee) applies.

**PN.6.2 Patient Episode Initiation Fees (PEIs)**

Items in Groups P10 of the Pathology Services Table are only applicable to services performed:

(i)         by or on behalf of an Approved Pathology Practitioner who is a recognised specialist pathologist; and

(ii)        in private practice.

Accordingly, these fees are not payable for pathology services rendered by an Approved Pathology Practitioner, being a specialist pathologist when requested for a privately referred out-patient of a recognised hospital.

The patient episode initiation fees (PEIs) will be applicable on an episodic basis i.e. a claim may be made for the provision of pathology services requested by a practitioner in respect of one individual on the same day.  For example, if a practitioner orders three pathology tests for a person on the one day, Medicare benefits will be payable for each of those tests but only one PEI will be applicable.

This Rule applies even when the treating practitioner has requested pathology tests from two or more Approved Pathology Practitioners. Thus a PEI will only be paid for the first account submitted unless an exemption listed in Rule 4 or 14.(7) applies or an exemption has been granted under "S4B(3)".

Under Rule 14.(7) two PEIs are payable in relation to the same patient episode where a referring practitioner refers two different specimens to two different Approved Pathology Authorities in the following circumstances:

-           a tissue pathology specimen and any other non-tissue pathology specimen; or

-           a cytopathology specimen and any other non-cytopathology specimen.

Rule 14.(8) also provides that only one PEI will be paid for the collection of specimens from a patient on one day in or by a single Approved Pathology Authority.

The patient episode initiation benefits are two-tiered.  Higher benefits are paid for the collection of specimens from patients  who are not private inpatients or private outpatients of a recognised hospital where the specimens are tested in a private laboratory.

A lower and uniform PEI benefit is paid where patients are private patients associated with a recognised hospital and the specimens are tested in a private laboratory or where the testing is performed by a prescribed laboratory on specimen collected from a patient eligible to claim Medicare benefits.

**PN.6.3 Patient Episode Initiation Fees for Certain Tissue Pathology and Screening Items**

Tissue Pathology items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 and Cervical screening items 73070, 73071, 73072, 73074, 73075, 73076 will be subject to a different patient episode initiation fee structure - items 73922 to 73939 refer.

**PN.6.4 Hospital, Government etc Laboratories**

The following laboratories have been prescribed for the purposes of payment of Medicare benefits:

(i)         laboratories operated by the Australian Government (these include health laboratories operated by the Australian Government Department of Health and Aged Care as well as the laboratories operated by other Departments, e.g. the Departments of Defence and Veterans' Affairs operate laboratories from which pathology services are provided);

(ii)        laboratories operated by a State Government or authority of a State (laboratories operated or associated with recognised hospitals are also included);

(iii)       laboratories operated by the Northern Territory and the Australian Capital Territory; and

(iv)       laboratories operated by Australian tertiary education institutions eg Universities.

**PN.7.1 Assignment of Medicare Benefits - Patient Assignment**

In addition to the general arrangements relating to the assignment of benefits, as outlined at paragraph 7 of the "General Explanatory Notes" in Section 1 of this book, it should be noted that, where the treating practitioner requests pathology services but the patient does not physically attend the Approved Pathology Practitioner, the patient may complete an assignment voucher at the time of the visit to the requesting doctor offering to assign benefits for the Approved Pathology Practitioner's services.

If an Approved Pathology Practitioner refers some of the tests requested by the treating practitioner to another Approved Pathology Authority, he/she should provide the second Approved Pathology Authority with a photocopy of the patient's assignment voucher so that the second Approved Pathology Authority can also direct-bill Medicare.

**PN.7.2 Approved Pathology Practitioner Eligibility**

If a practitioner requests an Approved Pathology Practitioner to perform a necessary pathology service, that Approved Pathology Practitioner must personally perform the service or have it performed on his/her behalf in order to be eligible to receive benefits by way of assignment.  If, however, the first Approved Pathology Practitioner arranges for the service to be rendered by a second Approved Pathology Practitioner with the same Approved Pathology Authority, the second Approved Pathology Practitioner and not the first, is eligible to receive an assignment of the Medicare benefit for the service in question.

**PN.7.3 Cystic fibrosis gene testing**

(1) For any particular patient, item 73345, 73347, 73348 and 73349 is applicable not more than once in a lifetime.

(2) For any particular patient, item 73346 and 73350 is applicable not more than once in a pregnancy.

(3) The testing laboratory used to undertake tests for items 73345, 73346, 73347, 73348, 73349 and 73350 must use a cystic fibrosis transmembrane conductance regulator methodology appropriate to the clinical setting with:

                (a) sufficient diagnostic range and sensitivity to detect at least 95% of pathogenic cystic fibrosis transmembrane conductance regulator variants likely to be present in the patient; and

                (b) with at least 25 of the most frequently encountered cystic fibrosis transmembrane conductance regulator variants in the Australian population.

**PN.7.4 Intellectual disability or global developmental delay**

Intellectual disability or global developmental delay of at least moderate severity, to be determined by a specialist paediatrician according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria.

**PN.7.5 'Abnormal red cell indices' for the purpose of genetic testing for thalassaemia and item 73410**

‘Abnormal red cell indices’ refers to a mean corpuscular volume <80 fL and/or mean corpuscular haemoglobin <28 pg and haematological studies suggestive of thalassaemia.

**PN.7.6 Genetic testing for the diagnosis of neuromuscular disorders (NMDs)**

Where a neuromuscular disorder (NMD) is clinically suspected that is tested for using a single gene test described under items 73434 or 73435, the single gene test should be conducted prior to gene panel testing items on the Medicare Benefits Schedule (MBS).

**PN.7.7 Genetic testing for the diagnosis of neuromuscular disorders (NMDs) - data reanalysis**

Variants may be previously unreported because the relevant gene was not included in the original virtual panel, or because the pathogenicity of the variant has been re-classified in the interim.

**PN.7.10 Somatic gene testing for the diagnosis and characterisation of gliomas - Item 73429**

Testing should include, but not be restricted to, genes described in the current World Health Organization Classification of Tumours.

**PN.7.11 Single gene testing for the diagnosis of heritable neuromuscular disorders - item 73434**

Where a recessive variant has been identified using item 73434, reproductive partners should first be tested using item 73434, prior to gene sequencing under item 73427 where no relevant variant was detected by item 73434 and if considered appropriate, after genetic counselling.

**PN.7.12 Item 73434 minimum gene list**

Testing for pathogenic or likely pathogenic gene variants associated with neuromuscular disorders (item 73434) should include, but is not limited to, any one of the following genes: DMPK, CNBP, HTT, PABPN1, C9orf72, AR, SMN1, PRNP, MTND1, MT-ND4, MT-ND4L, MT-ND6, MT-TK, MT-L1, MT-ATP6, FXN, ATN1; or all five of the following genes: ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7.

**PN.7.13 Genetic testing for childhood hearing loss - MBS items 73440, 73441, 73443, 73444**

**MBS Items 73440 and 73441**

When determining the genes to be assessed on the virtual panel, the list of phenotypically driven genes should be based on a recognised test directory.

**MBS Items 73443 and 73444**

Prior to requesting or performing these tests, the requesting practitioner or pathologist should consider if the patient has previously received equivalent testing. Testing should not be required more than:

* once per variant per lifetime, for item 73443
* once per gene per lifetime, for item 73444

Additional testing should only be performed if it is clinically relevant.

**PN.7.14 Note for haematological malignancy gene panel tests**

Testing should include, but not be restricted to, genes described in the current World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms or other appropriate international guidelines.

**PN.7.15 Repeat testing for non-small cell lung cancer (NSCLC) by multiple methodologies**

Prior to requesting or performing these tests, the requesting practitioner or pathologist should consider if the patient has already received equivalent testing under the same or another methodology in the same new diagnosis of non-small cell lung cancer (NSCLC).  
Repeat testing by multiple methods in the same new diagnosis of NSCLC should only be performed if it is clinically relevant.

Items 73337, 73341, 73344 and 73436 support sequential single-gene testing for biomarkers in patients with NSCLC.

Item 73437 supports use of one next generation sequencing (NGS) panel for testing of all biomarkers supported under items 73337, 73341, 73344 and 73436.

Items 73438 and 73439 support sequential use of two NGS panels for testing of all biomarkers supported under 73337 and 73436, and 73341 and 73344 respectively.

**PN.7.16 Reproductive carrier testing for cystic fibrosis, spinal muscular atrophy, and fragile X syndrome - MBS items 73451 and 73452**

**MBS items 73451 and 73452**

Fragile X syndrome (FXS) is inherited in an X-linked dominant fashion.

The sex chromosomal pattern of a patient determines the likelihood of being a genetic carrier of FXS and the risk of FXS carriers passing on a variant(s) in the FMR1 gene that would cause their child to be born with the condition. Patients with certain sex chromosomal patterns have no risk of influencing whether their child is born with FXS, regardless of whether they are a carrier of the condition.

The intent of MBS item 73451 is to test a patient who:

(a) is either planning a pregnancy or is already pregnant; and   
(b) if found to be a genetic carrier of fragile X syndrome, is at risk of passing on a variant(s) in the FMR1 gene that would cause their child to be born with the condition

The intent of MBS item 73452 is to test a patient who:

(a) is the reproductive partner of the patient planning pregnancy or already pregnant tested under item 73451.   
(b) is not at risk of passing on a variant(s) in the FMR1 gene that would cause their child to be born with fragile X syndrome, regardless of whether they are a genetic carrier of the condition

The patient who is planning pregnancy or already pregnant must be tested first under MBS item 73451 prior to testing the reproductive partner patient under MBS item 73452, to ensure an informative and clinically relevant test result is obtained in the FMR1 gene.

**MBS item 73451**

The laboratory used to undertake reproductive carrier testing under item 73451 should use a methodology appropriate to the clinical setting with:

(a) sufficient diagnostic range and sensitivity to detect at least 95% of pathogenic variants likely to be present in the patient; and   
(b) at least 50 of the most frequently encountered cystic fibrosis transmembrane conductance regulator variants in the Australian population.

**PN.7.18 Targeted carrier testing for severe monogenic conditions - MBS item 73453**

Where the couple is already pregnant and both patients are of Ashkenazi Jewish descent, concurrent testing of any partner(s) not already tested is recommended.

**PN.7.20 PN.7.20**

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

**PN.8.1 Accredited Pathology Laboratories - Need for Accreditation**

A pathology service will not attract Medicare benefits unless that service is provided in a pathology laboratory which is accredited for that kind of service.  Details of the administration of the pathology laboratory accreditation arrangements are set out below.

**PN.8.2 Applying for Accreditation**

To become an Accredited Pathology Laboratory it is necessary to lodge a completed application form with the Manager, Pathology Section, Services Australia, PO Box 1001, TUGGERANONG ACT 2901. The prescribed fees for Approved Pathology Laboratories are:

-           $2500 for Category GX labs

-           $2000 for Category GY labs

-           $1500 for Category B labs

-           $ 750 for Category M & S labs.

It is necessary for an application for inspection be made to the National Association of Testing Authorities (NATA) NATA is the independent body chosen to act on the Australian Government's behalf as the primary inspection agency.  The Royal Australian College of General Practitioners (RACGP) has also been appointed to inspect laboratories in Category M (general practitioner) in Victoria only.

Details of laboratory categories and associated supervisory requirements can be found on the Department of Health and Aged Care's internet site ([www.health.gov.au/topics/pathology](https://www.health.gov.au/topics/pathology)).

**PN.8.3 Effective Period of Accreditation**

Accreditation takes effect from the date of approval by the Minister for Health and Ageing.  The Minister has no power to backdate an approval.  Transitional accreditation may be given pending full accreditation.  An application and fee are required annually.

**PN.8.4 Assessment of Applications for Accreditation**

The principles of accreditation for pathology laboratories as determined by the Minister are used to assess applications for accreditation. These principles also require pathology laboratories to address National Pathology Accreditation Advisory Council standards.  Copies of the principles and standards are available from the Secretariat, National Pathology Accreditation Advisory Council (see PH.6) on (02) 6289 4017 or email npaac@health.gov.au.

**PN.8.5 Refusal of Accreditation and Right of Review**

An applicant who has been notified of the intention to refuse accreditation may, within 28 days of being notified, provide further information to the Minister which may be taken into consideration prior to a final decision being made.

Applicants refused accreditation or any person affected by the decision have the right to appeal to the Administrative Appeals Tribunal.

**PN.8.6 National Pathology Accreditation Advisory Council (NPAAC)**

NPAAC was established in 1979.  Its functions are to develop policy for accreditation of pathology laboratories, introduce and maintain uniform standards of practice in pathology services throughout Australia and initiate and coordinate educational programs in relation to pathology practice.  The agencies used to inspect laboratories on the Australian Government's behalf are required to conduct inspections using the standards set down by NPAAC.  For further information the NPAAC Secretariat can be contacted on (02) 6289 4017 or email [npaac@health.gov.au](mailto:npaac@health.gov.au).

**PN.8.7 Change of Address/Location**

Laboratories are accredited for the particular premises given on the application form.  Where a laboratory is relocated to other premises, any previously issued approvals for that Accredited Pathology Laboratory lapse.  Medicare benefits are not payable for any pathology services performed at the new location until a new application has been approved by the Minister for Health and Ageing.  Paragraph PH.2 sets out the method for applying for accreditation.

**PN.8.8 Change of Ownership of a Laboratory**

Part of the assessment of an application for an Accredited Pathology Laboratory relates to the Approved Pathology Authority status.  Where the ownership, or some other material change occurs affecting the laboratory, the Minister for Health and Ageing must be provided with those changed details.  Medicare benefits will not be payable for any pathology services performed on any premises other than those premises for which approval has been given.

**PN.8.9 Approved Collection Centres (ACC)**

New arrangements for specimen collection centres commenced on 1 December 2001 and replaced the Licensed Collection Centre (LCC) Scheme.

To enable the payment of Medicare benefits for pathology services performed on pathology specimens collected in a collection centre, the centre must first be approved.  The exception to this rule is collection centres on the premises of recognised hospitals (recognised hospital in this context means the same as "recognized hospital" in Part 1 Section 3 of the *Health Insurance Act 1973*) as they do not need approval.

In order for a collection centre to be approved, a public or private Approved Pathology Authority must submit a completed application form to Services Australia including details of the type of application (renewal, new or cancellation of collection centre), the location of the premises, the owner, and any leasing arrangements.

Application forms can be accessed by going to the [Services Australia website](https://www.servicesaustralia.gov.au/). Completed application forms and any enquiries should be forwarded to Pathology Registration, PO Box 9822 MELBOURNE VIC 3001.

**PN.9.1 Approved Pathology Practitioners**

**Introduction**

A pathology service will not attract Medicare benefits unless that service is provided by or on behalf of an Approved Pathology Practitioner.  (Approved Pathology Practitioners must be registered medical practitioners.)  Set out below is information which relates to Approved Pathology Practitioner requirements.

**PN.9.2 Applying for Acceptance of the Approved Pathology Practitioner Undertaking**

To apply for acceptance of an Approved Pathology Practitioner Undertaking, it is necessary to send:

(i)         a completed application for acceptance of an Approved Pathology Practitioner Undertaking; and

(ii)        a signed Approved Pathology Practitioner Undertaking to the Pathology Registration, Services Australia,

PO Box 9822, Melbourne Victoria 3001.

An application form, undertaking and associated literature can be obtained from the Pathology Registration Coordinator.

Payment of Acceptance Fee

On receipt of advice that the Minister has accepted an undertaking, a cheque for $500 should be sent to the Pathology Registration Coordinator.  Applicants are required to pay this fee within 14 days of the notice being given.  As there is no discretion under the *Health Insurance Act 1973* to accept late payments, failure to pay the fee within the required time means that:

(i)         acceptance of the undertaking will be revoked;

(ii)        a new application must be completed;

(iii)       acceptance of the new undertaking cannot be backdated; and

(iv)       there will therefore be a period during which Medicare benefits cannot be paid.

**PN.9.3 Undertakings - Approved Pathology Practitioner**

Consideration of Undertakings

The Minister is unable to accept an undertaking from a person in respect of whom there is a determination in force that the person has breached the undertaking, or from a person who, if the undertaking were accepted, would be likely to carry on the business of a prescribed person or would enable a person to avoid the financial consequences of the disqualification (or likely disqualification) of that prescribed person.  A 'prescribed person' includes, amongst other things, fully or partially disqualified persons (or persons likely to be so disqualified).

Similarly an undertaking cannot be accepted unless the Minister is satisfied that the person giving such undertaking is a fit and proper person to be an Approved Pathology Practitioner.

When an undertaking has been given, the Minister may require the person giving the undertaking to provide additional information within a fixed period of time and if the person does not comply the Minister may refuse to accept the undertaking.

Refusal of Undertaking and Rights of Review

Where the Minister refuses to accept an undertaking, for any of the reasons shown above, the Minister must notify the person of the decision.  The notification must include advice of a right of internal review of the decision and a right of further appeal to the Administrative Appeals Tribunal if the internal review upholds the original decision to refuse the undertaking.

Effective Period of Undertaking

The following applies:

(i)         Date of Effect   the earliest day from which the Minister or delegate can accept an undertaking is the day of the decision in respect of the undertaking.  The day the undertaking is signed is to be the day it is actually signed and must not be backdated;

(ii)        Period of Effect   in determining the period of effect of the undertaking the Minister shall, unless the Minister considers that special circumstances exist, determine that the period of effect shall be twelve months from the day on which the undertaking comes into force.  There is a requirement for the Minister to notify persons giving undertakings of the period of time for which the undertaking is to have effect, and the notice is to advise persons whose interests are affected by the decision of their rights of appeal to the Administrative Appeals Tribunal against the Minister's decision;

(iii)       Renewals   when an undertaking is given and accepted by the Minister while a former undertaking is current, the new undertaking does not take effect until the former undertaking ceases to be in force.  When an undertaking is given while a former undertaking is current and the date on which the former undertaking is to expire passes without the Minister giving notice to accept or reject the new undertaking, the former undertaking remains in force until the Minister gives such notification.  This provision does not apply when the renewal application is not received by Services Australia until after the expiry of the existing undertaking. Under these circumstances there will be a period during which Medicare benefits cannot be paid unless the new application can be backdated to the expiry of the previous undertaking.  This is a limited discretion for  periods up to one month and special conditions apply; and

(iv)       Cessation of Undertaking   the undertaking ceases to be in force if it is terminated, if the Minister revokes acceptance of the undertaking, or if the period of effect for the undertaking expires   whichever event first occurs.

An Approved Pathology Practitioner may terminate an undertaking at any time providing that the practitioner gives at least 30 days notice of his/her intention to do so.

**PN.9.4 Obligations and Responsibilities of Approved Pathology Practitioners**

The requirements of the legislation and the undertaking impose a number of obligations and responsibilities on Approved Pathology Practitioners and the Minister.  The more complex of these not already dealt with are considered in PK, PL and PM dealing with Breaches of Undertakings, Excessive Pathology Services and Personal Supervision.

**PN.10.1 Approved Pathology Authorities**

**Introduction**

A pathology service will not attract Medicare benefits unless the proprietor of the laboratory in which the pathology service is performed is an Approved Pathology Authority.  Following is information which relates to Approved Pathology Authority requirements.

**PN.10.2 Applying for Acceptance of an Approved Pathology Authority Undertaking**

To apply for acceptance of an Approved Pathology Authority Undertaking, it is necessary to send:

(i)         a completed application for acceptance of an Approved Pathology Authority Undertaking; and

(ii)        a signed Approved Pathology Authority Undertaking to the Pathology Registration, Services Australia,

PO Box 9822, Melbourne Victoria 3001.

An application form, undertaking and associated literature can be obtained from the Pathology Registration Coordinator.

Payment of Acceptance Fee

On receipt of advice that the Minister has accepted an undertaking, a cheque for $1,500 should be sent to the Pathology Registration Coordinator. Applicants are required to pay this fee within 14 days of the notice being given.  As there is no discretion under the *Health Insurance Act 1973* to accept late payments, failure to pay the fee within the required time means that:

(i)         acceptance of the undertaking will be revoked;

(ii)        a new application must be completed;

(iii)       acceptance of the new undertaking cannot be backdated; and

(iv)       there will therefore be a period during which Medicare benefits cannot be paid.

**PN.10.3 Undertakings - Approved Pathology Authority**

Consideration of Undertakings

The Minister is unable to accept undertakings from a person in respect of whom there is a determination in force that the person has breached the undertaking, or from a person who, if the undertaking were accepted, would be likely to carry on the business of a prescribed person or would enable a person to avoid the financial consequences of the disqualification (or likely disqualification) of that prescribed person.  A 'prescribed person' includes, inter alia, fully or partially disqualified persons (or persons likely to be so disqualified).

Similarly an undertaking cannot be accepted unless the Minister is satisfied that the person giving such undertaking is a fit and proper person to be an Approved Pathology Authority.

When an undertaking has been given the Minister may require the person giving the undertaking to provide additional information within a specified period of time and if the person does not comply the Minister may refuse to accept the undertaking.

Refusal of Undertaking and Rights of Review

Where the Minister refuses to accept an undertaking, the Minister must notify the person of the decision.  The notification must include advice of a right of internal review of the decision and a right of further appeal to the Administrative Appeals Tribunal if the internal review upholds the original decision to refuse the undertaking.

Effective Period of Undertaking

The following applies:

(i)         Date of Effect   the earliest day from which the Minister or delegate can accept an undertaking is the day of the decision in respect of the undertaking.  The day the undertaking is signed is to be the day it is actually signed and must not be backdated;

(ii)        Period of Effect   in determining the period of effect of the undertaking the Minister shall, unless the Minister considers that special circumstances exist, determine that the period of effect shall be twelve months from the day on which the undertaking comes into force. There is a requirement for the Minister to notify persons giving an undertaking of the period of time for which the undertaking is to have effect, and the notice is to advise persons whose interests are affected by the decision of their rights of appeal to the Administrative Appeals Tribunal against the Minister's decision;

(iii)       Renewals   when an undertaking is given and accepted by the Minister while a former undertaking is current, the new undertaking does not take effect until the former undertaking ceases to be in force. When an undertaking is given while a former undertaking is current and the date on which the former undertaking is to expire passes without the Minister giving notice to accept or reject the new undertaking, the former undertaking remains in force until the Minister gives such notification.  This provision does not apply when the renewal application is not received by Services Australia until after the expiry of the existing undertaking. Under these circumstances there will be a period during which Medicare benefits cannot be paid unless the new application can be backdated to the expiry of the previous undertaking.  This is a limited discretion for periods up to one month and special conditions apply; and

(iv)       Cessation of Undertaking   the undertaking ceases to be in force if it is terminated, if the Minister revokes acceptance of the undertaking, or if the period of effect for the undertaking expires   whichever event first occurs.

An Approved Pathology Authority may terminate an undertaking at any time providing that at least 30 days notice of the intention to terminate the undertaking is given.

**PN.10.4 Obligations and Responsibilities of Approved Pathology Authorities**

The requirements of the legislation and the undertaking impose a number of obligations and responsibilities on Approved Pathology Authorities and the Minister.  The more complex of these which have not already been covered are considered in paragraphs PK and PL dealing with Breaches of Undertakings and Excessive Pathology Services.

**PN.11.1 Breaches of Undertakings**

**Notice Required**

Where the Minister has reasonable grounds for believing that an Approved Pathology Practitioner or an Approved Pathology Authority has breached the undertaking, the Minister is required to give notice in writing to the person explaining the grounds for that belief and inviting the person to put a submission to the Minister to show cause why no further action should be taken in the matter.

**PN.11.2 Decisions by Minister**

Where a person provides a submission, the Minister may decide to take no further action against the person. Alternatively the Minister may refer the matter to a Medicare Participation Review Committee, notifying the grounds for believing that the undertaking has been breached.  If after 28 days no submission has been received from the person, the Minister must refer that matter to the Committee.

**PN.11.3 Appeals**

The Minister is empowered to suspend an undertaking where notice has been given to a Medicare Participation Review Committee of its possible breach, pending the outcome of the Committee's proceedings.  The Minister must give notice in writing to the person who provided the undertaking of the determination to suspend it, and the notice shall inform the person of a right of appeal against the determination to the Administrative Appeals Tribunal.  The Minister may also publish a notice of a determination in the Public Service Gazette.  Rights of appeal to the Administrative Appeals Tribunal also exist in respect of any determination made by a Medicare Participation Review Committee.

**PN.12.1 Initiation of Excessive Pathology Services**

**Notice Required**

Where the Minister has reasonable grounds for believing that a person, of a specified class of persons, has initiated, or caused or permitted the initiation of excessive pathology services the Minister is required to give notice in writing to the person explaining the grounds for the belief and inviting the person to put a submission to the Minister to show cause why no further action should be taken in the matter.

**PN.12.2 Classes of Persons**

The classes of persons are:

(i)         the practitioner who initiated the services;

(ii)        the employer of the practitioner who caused or permitted the practitioner to initiate the services; or

(iii)       an officer of the body corporate employing the practitioner who caused or permitted the practitioner to initiate the services.

**PN.12.3 Decisions by Minister for Health and Ageing**

Where a person provides a submission, the Minister may decide to take no further action against the person. Alternatively, the Minister may refer the matter to a Professional Services Review (PSR) Committee, notifying the grounds for believing that excessive pathology services have been initiated.  If after 28 days no submission has been received from the person, the Minister must refer the matter to the Committee.  The Minister must give to the person notice in writing of the decision.

**PN.12.4 Appeals**

Unlike the procedures relating to breaches of undertaking there is no power given to the Minister to determine a penalty.  The Minister's role is either deciding to take no further action or referring the matter to a PSR Committee.  Accordingly, there are no rights of appeal to the Administrative Appeals Tribunal applicable to the above procedures.  However, rights of appeal to the Administrative Appeals Tribunal exist in respect of any determination made by a Medicare Participation Review Committee.

**PN.13.1 Personal Supervision**

**Introduction**

The *Health Insurance Act 1973* provides that the form of undertaking to be given by an Approved Pathology Practitioner may make provision for pathology services carried out under the personal supervision of the Approved Pathology Practitioner.

**PN.13.2 Extract from Undertaking**

The following is an extract from the Approved Pathology Practitioner (APP) undertaking:

Part  2 - Personal supervision

2.1       I acknowledge that it is my obligation, subject to Parts 2.2 and 2.4, personally to supervise any person who renders any service on my behalf and I undertake to accept personal responsibility for the rendering of that service under the following conditions of personal supervision:

(i)         Subject to the following conditions, I will usually be physically available in the laboratory while services are being provided at the laboratory;

(ii)        I may, subject to paragraph (vi) below, be physically absent from the laboratory while services are being rendered outside its normal hours of operation but in that event I will leave with the person rendering the service particulars of the manner in which I may be contacted while the service is being rendered and I must be able to personally attend at the laboratory while the service is being rendered or formally designate another APP present while I am absent;

(iii)       I may, subject to paragraph (vi) below, be absent from the laboratory for brief periods due to illness or other personal necessity, or to take part in activities which, in accordance with normal and accepted practice, relate to the provision of services by that laboratory;

(iv)       I will personally keep a written log of my absences from the laboratory that extend beyond one workday in respect of that laboratory and will retain that log in the laboratory for 18 months from date of last entry;

(v)        If I am to be absent from the laboratory for more than 7 consecutive workdays, I will arrange for another APP to personally supervise the rendering of services in the laboratory. That arrangement shall be recorded in writing and retained in the laboratory for 18 months from date of last entry. Until such person is appointed, and his or her appointment is recorded in writing, I will remain personally responsible to comply with this undertaking;

(vi)       If a service is being rendered on my behalf by a person who is not:

(a)        a medical practitioner;

(b)        a scientist; or

(c)        a person having special qualifications or skills relevant to the service being rendered;

and no person in the above groups is physically present in the laboratory, then I must be physically present in the laboratory and closely supervise the rendering of the service;

(vii)      I accept responsibility for taking all reasonable steps to ensure that in regard to services rendered by me or on my behalf:

(a)        all persons who render services are adequately trained;

(b)        all services which are to be rendered in the laboratory are allocated to persons employed by the APA and, these persons shall have appropriate qualifications and experience to render the services;

(c)        the methods and procedures in operation in the laboratory for the purpose of rendering services are in accordance with proper and correct practices;

(d)        for services rendered, proper quality control methods are established and reviewed to ensure their reliability and effectiveness; and

(e)        results of services and tests rendered are accurately recorded and sent to the treating practitioner and, where applicable, a referring practitioner;

(viii)     If I perform, or there is performed on my behalf, a service which consists of the analysis of a specimen which I know, or have reason to believe, has been taken other than in accordance with the provisions of section 16A(5AA) of the Act I will endorse, or cause to be endorsed, on the assignment form or the account for that service, as the case may be, particulars of the circumstances in which I believe, or have reason to believe, the specimen was taken.

2.2       Where services are to be rendered on my behalf in a Category B laboratory as defined in the Health Insurance (Accredited Pathology Laboratories - Approval) Principles 2002, I undertake to take all reasonable measures to ensure that the service is rendered under the supervision of an appropriate person as required by those Principles as in force from time to time.

2.3       I acknowledge to the best of my ability that any act or omission by a person, when acting with my authority, whether express or implied, that would, had it been done by me, have resulted in a breach of this undertaking, constitutes a breach of this undertaking by me.

2.4       Parts 2.1(i) to 2.1(vi) and 2.2 of this undertaking do not apply where a laboratory is limited to services (and associated equipment for those services) as detailed in Schedule 3.

**PN.13.3 Notes on the Above**

Part 2 of the APP Undertaking outlines the requirements for the personal supervision by an Approved Pathology Practitioner where a pathology service is rendered by another person on behalf of the APP.  It should be noted that "on behalf of" does not relieve an Approved Pathology Practitioner of professional responsibility for the service or from being personally involved in the supervision of services in the laboratory.

**PR.2.2 Restriction on items 66551, 73812 and 73826—timing**

For any particular patient, item 66551 is applicable not more than 4 times in 12 months, either individually or in combination with a service to which item 73812 or 73826 applies.

**PR.5.1 Limitation of item 72860**

Item 72860 applies to a service (the relevant service) for a patient if:

                     (a)  the relevant service is subsequent to one or more earlier patient episodes involving:

                              (i)  the rendering of services to which one or more items in Groups P5, P6 or P7 apply (other than item 72860); and

                             (ii)  the collection of tissue material (either biopsy material or samples submitted for cytology) from which a tissue block was prepared; and

                            (iii)  the archiving of the tissue material in formalin fixed paraffin embedded blocks; and

                     (b)  following the earlier patient episode or episodes, the treating practitioner determines that a service to which an item in Group P7 (which deal with genetic testing) applies is clinically necessary for the patient; and

                     (c)  the relevant service is rendered in a patient episode with services to which one or more items in Group P7 apply, but is not rendered in the same accredited pathology laboratory as those services.

**PR.6.1 Episode Cone**

The episode cone is an arrangement, described in Rule 18, which effectively places an upper limit on the number of items for which Medicare benefits are payable in a patient episode.  This cone only applies to services requested by general practitioners for their non-hospitalised patients.  Pathology services requested for hospital in-patients, or ordered by specialists, are not subject to these coning arrangements.

When more than 3 items are requested by a general practitioner in a patient episode, the benefits payable will be equivalent to the sum of the benefits for the three items with the highest Schedule fees.  Rule 18 provides that for the two items with the highest Schedule fees, Medicare benefits will be payable for each item.  The remaining items are regarded as one service for which the benefit payable will be equivalent to that for the item with the third highest Schedule fee.  Where items have the same Schedule fee, their item numbers are used as an artificial means to rank them.

 The episode cone will apply even when the pathology services in a patient episode are performed by 2 or more Approved Pathology Authorities, with the exception of the services listed below.

 The following items are not included in the count of the items performed when applying the episode cone:

(i)         all the items in Groups P10, P11, P12 and P13;

(ii)        Cervical Screening (items 73070, 73071, 73072, 73074, 73075, 73076);

(iii)       all the items detailed at Rule 18 (e) (items 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66609, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69451, 69500, 69489, 69492, 69497, 69498, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318);

(iv)       supplementary test for Hepatitis B and Hepatitis C (item 69484); and

(v)        the carbon-labelled urea breath test to confirm or monitor Helicobacter pylori (item 66900).

**PR.7.1 Items 73384 to 73387 (relating to pre implantation genetic testing under clause 2.7.3A of the pathology services table)—patient eligibility**

A patient is eligible for a service described in any of items 73384 to 73387 only if:

(a)  the patient or the patient’s reproductive partner:

1. has an identified gene variant which places the patient at risk of having a pregnancy affected by a Mendelian or mitochondrial disorder; or
2. is at risk of an autosomal dominant disorder which places the patient at risk of having a child who develops the autosomal dominant disorder; or
3. has a chromosome re‑arrangement or copy number variant which places the patient at risk of having a pregnancy affected by a chromosome disorder; and

(b)  there is no curative treatment for the disorder and there is severe limitation of quality of life despite contemporary management of the disorder; and

(c)  the patient has previously had a consultation, with a specialist or consultant physician practising as a clinical geneticist, that included a discussion about the disorder.

**PR.7.2 Restriction on item 73290—conjunction with item 73391**

2.7.1B  Restriction on item 73290—conjunction with item 73391

Item 73290 applies to a service described in that item only if the service is not performed in conjunction with a service described in item 73391.

**PR.7.3 Restriction on item 73287—conjunction with item 73388**

2.7.1A  Restriction on item 73287—conjunction with item 73388

Item 73287 applies to a service described in that item only if the service is not performed in conjunction with a service described in item 73388.

**PR.9.1 Quality Assurance in Aboriginal Medical Services (QAAMS) Program items**

Item numbers 73839, 73840 and 73844 can only be performed in the following circumstances:

a) the service is rendered by or on behalf of a medical practitioner;    
b) the practitioner referred to in paragraph (a), or the organisation for which the practitioner works, is participating in the Quality Assurance in  Aboriginal Medical Services Program; and  
c) the service is provided in accordance with that Program; and   
d) the practitioner referred to in paragraph (a) has determined the service to be necessary for his or her patient.

**PR.9.3 Limitation of item 73826**

Item 73826 does not apply to a service provided to a patient who has already been provided, in the last 12 months, 4 other services to which any of the following apply:

1. item 73826;
2. item 66551;
3. item 73812.

**PR.9.4 Limitation of item 73812**

Item 73812 does not apply to a service provided to a patient who has already been provided, in the last 12 months, 4 other services to which any of the following apply:

1. item 73812;
2. item 66551;
3. item 73826.

**PATHOLOGY SERVICES ITEMS**

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P1. HAEMATOLOGY** |  | | |
|  | Group P1. Haematology |
| 65060 | Haemoglobin, erythrocyte sedimentation rate, blood viscosity - 1 or more tests  (See para PN.0.33, PN.1.1 of explanatory notes to this Category)  **Fee:** $7.85 **Benefit:** 75% = $5.90 85% = $6.70 |
| 65066 | Examination of:  (a)    a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or  (b)    a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha-naphthyl acetate esterase or chloroacetate esterase; or  (c)    a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or  (d)    a urinary sediment for haemosiderin  including a service described in item 65072  **Fee:** $10.40 **Benefit:** 75% = $7.80 85% = $8.85 |
| 65070 | Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count - not being a service where haemoglobin only is requested - one or more instrument generated sets of results from a single sample; and (if performed)  (a)     a morphological assessment of a blood film;  (b)     any service in item 65060 or 65072  **Fee:** $16.95 **Benefit:** 75% = $12.75 85% = $14.45 |
| 65072 | Examination for reticulocytes including a reticulocyte count by any method - 1 or more tests  **Fee:** $10.20 **Benefit:** 75% = $7.65 85% = $8.70 |
| 65075 | Haemolysis or metabolic enzymes - assessment by:  (a)    erythrocyte autohaemolysis test; or  (b)    erythrocyte osmotic fragility test; or  (c)    sugar water test; or  (d)    G-6-P D (qualitative or quantitative) test; or  (e)    pyruvate kinase (qualitative or quantitative) test; or  (f)    acid haemolysis test; or  (g)     quantitation of muramidase in serum or urine; or  (h)     Donath Landsteiner antibody test; or  (i)     other erythrocyte metabolic enzyme tests  1 or more tests  **Fee:** $51.95 **Benefit:** 75% = $39.00 85% = $44.20 |
| 65078 | Tests for the diagnosis of thalassaemia consisting of haemoglobin electrophoresis or chromatography and at least 2 of:  (a)    examination for HbH; or  (b)    quantitation of HbA2; or  (c)    quantitation of HbF;  including (if performed) any service described in item 65060 or 65070  **Fee:** $90.20 **Benefit:** 75% = $67.65 85% = $76.70 |
| 65079 | Tests described in item 65078 if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)  **Fee:** $90.20 **Benefit:** 75% = $67.65 85% = $76.70 |
| 65081 | Tests for the investigation of haemoglobinopathy consisting of haemoglobin electrophoresis or chromatography and at least 1 of:  (a)    heat denaturation test; or  (b)    isopropanol precipitation test; or  (c)    tests for the presence of haemoglobin S; or  (d)    quantitation of any haemoglobin fraction (including S, C, D, E);  including (if performed) any service described in item 65060, 65070 or 65078  **Fee:** $96.60 **Benefit:** 75% = $72.45 85% = $82.15 |
| 65082 | Tests described in item 65081 if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)  **Fee:** $96.60 **Benefit:** 75% = $72.45 85% = $82.15 |
| 65084 | Bone marrow trephine biopsy - histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed):  any test described in item 65060, 65066 or 65070  **Fee:** $165.85 **Benefit:** 75% = $124.40 85% = $141.00 |
| 65087 | Bone marrow - examination of aspirated material (including clot sections where necessary), including (if performed):  any test described in item 65060, 65066 or 65070  **Fee:** $83.10 **Benefit:** 75% = $62.35 85% = $70.65 |
| 65090 | Blood grouping (including back-grouping if performed) - ABO and Rh (D antigen)  (See para PN.0.33, PN.1.1 of explanatory notes to this Category)  **Fee:** $11.15 **Benefit:** 75% = $8.40 85% = $9.50 |
| 65093 | Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - 1 or more systems, including item 65090 (if performed)  **Fee:** $22.00 **Benefit:** 75% = $16.50 85% = $18.70 |
| 65096 | Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:  (a)    identification and quantitation of any antibodies detected; and  (b)    (if performed) any test described in item 65060 or 65070  (See para PN.1.1 of explanatory notes to this Category)  **Fee:** $41.00 **Benefit:** 75% = $30.75 85% = $34.85 |
| 65099 | Compatibility tests by crossmatch - all tests performed on any 1 day for up to 6 units, including:  (a)    direct testing of donor red cells from each unit against the serum of the patient by one or more accepted crossmatching techniques; and  (b)    all grouping checks of the patient and donor; and  (c)    examination for antibodies, and if necessary identification of any antibodies detected; and  (d)    (if performed) any tests described in item 65060, 65070, 65090 or 65096  (Item is subject to rule 5)  **Fee:** $108.90 **Benefit:** 75% = $81.70 85% = $92.60 |
| 65102 | Compatibility tests by crossmatch - all tests performed on any 1 day in excess of 6 units, including:  (a)    direct testing of donor red cells from each unit against serum of the patient by one or more accepted crossmatching techniques; and  (b)    all grouping checks of the patient and donor; and  (c)    examination for antibodies, and if necessary identification of any antibodies detected; and  (d)    (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105  (Item is subject to rule 5)  **Fee:** $164.60 **Benefit:** 75% = $123.45 85% = $139.95 |
| 65105 | Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion - all tests performed on any one day for up to 6 units, including:  (a)     all grouping checks of the patient and donor; and  (b)     examination for antibodies and, if necessary, identification of any antibodies detected; and  (c)     (if performed) any tests described in item 65060, 65070, 65090 or 65096  (Item is subject to rule 5)  **Fee:** $108.90 **Benefit:** 75% = $81.70 85% = $92.60 |
| 65108 | Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion - all tests performed on any one day in excess of 6 units, including:  (a)    all grouping checks of the patient and donor; and  (b)    examination for antibodies and, if necessary, identification of any antibodies detected; and  (c)     (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105  (Item is subject to rule 5)  **Fee:** $164.60 **Benefit:** 75% = $123.45 85% = $139.95 |
| 65109 | Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy - 1 release.  **Fee:** $12.90 **Benefit:** 75% = $9.70 85% = $11.00 |
| 65110 | Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimize bleeding or during active bleeding - 1 release.  **Fee:** $12.90 **Benefit:** 75% = $9.70 85% = $11.00 |
| 65111 | Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)  **Fee:** $23.20 **Benefit:** 75% = $17.40 85% = $19.75 |
| 65114 | 1 or more of the following tests:  (a)    direct Coombs (antiglobulin) test;  (b)    qualitative or quantitative test for cold agglutinins or heterophil antibodies  **Fee:** $9.10 **Benefit:** 75% = $6.85 85% = $7.75 |
| 65117 | 1 or more of the following tests:  (a)    Spectroscopic examination of blood for chemically altered haemoglobins;  (b)    detection of methaemalbumin (Schumm's test)  **Fee:** $20.25 **Benefit:** 75% = $15.20 85% = $17.25 |
| 65120 | Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or 1 of fibrinogen degradation products, fibrin monomer or D-dimer - 1 test  **Fee:** $13.70 **Benefit:** 75% = $10.30 85% = $11.65 |
| 65123 | 2 tests described in item 65120  **Fee:** $20.35 **Benefit:** 75% = $15.30 85% = $17.30 |
| 65126 | 3 tests described in item 65120  **Fee:** $27.85 **Benefit:** 75% = $20.90 85% = $23.70 |
| 65129 | 4 or more tests described in item 65120  (See para PN.0.28 of explanatory notes to this Category)  **Fee:** $35.50 **Benefit:** 75% = $26.65 85% = $30.20 |
| 65137 | Test for the presence of lupus anticoagulant not being a service associated with any service to which items 65175, 65176, 65177, 65178 and 65179 apply  **Fee:** $25.35 **Benefit:** 75% = $19.05 85% = $21.55 |
| 65142 | Confirmation or clarification of an abnormal or indeterminate result from a test described in item 65175, by testing a specimen collected on a different day - 1 or more tests  **Fee:** $25.35 **Benefit:** 75% = $19.05 85% = $21.55 |
| 65144 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs - 1 or more tests  **Fee:** $56.55 **Benefit:** 75% = $42.45 85% = $48.10 |
| 65147 | Quantitation of anti-Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid - 1 test  **Fee:** $37.90 **Benefit:** 75% = $28.45 85% = $32.25 |
| 65150 | Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay - 1 test  (Item is subject to rule 6 )  **Fee:** $70.90 **Benefit:** 75% = $53.20 85% = $60.30 |
| 65153 | 2 tests described in item 65150  (Item is subject to rule 6 )  **Fee:** $141.85 **Benefit:** 75% = $106.40 85% = $120.60 |
| 65156 | 3 or more tests described in item 65150  (Item is subject to rule 6 )  **Fee:** $212.75 **Benefit:** 75% = $159.60 85% = $180.85 |
| 65157 | A test described in item 65150, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test (Item is subject to rule 6 and 18)  **Fee:** $70.90 **Benefit:** 75% = $53.20 85% = $60.30 |
| 65158 | Tests described in item 65150, other than that described in 65157, if rendered by a receiving APP - each test to a maximum of 2 tests  (Item is subject to rule 6 and 18)  **Fee:** $70.90 **Benefit:** 75% = $53.20 85% = $60.30 |
| 65159 | Quantitation of circulating coagulation factor inhibitors by Bethesda assay - 1 test  **Fee:** $70.90 **Benefit:** 75% = $53.20 85% = $60.30 |
| 65162 | Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)  **Fee:** $10.45 **Benefit:** 75% = $7.85 85% = $8.90 |
| 65165 | Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162  **Fee:** $34.45 **Benefit:** 75% = $25.85 85% = $29.30 |
| 65166 | A test described in item 65165 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $34.45 **Benefit:** 75% = $25.85 85% = $29.30 |
| 65171 | Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven defect of any of the above - 1 or more tests  **Fee:** $25.35 **Benefit:** 75% = $19.05 85% = $21.55 |
| 65175 | Test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance - where the request for the test(s) specifically identifies that the patient has a history of venous thromboembolism - quantitation by 1 or more techniques - 1 test  (Item is subject to Rule 6)  **Fee:** $25.35 **Benefit:** 75% = $19.05 85% = $21.55 |
| 65176 | 2 tests described in item 65175  (Item is subject to rule 6)  **Fee:** $48.65 **Benefit:** 75% = $36.50 85% = $41.40 |
| 65177 | 3 tests described in item 65175  (Item is subject to rule 6)  **Fee:** $71.95 **Benefit:** 75% = $54.00 85% = $61.20 |
| 65178 | 4 tests described in item 65175  (Item is subject to rule 6)  **Fee:** $95.20 **Benefit:** 75% = $71.40 85% = $80.95 |
| 65179 | 5 tests described in item 65175  (Item is subject to rule 6)  **Fee:** $118.50 **Benefit:** 75% = $88.90 85% = $100.75 |
| 65180 | A test described in item 65175, if rendered by a receiving APA, where no tests in the item have been rendered by the referring APA - 1 test  (Item is subject to rule  6 and 18)  **Fee:** $25.35 **Benefit:** 75% = $19.05 85% = $21.55 |
| 65181 | A test described in item 65175, if rendered by a receiving APP, if one or more tests described in the item have been rendered by the referring APP - one test  (Item is subject to rule 6 and 18)  **Fee:** $23.30 **Benefit:** 75% = $17.50 85% = $19.85 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P2. CHEMICAL** |  | | |
|  | Group P2. Chemical |
| 66500 | Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method except reagent tablet or reagent strip (with or without reflectance meter) of: acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), C-reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, total protein, total cholesterol, triglycerides, urate or urea - 1 test  **Fee:** $9.70 **Benefit:** 75% = $7.30 85% = $8.25 |
| 66503 | 2 tests described in item 66500  **Fee:** $11.65 **Benefit:** 75% = $8.75 85% = $9.95 |
| 66506 | 3 tests described in item 66500  **Fee:** $13.65 **Benefit:** 75% = $10.25 85% = $11.65 |
| 66509 | 4 tests described in item 66500  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 66512 | 5 or more tests described in item 66500  **Fee:** $17.70 **Benefit:** 75% = $13.30 85% = $15.05 |
| 66517 | Quantitation of bile acids in blood in pregnancy.  Applicable not more than 3 times in a pregnancy.  **Fee:** $19.65 **Benefit:** 75% = $14.75 85% = $16.75 |
| 66518 | Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood - testing on 1 specimen in a 24 hour period  **Fee:** $20.05 **Benefit:** 75% = $15.05 85% = $17.05 |
| 66519 | Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood - testing on 2 or more specimens in a 24 hour period  **Fee:** $40.15 **Benefit:** 75% = $30.15 85% = $34.15 |
| 66522 | Faecal calprotectin test for the diagnosis of inflammatory bowel disease, if all the following apply:   1. the patient is under 50 years of age; 2. the patient has gastrointestinal symptoms suggestive of inflammatory or functional bowel disease of more than 6 weeks’ duration; 3. infectious causes have been excluded; 4. the likelihood of malignancy has been assessed as low; 5. no relevant clinical alarms are present   **Fee:** $75.00 **Benefit:** 75% = $56.25 85% = $63.75 |
| 66523 | Faecal calprotectin test for the diagnosis of inflammatory bowel disease, if all the following apply:   1. the results of a service to which item 66522 applies were inconclusive for the patient (that is, the results showed a faecal calprotectin level of more than 50 μg/g but not more than 100 μg/g); 2. the patient has ongoing gastrointestinal symptoms suggestive of inflammatory or functional bowel disease; 3. the service is requested by a specialist or consultant physician practising as a specialist gastroenterologist; 4. the request indicates that an endoscopic examination is not initially required; 5. no relevant clinical alarms are present   **Fee:** $75.00 **Benefit:** 75% = $56.25 85% = $63.75 |
| 66536 | Quantitation of HDL cholesterol  **Fee:** $11.05 **Benefit:** 75% = $8.30 85% = $9.40 |
| 66539 | Electrophoresis of serum for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L or in the diagnosis of types III and IV hyperlipidaemia - (Item is subject to rule 25)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66542 | Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes:  (a)    administration of glucose; and  (b)    at least 2 measurements of blood glucose; and  (c)    (if performed) any test described in item 66695  **Fee:** $18.95 **Benefit:** 75% = $14.25 85% = $16.15 |
| 66545 | Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:  (a)    administration of glucose; and  (b)    1 or 2 measurements of blood glucose; and  (c)    (if performed) any test in item 66695  **Fee:** $15.80 **Benefit:** 75% = $11.85 85% = $13.45 |
| 66548 | Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:  (a)    administration of glucose; and  (b)    at least 3 measurements of blood glucose; and  (c)    any test in item 66695 (if performed)  **Fee:** $19.90 **Benefit:** 75% = $14.95 85% = $16.95 |
| 66551 | Quantitation of glycated haemoglobin performed in the management of established diabetes  (See para PR.2.2 of explanatory notes to this Category)  (See para PR.2.2 of explanatory notes to this Category)  **Fee:** $16.80 **Benefit:** 75% = $12.60 85% = $14.30 |
| 66554 | Quantitation of glycated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant - including a service in item 66551 (if performed) - (Item is subject to rule 25)  **Fee:** $16.80 **Benefit:** 75% = $12.60 85% = $14.30 |
| 66557 | Quantitation of fructosamine performed in the management of established diabetes - each test to a maximum of 4 tests in a 12 month period  **Fee:** $9.70 **Benefit:** 75% = $7.30 85% = $8.25 |
| 66560 | Microalbumin - quantitation in urine  **Fee:** $20.10 **Benefit:** 75% = $15.10 85% = $17.10 |
| 66563 | Osmolality, estimation by osmometer, in serum or in urine - 1 or more tests  **Fee:** $24.70 **Benefit:** 75% = $18.55 85% = $21.00 |
| 66566 | Quantitation of:  (a)    blood gases (including pO2, oxygen saturation and pCO2); and  (b)    bicarbonate and pH;  including any other measurement (eg. haemoglobin, lactate, potassium or ionised calcium) or calculation performed on the same specimen - 1 or more tests on 1 specimen  **Fee:** $33.70 **Benefit:** 75% = $25.30 85% = $28.65 |
| 66569 | Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed within any 1 day  **Fee:** $42.60 **Benefit:** 75% = $31.95 85% = $36.25 |
| 66572 | Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed within any 1 day  **Fee:** $51.55 **Benefit:** 75% = $38.70 85% = $43.85 |
| 66575 | Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed within any 1 day  **Fee:** $60.45 **Benefit:** 75% = $45.35 85% = $51.40 |
| 66578 | Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed within any 1 day  **Fee:** $69.35 **Benefit:** 75% = $52.05 85% = $58.95 |
| 66581 | Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed within any 1 day  **Fee:** $78.25 **Benefit:** 75% = $58.70 85% = $66.55 |
| 66584 | Quantitation of ionised calcium (except if performed as part of item 66566) - 1 test  **Fee:** $9.70 **Benefit:** 75% = $7.30 85% = $8.25 |
| 66585 | Quantification of laboratory‑based BNP or NT‑proBNP testing in a patient with systemic sclerosis (scleroderma) to assess risk of pulmonary arterial hypertension  Maximum of 2 tests in a 12 month period    (See para PN.2.5 of explanatory notes to this Category)  **Fee:** $58.50 **Benefit:** 75% = $43.90 85% = $49.75 |
| **New**  66586 | Quantification of BNP or NT-proBNP testing in a patient with diagnosed pulmonary arterial hypertension to monitor for disease progression  Applicable 4 times in any 12-month period  (See para PN.2.5 of explanatory notes to this Category)  **Fee:** $58.50 **Benefit:** 75% = $43.90 85% = $49.75 |
| 66587 | Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least 1 blood specimen  **Fee:** $47.55 **Benefit:** 75% = $35.70 85% = $40.45 |
| 66590 | Calculus, analysis of 1 or more  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66593 | Ferritin - quantitation, except if requested as part of iron studies  **Fee:** $18.00 **Benefit:** 75% = $13.50 85% = $15.30 |
| 66596 | Iron studies, consisting of quantitation of:  (a)    serum iron; and  (b)    transferrin or iron binding capacity; and  (c)    ferritin  **Fee:** $32.55 **Benefit:** 75% = $24.45 85% = $27.70 |
| 66605 | Vitamins - quantitation of vitamins B1, B2, B3, B6 or C  in blood, urine or other body fluid - 1 or more tests  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66606 | A test described in item 66605 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18 and 25)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66607 | Vitamins - quantitation of vitamins A or E in blood, urine or other body fluid - 1 or more tests within a 6 month period  **Fee:** $75.75 **Benefit:** 75% = $56.85 85% = $64.40 |
| 66610 | A test described in item 66607 if rendered by a receiving APP - 1 or more tests  **Fee:** $75.75 **Benefit:** 75% = $56.85 85% = $64.40 |
| 66623 | All qualitative and quantitative tests on blood, urine or other body fluid for:  (a)    a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or  (b)    ingested or absorbed toxic chemicals;  including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding:  (c)    the surveillance of sports people and athletes for performance improving substances; and  (d)    the monitoring of patients participating in a drug abuse treatment program  **Fee:** $41.50 **Benefit:** 75% = $31.15 85% = $35.30 |
| 66626 | Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program; but excluding the surveillance of sports people and athletes for performance improving substances; including all tests on blood, urine or other body fluid  (Item is subject to rule 25)  **Fee:** $24.10 **Benefit:** 75% = $18.10 85% = $20.50 |
| 66629 | Beta-2-microglobulin - quantitation in serum, urine or other body fluids - 1 or more tests  **Fee:** $20.10 **Benefit:** 75% = $15.10 85% = $17.10 |
| 66632 | Caeruloplasmin, haptoglobins, or prealbumin - quantitation in serum, urine or other body fluids - 1 or more tests  **Fee:** $20.10 **Benefit:** 75% = $15.10 85% = $17.10 |
| 66635 | Alpha-1-antitrypsin - quantitation in serum, urine or other body fluid - 1 or more tests  **Fee:** $20.10 **Benefit:** 75% = $15.10 85% = $17.10 |
| 66638 | Isoelectric focussing or similar methods for determination of alpha-1-antitrypsin phenotype in serum - 1 or more tests  **Fee:** $49.05 **Benefit:** 75% = $36.80 85% = $41.70 |
| 66639 | A test described in item 66638 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $29.20 **Benefit:** 75% = $21.90 85% = $24.85 |
| 66641 | Electrophoresis of serum or other body fluid to demonstrate:  (a)    the isoenzymes of lactate dehydrogenase; or  (b)    the isoenzymes of alkaline phosphatase;  including the preliminary quantitation of total relevant enzyme activity - 1 or more tests  **Fee:** $29.20 **Benefit:** 75% = $21.90 85% = $24.85 |
| 66642 | A test described in item 66641 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $29.20 **Benefit:** 75% = $21.90 85% = $24.85 |
| 66644 | C-1 esterase inhibitor - quantitation  **Fee:** $20.15 **Benefit:** 75% = $15.15 85% = $17.15 |
| 66647 | C-1 esterase inhibitor - functional assay  **Fee:** $45.10 **Benefit:** 75% = $33.85 85% = $38.35 |
| 66650 | Alpha-fetoprotein, CA-15.3 antigen (CA15.3), CA-125 antigen (CA125), CA-19.9 antigen (CA19.9), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), neuron specific enolase (NSE), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of hepatic tumours, gestational trophoblastic disease or germ cell tumour - quantitation - 1 test  (Item is subject to rule 6)  **Fee:** $24.35 **Benefit:** 75% = $18.30 85% = $20.70 |
| 66651 | A test described in item 66650 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $24.35 **Benefit:** 75% = $18.30 85% = $20.70 |
| 66652 | A test described in item 66650 if rendered by a receiving APP - other than that described in 66651, if rendered by a receiving APP, 1 test  (Item is subject to rule 6 and 18)  **Fee:** $20.30 **Benefit:** 75% = $15.25 85% = $17.30 |
| 66653 | 2 or more tests described in item 66650  (Item is subject to rule 6)  **Fee:** $44.60 **Benefit:** 75% = $33.45 85% = $37.95 |
| 66654 | Prostate specific antigen – quantitation in the monitoring of high-risk patients  For any particular patient, applicable not more than once in 11 months  **Fee:** $20.15 **Benefit:** 75% = $15.15 85% = $17.15 |
| 66655 | Prostate specific antigen—quantitation  For any particular patient, applicable not more than once in 23 months  **Fee:** $20.15 **Benefit:** 75% = $15.15 85% = $17.15 |
| 66656 | Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including prostate cancer, prostatitis or a premalignant condition such as atypical small acinar proliferation)  **Fee:** $20.15 **Benefit:** 75% = $15.15 85% = $17.15 |
| 66659 | Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result under item 66654 or 66655 that lies at:  (a) more than 2.0 ug/L but less than or equal to 5.5 ug/L for patients with a family history of prostate cancer; or  (b) more than 3.0 ug/L but less than or equal to 5.5 ug/L for patients who are at least 50 years of age but under 70 years of age; or  (c) more than 5.5 ug/L but less than or equal to 10.0 ug/L for patients who are at least 70 years of age  For any particular patient, applicable not more than once in 11 months  **Fee:** $37.30 **Benefit:** 75% = $28.00 85% = $31.75 |
| 66660 | Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, in the monitoring of previously diagnosed prostatic disease, including, if performed, a test described in item 66656, if the current PSA level lies at:  (a) more than 2.0 ug/L but less than or equal to 5.5 ug/L for patients with a family history of prostate cancer; or  (b) more than 3.0 ug/L but less than or equal to 5.5 ug/L for patients who are at least 50 years of age but under 70 years of age; or  (c) more than 5.5 ug/L but less than or equal to 10.0 ug/L for patients who are at least 70 years of age  For any particular patient, applicable not more than 4 times in 11 months  **Fee:** $37.30 **Benefit:** 75% = $28.00 85% = $31.75 |
| 66662 | Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast - 1 or more tests  **Fee:** $79.95 **Benefit:** 75% = $60.00 85% = $68.00 |
| 66663 | A test described in item 66662 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $79.95 **Benefit:** 75% = $60.00 85% = $68.00 |
| 66665 | Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period - each test  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66666 | A test described in item 66665 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66667 | Quantitation of serum zinc in a patient receiving intravenous alimentation - each test  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66671 | Quantitation of serum aluminium in a patient in a renal dialysis program - each test  **Fee:** $36.90 **Benefit:** 75% = $27.70 85% = $31.40 |
| 66674 | Quantitation of:  (a)    faecal fat; or  (b)    breath hydrogen in response to loading with disaccharides;  1 or more tests within a 28 day period  **Fee:** $39.95 **Benefit:** 75% = $30.00 85% = $34.00 |
| 66677 | Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old  **Fee:** $11.15 **Benefit:** 75% = $8.40 85% = $9.50 |
| 66680 | Quantitation of disaccharidases and other enzymes in intestinal tissue - 1 or more tests  **Fee:** $74.45 **Benefit:** 75% = $55.85 85% = $63.30 |
| 66683 | Enzymes - quantitation in solid tissue or tissues other than blood elements or intestinal tissue - 1 or more tests  **Fee:** $74.45 **Benefit:** 75% = $55.85 85% = $63.30 |
| 66686 | Performance of 1 or more of the following procedures:  (a)    growth hormone suppression by glucose loading;  (b)    growth hormone stimulation by exercise;  (c)    dexamethasone suppression test;  (d)    sweat collection by iontophoresis for chloride analysis;  (e)    pharmacological stimulation of growth hormone  **Fee:** $50.65 **Benefit:** 75% = $38.00 85% = $43.10 |
| 66695 | Quantitation in blood or urine of hormones and hormone binding proteins - ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF-1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide,  - 1 test  (Item is subject to rule 6)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $30.50 **Benefit:** 75% = $22.90 85% = $25.95 |
| 66696 | A test described in item 66695, if rendered by a receiving APP - where no tests in the item have been rendered by the referring APP  (Item is subject to rule 6 and 18)  **Fee:** $30.50 **Benefit:** 75% = $22.90 85% = $25.95 |
| 66697 | Tests described in item 66695, other than that described in 66696, if rendered by a receiving APP - each test to a maximum of 4 tests  (Item is subject to rule 6 and 18)  **Fee:** $13.20 **Benefit:** 75% = $9.90 85% = $11.25 |
| 66698 | 2 tests described in item 66695  (Item is subject to rule 6)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $43.70 **Benefit:** 75% = $32.80 85% = $37.15 |
| 66701 | 3 tests described in item 66695  (Item is subject to rule 6)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $56.90 **Benefit:** 75% = $42.70 85% = $48.40 |
| 66704 | 4 tests described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 4 tests specified on the request form or performs 4 tests and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $70.15 **Benefit:** 75% = $52.65 85% = $59.65 |
| 66707 | 5 or more tests described in item 66695  (Item is subject to rule 6)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $83.35 **Benefit:** 75% = $62.55 85% = $70.85 |
| 66711 | Quantitation in saliva of cortisol in:  (a)    the investigation of Cushing's syndrome; or  (b)    the management of children with congenital adrenal hyperplasia  (Item is subject to rule 6)  **Fee:** $30.15 **Benefit:** 75% = $22.65 85% = $25.65 |
| 66712 | Two tests described in item 66711  (Item is subject to rule 6)  **Fee:** $43.05 **Benefit:** 75% = $32.30 85% = $36.60 |
| 66714 | A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP  (Item is subject to rule 6 and 18)  **Fee:** $30.15 **Benefit:** 75% = $22.65 85% = $25.65 |
| 66715 | Tests described in item 66711, other than that described in 66714, if rendered by a receiving APP, each test to a maximum of 1 test  (Item is subject to rule 6 and 18)  **Fee:** $12.85 **Benefit:** 75% = $9.65 85% = $10.95 |
| 66716 | TSH quantitation  **Fee:** $25.05 **Benefit:** 75% = $18.80 85% = $21.30 |
| 66719 | Thyroid function tests (comprising the service described in item 66716 and either or both of a test for free thyroxine and a test for free T3) for a patient, if:     (a)    the patient has a level of TSH that is outside the normal reference range for the particular method of assay used to determine the level; or     (b)    the request from the requesting medical practitioner indicates that the tests are performed:         (i)    for the purpose of monitoring thyroid disease in the patient; or         (ii)    to investigate the sick euthyroid syndrome if the patient is an admitted patient; or         (iii)    to investigate dementia or psychiatric illness of the patient; or         (iv)    to investigate amenorrhoea or infertility of the patient; or     (c)    the request from the requesting medical practitioner indicates that the medical practitioner suspects the patient has a pituitary dysfunction; or     (d)    the request from the requesting medical practitioner indicates that the patient is on drugs that interfere with thyroid hormone metabolism or function  **Fee:** $34.80 **Benefit:** 75% = $26.10 85% = $29.60 |
| 66722 | TSH quantitation described in item 66716 and 1 test described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 tests specified on the request form or performs 2 tests and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  **Fee:** $37.90 **Benefit:** 75% = $28.45 85% = $32.25 |
| 66723 | Tests described in item 66722, that is, TSH quantitation and 1 test described in 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $37.90 **Benefit:** 75% = $28.45 85% = $32.25 |
| 66724 | Tests described in item 66722, if rendered by a receiving APP, other than that described in 66723. It is to include a quantitation of TSH - each test to a maximum of 4 tests described in item 66695  (Item is subject to rule 6 and 18)  **Fee:** $13.15 **Benefit:** 75% = $9.90 85% = $11.20 |
| 66725 | TSH quantitation described in item 66716 and 2 tests described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 3 tests specified on the request form or performs 3 tests and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  **Fee:** $51.05 **Benefit:** 75% = $38.30 85% = $43.40 |
| 66728 | TSH quantitation described in item 66716 and 3 tests described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 4 tests specified on the request form or performs 4 tests and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  **Fee:** $64.20 **Benefit:** 75% = $48.15 85% = $54.60 |
| 66731 | TSH quantitation described in item 66716 and 4 tests described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 5 tests specified on the request form or performs 5 tests and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  **Fee:** $77.40 **Benefit:** 75% = $58.05 85% = $65.80 |
| 66734 | TSH quantitation described in item 66716 and 5 tests described in item 66695  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs 6 or more tests specified on the request form)  (Item is subject to rule 6)  **Fee:** $90.55 **Benefit:** 75% = $67.95 85% = $77.00 |
| 66743 | Quantitation of alpha-fetoprotein in serum or other body fluids during pregnancy except if requested as part of items 66750 or 66751  **Fee:** $20.10 **Benefit:** 75% = $15.10 85% = $17.10 |
| 66749 | Amniotic fluid, spectrophotometric examination of, and quantitation of:  (a)    lecithin/sphingomyelin ratio; or  (b)    palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or  (c)    bilirubin, including correction for haemoglobin  1 or more tests  **Fee:** $32.95 **Benefit:** 75% = $24.75 85% = $28.05 |
| 66750 | Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality - total human chorionic gonadotrophin (total HCG), free alpha human chorionic gonadotrophin (free alpha HCG), free beta human chorionic gonadotrophin (free beta HCG), pregnancy associated plasma protein A (PAPP-A), unconjugated oestriol (uE3), alpha-fetoprotein (AFP) - including (if performed) a service described in item 73527 or 73529  - Applicable not more than once in a pregnancy  **Fee:** $39.75 **Benefit:** 75% = $29.85 85% = $33.80 |
| 66751 | Quantitation, in pregnancy, of any three or more tests described in 66750  (Item is subject to rule 25)  **Fee:** $55.25 **Benefit:** 75% = $41.45 85% = $47.00 |
| 66752 | Quantitation of acetoacetate, beta-hydroxybutyrate, citrate, oxalate, total free fatty acids, cysteine, homocysteine, cystine, lactate, pyruvate or other amino acids and hydroxyproline (except if performed as part of item 66773 or 66776) - 1 test  **Fee:** $24.70 **Benefit:** 75% = $18.55 85% = $21.00 |
| 66755 | 2 or more tests described in item 66752  **Fee:** $38.85 **Benefit:** 75% = $29.15 85% = $33.05 |
| 66756 | Quantitation of 10 or more amino acids for the diagnosis of inborn errors of metabolism - up to 4 tests in a 12 month period on specimens of plasma, CSF and urine.  **Fee:** $98.30 **Benefit:** 75% = $73.75 85% = $83.60 |
| 66757 | Quantitation of 10 or more amino acids for monitoring of previously diagnosed inborn errors of metabolism in 1 tissue type.  **Fee:** $98.30 **Benefit:** 75% = $73.75 85% = $83.60 |
| 66758 | Quantitation of angiotensin converting enzyme, or cholinesterase - 1 or more tests  **Fee:** $24.70 **Benefit:** 75% = $18.55 85% = $21.00 |
| 66761 | Test for reducing substances in faeces by any method (except reagent strip or dipstick)  **Fee:** $13.15 **Benefit:** 75% = $9.90 85% = $11.20 |
| 66764 | Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces except by reagent strip or dip stick methods)  with a maximum of 3 examinations on specimens collected on separate days in a 28 day period  **Fee:** $8.90 **Benefit:** 75% = $6.70 85% = $7.60 |
| 66767 | 2 examinations described in item 66764 performed on separately collected and identified specimens  **Fee:** $17.85 **Benefit:** 75% = $13.40 85% = $15.20 |
| 66770 | 3 examinations described in item 66764 performed on separately collected and identified specimens  **Fee:** $26.70 **Benefit:** 75% = $20.05 85% = $22.70 |
| 66773 | Quantitation of products of collagen breakdown or formation for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66752 - 1 or more tests  *(Low bone densitometry is defined in the explanatory notes to Category 2 - Diagnostic Procedures and Investigations of the Medicare Benefits Schedule)*  **Fee:** $24.65 **Benefit:** 75% = $18.50 85% = $21.00 |
| 66776 | Quantitation of products of collagen breakdown or formation for the monitoring of patients with metabolic bone disease or Paget's disease of bone, and if performed, a service described in item 66752 - 1 or more tests  **Fee:** $24.65 **Benefit:** 75% = $18.50 85% = $21.00 |
| 66779 | Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin  quantitation - 1 or more tests  **Fee:** $39.95 **Benefit:** 75% = $30.00 85% = $34.00 |
| 66780 | A test described in item 66779 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $39.95 **Benefit:** 75% = $30.00 85% = $34.00 |
| 66782 | Porphyrins or porphyrins precursors - detection in plasma, red cells, urine or faeces - 1 or more tests  **Fee:** $13.15 **Benefit:** 75% = $9.90 85% = $11.20 |
| 66783 | A test described in item 66782 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $13.15 **Benefit:** 75% = $9.90 85% = $11.20 |
| 66785 | Porphyrins or porphyrins precursors - quantitation in plasma, red cells, urine or faeces - 1 test  (Item is subject to rule 6)  **Fee:** $39.95 **Benefit:** 75% = $30.00 85% = $34.00 |
| 66788 | Porphyrins or porphyrins precursors - quantitation in plasma, red cells, urine or faeces - 2 or more tests  (Item is subject to rule 6)  **Fee:** $65.85 **Benefit:** 75% = $49.40 85% = $56.00 |
| 66789 | A test described in item 66785 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $39.95 **Benefit:** 75% = $30.00 85% = $34.00 |
| 66790 | A test described in item 66785 other than that described in 66789, if rendered by a receiving APP - to a maximum of 1 test  (Item is subject to rule 6 and 18)  **Fee:** $25.90 **Benefit:** 75% = $19.45 85% = $22.05 |
| 66791 | Porphyrin biosynthetic enzymes - measurement of activity in blood cells or other tissues - 1 or more tests  **Fee:** $74.45 **Benefit:** 75% = $55.85 85% = $63.30 |
| 66792 | A test described in item 66791 if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $74.45 **Benefit:** 75% = $55.85 85% = $63.30 |
| 66800 | Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following being used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lithium, lignocaine, netilmicin, paracetamol, phenobarbitone, primidone, phenytoin, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin - 1 test  (Item to be subject to rule 6)  (See para PN.0.17 of explanatory notes to this Category)  **Fee:** $18.15 **Benefit:** 75% = $13.65 85% = $15.45 |
| 66803 | 2 tests described in item 66800  (Item is subject to rule 6)  **Fee:** $30.50 **Benefit:** 75% = $22.90 85% = $25.95 |
| 66804 | A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $18.15 **Benefit:** 75% = $13.65 85% = $15.45 |
| 66805 | A test described in item 66800 other than that described in 66804, if rendered by a receiving APP - each test to a maximum of 2 tests  (Item is subject to rule 6 and 18)  **Fee:** $12.35 **Benefit:** 75% = $9.30 85% = $10.50 |
| 66806 | 3 tests described in item 66800  (Item is subject to rule 6)  **Fee:** $41.85 **Benefit:** 75% = $31.40 85% = $35.60 |
| 66812 | Quantitation, not elsewhere described in this Table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken - 1 test  (This fee applies where 1 laboratory performs the only test specified on the request form or performs 1 test and refers the rest to the laboratory of a separate APA) (Item is subject to rule 6)  (See para PN.0.17 of explanatory notes to this Category)  **Fee:** $34.80 **Benefit:** 75% = $26.10 85% = $29.60 |
| 66815 | 2 tests described in item 66812  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 tests specified on the request form or performs 2 tests and refers the rest to the laboratory of a separate APA) (Item is subject to rule 6)  **Fee:** $59.55 **Benefit:** 75% = $44.70 85% = $50.65 |
| 66816 | A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $34.80 **Benefit:** 75% = $26.10 85% = $29.60 |
| 66817 | A test described in item 66812, other than that described in 66816, if rendered by a receiving APP - to a maximum of 1 test  (Item is subject to rule 6 and 18)  **Fee:** $24.75 **Benefit:** 75% = $18.60 85% = $21.05 |
| 66819 | Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid - 1 test.  (Item is subject to rule 6, 22 and 25)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66820 | A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6, 18, 22 and 25)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66821 | A test described in item 66819 other than that described in 66820 if rendered by a receiving APP to a maximum of 1 test  (Item is subject to rule 6, 18,  22 and 25)  **Fee:** $21.80 **Benefit:** 75% = $16.35 85% = $18.55 |
| 66822 | Quantitation of copper, manganese, selenium, or zinc (except if item 66667 applies), in blood, urine or other body fluid - 2 or more tests.  (Item is subject to rule 6, 22 and 25)  **Fee:** $52.45 **Benefit:** 75% = $39.35 85% = $44.60 |
| 66825 | Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue - 1 test. To a maximum of 3 of this item in a 6 month period  (Item is subject to rule 6, 22 and 25)  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66826 | A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP - 1 test  (Item is subject to rules 6, 18, 22 and 25 )  **Fee:** $30.60 **Benefit:** 75% = $22.95 85% = $26.05 |
| 66827 | A test described in item 66825, other than that described in 66826, if rendered by a receiving APP to a maximum of 1 test  (Item is subject to rules 6, 18, 22 and 25)  **Fee:** $21.80 **Benefit:** 75% = $16.35 85% = $18.55 |
| 66828 | Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel, or strontium, in blood, urine or other body fluid or tissue - 2 or more tests. To a maximum of 3 of this item in a 6 month period  (Item is subject to rule 6, 22 and 25)  **Fee:** $52.45 **Benefit:** 75% = $39.35 85% = $44.60 |
| 66830 | Quantitation of BNP or NT-proBNP for the diagnosis of heart failure in patients presenting with dyspnoea to a hospital Emergency Department  (Item is subject to rule 25)  **Fee:** $58.50 **Benefit:** 75% = $43.90 85% = $49.75 |
| 66831 | Quantitation of copper or iron in liver tissue biopsy  **Fee:** $30.95 **Benefit:** 75% = $23.25 85% = $26.35 |
| 66832 | A test described in item 66831 if rendered by a receiving APP  (Item is subject to rule 18A and 22)  **Fee:** $30.95 **Benefit:** 75% = $23.25 85% = $26.35 |
| 66833 | 25-hydroxyvitamin D, quantification in serum, for the investigation of a patient who:  (a)    has signs or symptoms of osteoporosis or osteomalacia; or  (b)    has increased alkaline phosphatase and otherwise normal liver function tests; or  (c)    has hyperparathyroidism, hypo- or hypercalcaemia, or hypophosphataemia; or  (d)    is suffering from malabsorption (for example, because the patient has cystic fibrosis, short bowel syndrome,     inflammatory bowel disease or untreated coeliac disease, or has had bariatric surgery); or  (e)     has deeply pigmented skin, or chronic and severe lack of sun exposure for cultural, medical, occupational or     residential reasons; or  (f)    is taking medication known to decrease 25OH-D levels (for example, anticonvulsants); or  (g)    has chronic renal failure or is a renal transplant recipient; or  (h)    is less than 16 years of age and has signs or symptoms of rickets; or  (i)    is an infant whose mother has established vitamin D deficiency; or  (j)    is a exclusively breastfed baby and has at least one other risk factor mentioned in a paragraph in this item; or  (k)    has a sibling who is less than 16 years of age and has vitamin D deficiency  **Fee:** $30.05 **Benefit:** 75% = $22.55 85% = $25.55 |
| 66834 | A test described in item 66833 if rendered by a receiving APP  (Item is subject to Rule 18)  **Fee:** $30.05 **Benefit:** 75% = $22.55 85% = $25.55 |
| 66835 | 1, 25-dihydroxyvitamin D - quantification in serum, if the request for the test is made by, or on advice of, the specialist or consultant physician managing the treatment of the patient  **Fee:** $39.05 **Benefit:** 75% = $29.30 85% = $33.20 |
| 66836 | 1, 25-dihydroxyvitamin D-quantification in serum, if:  (a)    the patient has hypercalcaemia; and  (b)    the request for the test is made by a general practitioner managing the treatment of the patient  **Fee:** $39.05 **Benefit:** 75% = $29.30 85% = $33.20 |
| 66837 | A test described in item 66835 or 66836 if rendered by a receiving APP (Item is subject to Rule 18)  **Fee:** $39.05 **Benefit:** 75% = $29.30 85% = $33.20 |
| 66838 | Serum vitamin B12 test  (Item is subject to Rule 25)  **Fee:** $23.60 **Benefit:** 75% = $17.70 85% = $20.10 |
| 66839 | Quantification of vitamin B12 markers such as holoTranscobalamin or methylmalonic acid, where initial serum vitamin B12 result is low or equivocal  **Fee:** $42.95 **Benefit:** 75% = $32.25 85% = $36.55 |
| 66840 | Serum folate test and, if required, red cell folate test for a patient at risk of folate deficiency, including patients with malabsorption conditions, macrocytic anaemia or coeliac disease  **Fee:** $23.60 **Benefit:** 75% = $17.70 85% = $20.10 |
| 66841 | Quantitation of HbA1c (glycated haemoglobin) performed for the diagnosis of diabetes in asymptomatic patients at high risk.  (Item is subject to rule 25)  **Fee:** $16.80 **Benefit:** 75% = $12.60 85% = $14.30 |
| 66900 | CARBON-LABELLED UREA BREATH TEST using oral C-13 or C-14 urea, including the measurement of exhaled 13CO2 or 14CO2 (except if item 12533 applies) for either:-  (a)        the confirmation of *Helicobacter pylori* colonisation OR  (b)        the monitoring of the success of eradication of *Helicobacter pylori.*  **Fee:** $77.65 **Benefit:** 75% = $58.25 85% = $66.05 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P3. MICROBIOLOGY** |  | | |
|  | Group P3. Microbiology |
| 69300 | Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:  (a)    differential cell count (if performed); or  (b)    examination for dermatophytes; or  (c)    dark ground illumination; or  (d)    stained preparation or preparations using any relevant stain or stains;  1 or more tests  **Fee:** $12.50 **Benefit:** 75% = $9.40 85% = $10.65 |
| 69303 | Culture and (if performed) microscopy to detect pathogenic micro-organisms from nasal swabs, throat swabs, eye swabs and ear swabs (excluding swabs taken for epidemiological surveillance), including (if performed):  (a)    pathogen identification and antibiotic susceptibility testing; or  (b)    a service described in item 69300;  specimens from 1 or more sites  **Fee:** $22.00 **Benefit:** 75% = $16.50 85% = $18.70 |
| 69306 | Microscopy and culture to detect pathogenic micro-organisms from skin or other superficial sites, including (if performed):  (a)    pathogen identification and antibiotic susceptibility testing; or  (b)    a service described in items 69300, 69303, 69312, 69318;  1 or more tests on 1 or more specimens  **Fee:** $33.75 **Benefit:** 75% = $25.35 85% = $28.70 |
| 69309 | Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):  (a)    the detection of antigens not elsewhere specified in this Schedule; or  (b)    a service described in items 69300, 69303, 69306, 69312, 69318;  1 or more tests on 1 or more specimens  **Fee:** $48.15 **Benefit:** 75% = $36.15 85% = $40.95 |
| 69312 | Microscopy and culture to detect pathogenic micro-organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):  (a)    pathogen identification and antibiotic susceptibility testing; or  (b)     a service described in items 69300, 69303, 69306 and 69318;  1 or more tests on 1 or more specimens  **Fee:** $33.75 **Benefit:** 75% = $25.35 85% = $28.70 |
| 69316 | Detection of Chlamydia trachomatis by any method - 1 test (Item is subject to rule 26)  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |
| 69317 | 1 test described in item 69494 and a test described in 69316.  (Item is subject to rule 26)  **Fee:** $35.85 **Benefit:** 75% = $26.90 85% = $30.50 |
| 69318 | Microscopy and culture to detect pathogenic micro-organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):  (a)     pathogen identification and antibiotic susceptibility testing; or  (b)    a service described in items 69300, 69303, 69306 and 69312;  1 or more tests on 1 or more specimens  **Fee:** $33.75 **Benefit:** 75% = $25.35 85% = $28.70 |
| 69319 | 2 tests described in item 69494 and a test described in 69316. (Item is subject to rule 26)  **Fee:** $42.95 **Benefit:** 75% = $32.25 85% = $36.55 |
| 69321 | Microscopy and culture of post-operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):  (a)    pathogen identification and antibiotic susceptibility testing; or  (b)    a service described in item 69300, 69303, 69306, 69312 or 69318;  specimens from 1 or more sites  **Fee:** $48.15 **Benefit:** 75% = $36.15 85% = $40.95 |
| 69324 | Microscopy (with appropriate stains) and culture for mycobacteria - 1 specimen of sputum, urine, or other body fluid or 1 operative or biopsy specimen, including (if performed):  (a)    microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b)    pathogen identification and antibiotic susceptibility testing;  including a service described in item 69300  **Fee:** $43.00 **Benefit:** 75% = $32.25 85% = $36.55 |
| 69325 | A test described in item 69324 if rendered by a receiving APP  (Item is subject to rule 18)  **Fee:** $43.00 **Benefit:** 75% = $32.25 85% = $36.55 |
| 69327 | Microscopy (with appropriate stains) and culture for mycobacteria - 2 specimens of sputum, urine, or other body fluid or 2 operative or biopsy specimens, including (if performed):  (a)    microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b)    pathogen identification and antibiotic susceptibility testing;  including a service mentioned in item 69300  **Fee:** $85.00 **Benefit:** 75% = $63.75 85% = $72.25 |
| 69328 | A test described in item 69327 if rendered by a receiving APP  (Item is subject to rule 18)  **Fee:** $85.00 **Benefit:** 75% = $63.75 85% = $72.25 |
| 69330 | Microscopy (with appropriate stains) and culture for mycobacteria - 3 specimens of sputum, urine, or other body fluid or 3 operative or biopsy specimens, including (if performed):  (a)    microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or  (b)    pathogen identification and antibiotic susceptibility testing;  including a service mentioned in item 69300  **Fee:** $128.00 **Benefit:** 75% = $96.00 85% = $108.80 |
| 69331 | A test described in item 69330 if rendered by a receiving APP  (Item is subject to rule 18)  **Fee:** $128.00 **Benefit:** 75% = $96.00 85% = $108.80 |
| 69333 | Urine examination (including serial examinations) by any means other than simple culture by dip slide, including:  (a)    cell count; and  (b)    culture; and  (c)    colony count; and  (d)    (if performed) stained preparations; and  (e)    (if performed) identification of cultured pathogens; and  (f)    (if performed) antibiotic susceptibility testing; and  (g)    (if performed) examination for pH, specific gravity, blood, protein, urobilinogen, sugar, acetone or bile salts  **Fee:** $20.55 **Benefit:** 75% = $15.45 85% = $17.50 |
| 69336 | Microscopy of faeces for ova, cysts and parasites that must include a concentration technique, and the use of fixed stains or antigen detection for cryptosporidia and giardia - including (if performed) a service described in item 69300 - 1 of this item in any 7 day period  **Fee:** $33.45 **Benefit:** 75% = $25.10 85% = $28.45 |
| 69339 | Microscopy of faeces for ova, cysts and parasites using concentration techniques examined subsequent to item 69336 on a separately collected and identified specimen collected within 7 days of the examination described in 69336 - 1 examination in any 7 day period  **Fee:** $19.10 **Benefit:** 75% = $14.35 85% = $16.25 |
| 69345 | Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):  (a)    pathogen identification and antibiotic susceptibility testing; and  (b)    the detection of clostridial toxins; and  (c)    a service described in item 69300;  - 1 examination in any 7 day period  **Fee:** $52.90 **Benefit:** 75% = $39.70 85% = $45.00 |
| 69354 | Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):  (a)    identification of any cultured pathogen;  and  (b)    necessary antibiotic susceptibility testing;  to a maximum of 3 sets of cultures - 1 set of cultures  **Fee:** $30.75 **Benefit:** 75% = $23.10 85% = $26.15 |
| 69357 | 2 sets of cultures described in item 69354  **Fee:** $61.45 **Benefit:** 75% = $46.10 85% = $52.25 |
| 69360 | 3 sets of cultures described in item 69354  **Fee:** $92.20 **Benefit:** 75% = $69.15 85% = $78.40 |
| 69363 | Detection of *Clostridium difficile* or *Clostridium difficile* toxin (except if a service described in item 69345 has been performed) - one or more tests  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |
| 69378 | Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero-positive patient not on antiretroviral therapy - 1 or more tests  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69379 | A test described in item 69378 if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69380 | Genotypic testing for HIV antiretroviral resistance in a patient with confirmed HIV infection if the patient's viral load is greater than 1,000 copies per ml at any of the following times:  (a)    at presentation; or  (b)    before antiretroviral therapy: or  (c)    when treatment with combination antiretroviral agents fails;  maximum of 2 tests in a 12 month period  **Fee:** $770.30 **Benefit:** 75% = $577.75 85% = $671.60 |
| 69381 | Quantitation of HIV viral RNA load in plasma or serum in the monitoring of antiretroviral therapy in a HIV sero-positive patient - 1 or more tests on 1 or more specimens  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69382 | Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero-positive patient - 1 or more tests on 1 or more specimens  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69383 | A test described in item 69381 if rendered by a receiving APP - 1 or more tests on 1 or more specimens  (Item is subject to rule 18)  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69384 | Quantitation of 1 antibody to microbial antigens not elsewhere described in the Schedule - 1 test  (This fee applies where a laboratory performs the only antibody test specified on the request form or performs 1 test and refers the rest to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 69387 | 2 tests described in item 69384  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 2 estimations specified on the request form or performs 2 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $29.00 **Benefit:** 75% = $21.75 85% = $24.65 |
| 69390 | 3 tests described in item 69384  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 3 estimations specified on the request form or performs 3 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $42.35 **Benefit:** 75% = $31.80 85% = $36.00 |
| 69393 | 4 tests described in item 69384  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 4 estimations specified on the request form or performs 4 of the antibody estimations specified on the request form and refers the remainder to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $55.70 **Benefit:** 75% = $41.80 85% = $47.35 |
| 69396 | 5 or more tests described in item 69384  (This fee applies where 1 laboratory, or more than 1 laboratory belonging to the same APA, performs the only 5 estimations specified on the request form or performs 5 of the antibody tests specified on the request form and refers the remainder to the laboratory of a separate APA)  (Item is subject to rule 6)  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $69.10 **Benefit:** 75% = $51.85 85% = $58.75 |
| 69400 | A test described in item 69384, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rules 6 and 18)  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 69401 | A test described in item 69384, other than that described in 69400, if rendered by a receiving APP - each test to a maximum of 4 tests  (Item is subject to rule 6, 18 and 18A)  **Fee:** $13.35 **Benefit:** 75% = $10.05 85% = $11.35 |
| 69405 | Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:  (a)    the determination of 1 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and  (b)    (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 69408 | Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:  (a)    the determination of 2 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and  (b)    (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $29.00 **Benefit:** 75% = $21.75 85% = $24.65 |
| 69411 | Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:  (a)    the determination of 3 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and  (b)    (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $42.35 **Benefit:** 75% = $31.80 85% = $36.00 |
| 69413 | Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:  (a)    the determination of 4 of the following - rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody and  (b)    (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $55.70 **Benefit:** 75% = $41.80 85% = $47.35 |
| 69415 | Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:  (a)    the determination of all 5 of the following - rubella immune status, specific syphilis serology, carriage of      Hepatitis B, Hepatitis C antibody, HIV antibody and  (b)    (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481  (See para PN.0.18 of explanatory notes to this Category)  **Fee:** $69.10 **Benefit:** 75% = $51.85 85% = $58.75 |
| **New**  69421 | Detection of respiratory pathogen nucleic acid from a nasal swab, throat swab, nasopharyngeal aspirate and/or lower respiratory tract sample;  Testing of 4 pathogens  **Fee:** $78.25 **Benefit:** 75% = $58.70 85% = $66.55 |
| **New**  69422 | Detection of respiratory pathogen nucleic acid from a nasal swab, throat swab, nasopharyngeal aspirate and/or lower respiratory tract sample, including a service described in item 69421;  Testing of 5 or more pathogens  **Fee:** $85.55 **Benefit:** 75% = $64.20 85% = $72.75 |
| 69445 | Detection of Hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499) - 1 test. To a maximum of 4 of this item in a 12 month period  (Item is subject to rule 25)  **Fee:** $92.20 **Benefit:** 75% = $69.15 85% = $78.40 |
| 69451 | A test described in item 69445 if rendered by a receiving APP - 1 test.  (Item is subject to rule 18 and 25)  **Fee:** $92.20 **Benefit:** 75% = $69.15 85% = $78.40 |
| 69471 | Test of cell‑mediated immune response in blood for the detection of latent tuberculosis by interferon gamma release assay (IGRA) in the following people:  (a) a person who has been exposed to a confirmed case of active tuberculosis;  (b) a person who is infected with human immunodeficiency virus;  (c) a person who is to commence, or has commenced, tumour necrosis factor (TNF) inhibitor therapy;  (d) a person who is to commence, or has commenced, renal dialysis;  (e) a person with silicosis;  (f) a person who is, or is about to become, immunosuppressed because of a disease, or a medical treatment, not mentioned in paragraphs (a) to (e)  (See para PN.3.4 of explanatory notes to this Category)  **Fee:** $34.90 **Benefit:** 75% = $26.20 85% = $29.70 |
| 69472 | Detection of antibodies to Epstein Barr Virus using specific serology - 1 test  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 69474 | Detection of antibodies to Epstein Barr Virus using specific serology - 2 or more tests  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |
| 69475 | One test for hepatitis antigen or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D  (Item subject to rule 11)  **Fee:** $15.65 **Benefit:** 75% = $11.75 85% = $13.35 |
| 69478 | 2 tests described in 69475  (Item subject to rule 11)  **Fee:** $29.25 **Benefit:** 75% = $21.95 85% = $24.90 |
| 69481 | Investigation of infectious causes of acute or chronic hepatitis - 3 tests for hepatitis antibodies or antigens,  (Item subject to rule 11)  (See para PN.0.19 of explanatory notes to this Category)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 69482 | Quantitation of Hepatitis B viral DNA in patients who are Hepatitis B surface antigen positive and have chronic hepatitis B, but are not receiving antiviral therapy - 1 test  (Item is subject to rule 25)  **Fee:** $152.10 **Benefit:** 75% = $114.10 85% = $129.30 |
| 69483 | Quantitation of Hepatitis B viral DNA in patients who are Hepatitis B surface antigen positive and who have chronic hepatitis B and are receiving antiviral therapy - 1 test  (Item is subject to rule 25)  **Fee:** $152.10 **Benefit:** 75% = $114.10 85% = $129.30 |
| 69484 | Supplementary testing for Hepatitis B surface antigen or Hepatitis C antibody using a different assay on the specimen which yielded a reactive result on initial testing  (Item is subject to rule 18)  **Fee:** $17.10 **Benefit:** 75% = $12.85 85% = $14.55 |
| 69488 | Quantitation of HCV RNA load in plasma or serum in:  (a) the pre-treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or  (b) the assessment of efficacy of antiviral therapy for such a patient  (including a service in item 69499 or 69445)  (Item is subject to rule 18 and 25)  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69489 | A test described in item 69488 if rendered by a receiving APP  (Item is subject to rule 18 and 25)  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 69491 | Nucleic acid amplification and determination of Hepatitis C virus (HCV) genotype if the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis.  To a maximum of 1 of this item in a 12 month period  **Fee:** $204.80 **Benefit:** 75% = $153.60 85% = $174.10 |
| 69492 | A test described in item 69491 if rendered by a receiving APP - 1 test  (Item is subject to rule 18 and 25)  **Fee:** $204.80 **Benefit:** 75% = $153.60 85% = $174.10 |
| 69494 | Detection of a virus or microbial antigen or microbial nucleic acid (not elsewhere specified)  1 test  (Item is subject to rule 6 and 26)  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |
| 69495 | 2 tests described in 69494  (Item is subject to rule 6 and 26)  **Fee:** $35.85 **Benefit:** 75% = $26.90 85% = $30.50 |
| 69496 | 3 or more tests described in 69494  (Item is subject to rule 6 and 26)  **Fee:** $43.05 **Benefit:** 75% = $32.30 85% = $36.60 |
| 69497 | A test described in item 69494, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test (Item is subject to rule 6, 18 and 26)  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |
| 69498 | A test described in item 69494, other than that described in 69497, if rendered by a receiving APP - each test to a maximum of 2 tests (Item is subject to rule 6, 18 and 26)  **Fee:** $7.20 **Benefit:** 75% = $5.40 85% = $6.15 |
| 69499 | Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:  (a)    the patient is Hepatitis C seropositive;  (b)    the patient's serological status is uncertain after testing;  (c)    the test is performed for the purpose of:      (i)    determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or      (ii)    the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical          management of the patient;  To a maximum of 1 of this item in a 12 month period  (Item is subject to rule 19 and 25)  **Fee:** $92.20 **Benefit:** 75% = $69.15 85% = $78.40 |
| 69500 | A test described in item 69499 if rendered by a receiving APP - 1 test (Item is subject to rule 18,19 and 25)  **Fee:** $92.20 **Benefit:** 75% = $69.15 85% = $78.40 |
| 69505 | Sequencing and analysis of the genome of mycobacterium tuberculosis complex from an isolate or nucleic acid extract:  (a) to speciate the organism:  (i) at the time of a patient’s initial diagnosis and commencement of initial empiric therapy; or  (ii) following recurrence of a patient’s symptoms or a patient’s failure to respond to treatment within the expected timeframe; and  (b) for the purpose of:  (i) genome‑wide determination of the antimicrobial resistance markers (resistome) of the isolate; and  (ii) individualising the patient’s treatment  Applicable once at initial diagnosis and once per episode of disease recurrence  **Fee:** $150.00 **Benefit:** 75% = $112.50 85% = $127.50 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P4. IMMUNOLOGY** |  | | |
|  | Group P4. Immunology |
| 71057 | Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate:  (a)    protein classes; or  (b)    presence and amount of paraprotein;  including the preliminary quantitation of total protein, albumin and globulin - 1 specimen type  **Fee:** $32.90 **Benefit:** 75% = $24.70 85% = $28.00 |
| 71058 | Examination as described in item 71057 of 2 or more specimen types  **Fee:** $50.50 **Benefit:** 75% = $37.90 85% = $42.95 |
| 71059 | Immunofixation or immunoelectrophoresis or isoelectric focusing of:  (a)    urine for detection of Bence Jones proteins; or  (b)    serum, plasma or other body fluid;  and characterisation of a paraprotein or cryoglobulin  -  examination of 1 specimen type (eg. serum, urine or CSF)  **Fee:** $35.65 **Benefit:** 75% = $26.75 85% = $30.35 |
| 71060 | Examination as described in item 71059 of 2 or more specimen types  **Fee:** $44.05 **Benefit:** 75% = $33.05 85% = $37.45 |
| 71062 | Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient's serum for comparison purposes - 1 or more tests  **Fee:** $44.05 **Benefit:** 75% = $33.05 85% = $37.45 |
| 71064 | Detection and quantitation of cryoglobulins or cryofibrinogen - 1 or more tests  **Fee:** $20.75 **Benefit:** 75% = $15.60 85% = $17.65 |
| 71066 | Quantitation of total immunoglobulin A by any method in serum, urine or other body fluid - 1 test  **Fee:** $14.55 **Benefit:** 75% = $10.95 85% = $12.40 |
| 71068 | Quantitation of total immunoglobulin G by any method in serum, urine or other body fluid - 1 test  **Fee:** $14.55 **Benefit:** 75% = $10.95 85% = $12.40 |
| 71069 | 2 tests described in items 71066, 71068, 71072 or 71074  **Fee:** $22.75 **Benefit:** 75% = $17.10 85% = $19.35 |
| 71071 | 3 or more tests described in items 71066, 71068, 71072 or 71074  **Fee:** $30.95 **Benefit:** 75% = $23.25 85% = $26.35 |
| 71072 | Quantitation of total immunoglobulin M by any method in serum, urine or other body fluid - 1 test  **Fee:** $14.55 **Benefit:** 75% = $10.95 85% = $12.40 |
| 71073 | Quantitation of all 4 immunoglobulin G subclasses  **Fee:** $106.15 **Benefit:** 75% = $79.65 85% = $90.25 |
| 71074 | Quantitation of total immunoglobulin D by any method in serum, urine or other body fluid - 1 test  **Fee:** $14.55 **Benefit:** 75% = $10.95 85% = $12.40 |
| 71075 | Quantitation of immunoglobulin E (total), 1 test.  (Item is subject to rule 25)  **Fee:** $23.00 **Benefit:** 75% = $17.25 85% = $19.55 |
| 71076 | A test described in item 71073 if rendered by a receiving APP - 1 test  (Item is subject to rule 18)  **Fee:** $106.15 **Benefit:** 75% = $79.65 85% = $90.25 |
| 71077 | Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, 1 test.  (Item is subject to rule 25)  **Fee:** $27.05 **Benefit:** 75% = $20.30 85% = $23.00 |
| 71079 | Detection of specific immunoglobulin E antibodies to single or multiple potential allergens, 1 test  (Item is subject to rule 25)  **Fee:** $26.80 **Benefit:** 75% = $20.10 85% = $22.80 |
| 71081 | Quantitation of total haemolytic complement  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71083 | Quantitation of complement components C3 and C4 or properdin factor B - 1 test  **Fee:** $20.15 **Benefit:** 75% = $15.15 85% = $17.15 |
| 71085 | 2 tests described in item 71083  **Fee:** $28.95 **Benefit:** 75% = $21.75 85% = $24.65 |
| 71087 | 3 or more tests described in item 71083  **Fee:** $37.70 **Benefit:** 75% = $28.30 85% = $32.05 |
| 71089 | Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule - 1 test  (Item is subject to rule 6)  **Fee:** $29.15 **Benefit:** 75% = $21.90 85% = $24.80 |
| 71090 | A test described in item 71089, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $29.15 **Benefit:** 75% = $21.90 85% = $24.80 |
| 71091 | 2 tests described in item 71089  (Item is subject to rule 6)  **Fee:** $52.85 **Benefit:** 75% = $39.65 85% = $44.95 |
| 71092 | Tests described in item 71089, other than that described in 71090, if rendered by a receiving APP - each test to a maximum of 2 tests  (Item is subject to rule 6 and 18)  **Fee:** $23.70 **Benefit:** 75% = $17.80 85% = $20.15 |
| 71093 | 3 or more tests described in item 71089  (Item is subject to rule 6)  **Fee:** $76.45 **Benefit:** 75% = $57.35 85% = $65.00 |
| 71095 | Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years  (See para PN.0.20 of explanatory notes to this Category)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71096 | A test described in item 71095 if rendered by a receiving APP.  (Item is subject to rule 18)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71097 | Antinuclear antibodies - detection in serum or other body fluids, including quantitation if required  **Fee:** $24.45 **Benefit:** 75% = $18.35 85% = $20.80 |
| 71099 | Double-stranded DNA antibodies - quantitation by 1 or more methods other than the Crithidia method  **Fee:** $26.50 **Benefit:** 75% = $19.90 85% = $22.55 |
| 71101 | Antibodies to 1 or more extractable nuclear antigens - detection in serum or other body fluids  **Fee:** $17.40 **Benefit:** 75% = $13.05 85% = $14.80 |
| 71103 | Characterisation of an antibody detected in a service described in item 71101 (including that service)  **Fee:** $52.05 **Benefit:** 75% = $39.05 85% = $44.25 |
| 71106 | Rheumatoid factor - detection by any technique in serum or other body fluids, including quantitation if required  **Fee:** $11.30 **Benefit:** 75% = $8.50 85% = $9.65 |
| 71119 | Antibodies to tissue antigens not elsewhere specified in this Table - detection, including quantitation if required, of 1 antibody  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $17.35 **Benefit:** 75% = $13.05 85% = $14.75 |
| 71121 | Detection of 2 antibodies specified in item 71119  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $20.80 **Benefit:** 75% = $15.60 85% = $17.70 |
| 71123 | Detection of 3 antibodies specified in item 71119  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $24.25 **Benefit:** 75% = $18.20 85% = $20.65 |
| 71125 | Detection of 4 or more antibodies specified in item 71119  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $27.65 **Benefit:** 75% = $20.75 85% = $23.55 |
| 71127 | Functional tests for lymphocytes - quantitation other than by microscopy of:  (a)    proliferation induced by 1 or more mitogens; or  (b)    proliferation induced by 1 or more antigens; or  (c)    estimation of 1 or more mixed lymphocyte reactions;  including a test described in item 65066 or 65070 (if performed), 1 of this item to a maximum of 2 in a 12 month period  **Fee:** $176.35 **Benefit:** 75% = $132.30 85% = $149.90 |
| 71129 | 2 tests described in item 71127  **Fee:** $217.85 **Benefit:** 75% = $163.40 85% = $185.20 |
| 71131 | 3 or more tests described in item 71127  **Fee:** $259.35 **Benefit:** 75% = $194.55 85% = $220.45 |
| 71133 | Investigation of recurrent infection by qualitative assessment for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test  **Fee:** $10.40 **Benefit:** 75% = $7.80 85% = $8.85 |
| 71134 | Investigation of recurrent infection by quantitative assessment of oxidative pathways by flow cytometric techniques, including a test described in 71133 (if performed)  **Fee:** $104.05 **Benefit:** 75% = $78.05 85% = $88.45 |
| 71135 | Quantitation of neutrophil function, comprising at least 2 of the following:  (a)    chemotaxis;  (b)    phagocytosis;  (c)    oxidative metabolism;  (d)    bactericidal activity;  including any test described in items 65066, 65070, 71133 or 71134 (if performed), 1 of this item to a maximum of 2 in a 12 month period  **Fee:** $207.95 **Benefit:** 75% = $156.00 85% = $176.80 |
| 71137 | Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, 1 of this item to a maximum of 2 in a 12 month period  **Fee:** $30.25 **Benefit:** 75% = $22.70 85% = $25.75 |
| 71139 | Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid  **Fee:** $104.05 **Benefit:** 75% = $78.05 85% = $88.45 |
| 71141 | Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens  **Fee:** $197.35 **Benefit:** 75% = $148.05 85% = $167.75 |
| 71143 | Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis  (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue  **Fee:** $260.00 **Benefit:** 75% = $195.00 85% = $221.00 |
| 71145 | Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid  **Fee:** $424.50 **Benefit:** 75% = $318.40 85% = $360.85 |
| 71146 | Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pherisis collection  **Fee:** $104.05 **Benefit:** 75% = $78.05 85% = $88.45 |
| 71147 | HLA-B27 typing  (Item is subject to rule 27)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71148 | A test described in item 71147 if rendered by a receiving APP.  (Item is subject to rule 18 and 27)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71149 | Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147  **Fee:** $108.25 **Benefit:** 75% = $81.20 85% = $92.05 |
| 71151 | Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigens  **Fee:** $118.85 **Benefit:** 75% = $89.15 85% = $101.05 |
| 71153 | Investigations in the assessment or diagnosis of systemic inflammatory disease or vasculitis - antineutrophil cytoplasmic antibody immunofluorescence (ANCA test), antineutrophil proteinase 3 antibody (PR-3 ANCA test), antimyeloperoxidase antibody (MPO ANCA test) or antiglomerular basement membrane antibody (GBM test) - detection of 1 antibody  (Item is subject to rule 6 and 23)  **Fee:** $34.55 **Benefit:** 75% = $25.95 85% = $29.40 |
| 71154 | A test described in item 71153, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test.  (Item is subject to rule 6, 18 and 23)  **Fee:** $34.55 **Benefit:** 75% = $25.95 85% = $29.40 |
| 71155 | Detection of 2 antibodies described in item 71153  (Item is subject to rule 6 and 23)  **Fee:** $47.45 **Benefit:** 75% = $35.60 85% = $40.35 |
| 71156 | Tests described in item 71153, other than that described in 71154, if rendered by a receiving APP - each test to a maximum of 3 tests  (Item is subject to rule 6, 18 and 23)  **Fee:** $12.85 **Benefit:** 75% = $9.65 85% = $10.95 |
| 71157 | Detection of 3 antibodies described in item 71153  (Item is subject to rule 6 and 23)  **Fee:** $60.30 **Benefit:** 75% = $45.25 85% = $51.30 |
| 71159 | Detection of 4 or more antibodies described in item 71153  (Item is subject to rule 6 and 23)  **Fee:** $73.15 **Benefit:** 75% = $54.90 85% = $62.20 |
| 71163 | Detection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed):  a)    Antibodies to gliadin; or  b)    Antibodies to endomysium; or  c)    Antibodies to tissue transglutaminase;  - 1 test  **Fee:** $24.75 **Benefit:** 75% = $18.60 85% = $21.05 |
| 71164 | Two or more tests described in 71163 and including a service described in 71066 (if performed)  **Fee:** $39.90 **Benefit:** 75% = $29.95 85% = $33.95 |
| 71165 | Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) - detection, including quantitation if required, of 1 antibody  (Item is subject to rule 6)  **Fee:** $34.55 **Benefit:** 75% = $25.95 85% = $29.40 |
| 71166 | Detection of 2 antibodies described in item 71165  (Item is subject to rule 6)  **Fee:** $47.45 **Benefit:** 75% = $35.60 85% = $40.35 |
| 71167 | Detection of 3 antibodies described in item 71165  (Item is subject to rule 6)  **Fee:** $60.30 **Benefit:** 75% = $45.25 85% = $51.30 |
| 71168 | Detection of 4 or more antibodies described in item 71165  (Item is subject to rule 6)  **Fee:** $73.15 **Benefit:** 75% = $54.90 85% = $62.20 |
| 71169 | A test described in item 71165, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test  (Item is subject to rule 6 and 18)  **Fee:** $34.55 **Benefit:** 75% = $25.95 85% = $29.40 |
| 71170 | Tests described in item 71165, other than that described in 71169, if rendered by a receiving APP - each test to a maximum of 3 tests  (Item is subject to rule 6 and 18)  **Fee:** $12.85 **Benefit:** 75% = $9.65 85% = $10.95 |
| 71175 | A test, requested by a specialist or consultant physician, to diagnose neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein antibody‑related demyelination (MARD), by the detection of one or more antibodies, for a patient:   1. suspected of having NMOSD or MARD; and 2. with any of the following:    1. recurrent, bilateral or severe optic neuritis;    2. recurrent longitudinal extensive transverse myelitis (LETM);    3. area postrema syndrome (unexplained hiccups, nausea or vomiting);    4. acute brainstem syndrome;    5. symptomatic narcolepsy or acute diencephalic clinical syndrome with typical NMOSD magnetic resonance imaging lesions;    6. symptomatic cerebral syndrome with typical NMOSD magnetic resonance imaging lesions;    7. monophasic neuromyelitis optica (no recurrence, and simultaneous or closely related optic neuritis and LETM within 30 days of each other);    8. acute disseminated encephalomyelitis;    9. aseptic meningitis and encephalomyelitis;    10. poor recovery from multiple sclerosis relapses   Applicable not more than 4 times in 12 months  **Fee:** $50.00 **Benefit:** 75% = $37.50 85% = $42.50 |
| 71180 | Antibody to cardiolipin or beta-2 glycoprotein I - detection, including quantitation if required; one antibody specificity (IgG or IgM)  **Fee:** $34.55 **Benefit:** 75% = $25.95 85% = $29.40 |
| 71183 | Detection of two antibodies described in item 71180  **Fee:** $47.45 **Benefit:** 75% = $35.60 85% = $40.35 |
| 71186 | Detection of three or more antibodies described in item 71180  **Fee:** $60.30 **Benefit:** 75% = $45.25 85% = $51.30 |
| 71189 | Detection of specific IgG antibodies to 1 or more respiratory disease allergens not elsewhere specified.  **Fee:** $15.50 **Benefit:** 75% = $11.65 85% = $13.20 |
| 71192 | 2 items described in item 71189.  **Fee:** $28.35 **Benefit:** 75% = $21.30 85% = $24.10 |
| 71195 | 3 or more items described in item 71189.  **Fee:** $40.05 **Benefit:** 75% = $30.05 85% = $34.05 |
| 71198 | Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis.  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 71200 | Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias.  **Fee:** $59.60 **Benefit:** 75% = $44.70 85% = $50.70 |
| 71202 | Measurable residual disease (MRD) testing by flow cytometry, performed on bone marrow from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist    (See para PN.0.35 of explanatory notes to this Category)  **Fee:** $550.00 **Benefit:** 75% = $412.50 85% = $467.50 |
| 71203 | Determination of HLAB5701 status by flow cytometry or cytotoxity assay prior to the initiation of Abacavir therapy including item 73323 if performed.  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P5. TISSUE PATHOLOGY** |  | | |
|  | Group P5. Tissue Pathology |
| 72813 | Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $71.50 **Benefit:** 75% = $53.65 85% = $60.80 |
| 72814 | Immunohistochemical examination by immunoperoxidase or other labelled antibody techniques using the programmed cell death ligand 1 (PD‑L1) antibody of tumour material from a patient diagnosed with:  (a)   non‑small cell lung cancer; or  (b)   recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx; or  (c)   locally recurrent unresectable or metastatic triple-negative breast cancer.  **Fee:** $74.50 **Benefit:** 75% = $55.90 85% = $63.35 |
| 72816 | Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 separately identified specimen  (Item is subject to rule 13)  **Fee:** $86.35 **Benefit:** 75% = $64.80 85% = $73.40 |
| 72817 | Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 2 to 4 separately identified specimens  (Item is subject to rule 13)  **Fee:** $96.80 **Benefit:** 75% = $72.60 85% = $82.30 |
| 72818 | Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 5 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $107.05 **Benefit:** 75% = $80.30 85% = $91.00 |
| 72823 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 separately identified specimen  (Item is subject to rule 13)  **Fee:** $97.15 **Benefit:** 75% = $72.90 85% = $82.60 |
| 72824 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 2 to 4 separately identified specimens  (Item is subject to rule 13)  **Fee:** $141.35 **Benefit:** 75% = $106.05 85% = $120.15 |
| 72825 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 5 to 7 separately identified specimens  (Item is subject to rule 13)  **Fee:** $180.25 **Benefit:** 75% = $135.20 85% = $153.25 |
| 72826 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 8 to 11 separately identified specimens  (Item is subject to rule 13)  **Fee:** $194.60 **Benefit:** 75% = $145.95 85% = $165.45 |
| 72827 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 12 to 17 separately identified specimens  (Item is subject to Rule 13)  **Fee:** $208.95 **Benefit:** 75% = $156.75 85% = $177.65 |
| 72828 | Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions -  18 or more separately identified specimens  (Item is subject to Rule 13)  **Fee:** $223.30 **Benefit:** 75% = $167.50 85% = $189.85 |
| 72830 | Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $274.15 **Benefit:** 75% = $205.65 85% = $233.05 |
| 72836 | Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $417.20 **Benefit:** 75% = $312.90 85% = $354.65 |
| 72838 | Examination of complexicity level 7 biopsy material with multiple tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions - 1 or more separately identified specimens.  (Item is subject to rule 13)  **Fee:** $466.85 **Benefit:** 75% = $350.15 85% = $396.85 |
| 72844 | Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system - 1 or more tests  **Fee:** $30.75 **Benefit:** 75% = $23.10 85% = $26.15 |
| 72846 | Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 antibodies except those listed in 72848  (Item is subject to rule 13)  **Fee:** $59.60 **Benefit:** 75% = $44.70 85% = $50.70 |
| 72847 | Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 4-6 antibodies  (Item is subject to rule 13)  **Fee:** $89.40 **Benefit:** 75% = $67.05 85% = $76.00 |
| 72848 | Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 of the following antibodies - oestrogen, progesterone and c-erb-B2 (HER2)  (Item is subject to rule 13)  **Fee:** $74.50 **Benefit:** 75% = $55.90 85% = $63.35 |
| 72849 | Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 7-10 antibodies  (Item is subject to rule 13)  **Fee:** $104.30 **Benefit:** 75% = $78.25 85% = $88.70 |
| 72850 | Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies  (Item is subject to rule 13)  **Fee:** $119.20 **Benefit:** 75% = $89.40 85% = $101.35 |
| 72851 | Electron microscopic examination of biopsy material - 1 separately identified specimen  (Item is subject to rule 13)  **Fee:** $565.00 **Benefit:** 75% = $423.75 85% = $480.25 |
| 72852 | Electron microscopic examination of biopsy material - 2 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $753.00 **Benefit:** 75% = $564.75 85% = $654.30 |
| 72855 | Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 1 separately identified specimen  (Item is subject to rule 13)  **Fee:** $184.35 **Benefit:** 75% = $138.30 85% = $156.70 |
| 72856 | Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 2 to 4 separately identified specimens  (Item is subject to rule 13)  **Fee:** $245.80 **Benefit:** 75% = $184.35 85% = $208.95 |
| 72857 | Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear - 5 or more separately identified specimens  (Item is subject to rule 13)  **Fee:** $286.75 **Benefit:** 75% = $215.10 85% = $243.75 |
| 72858 | A second opinion, provided in a written report, where the opinion and report together require no more than 30 minutes to complete, on a patient specimen, requested by a treating practitioner, where further information is needed for accurate diagnosis and appropriate patient management.  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $180.00 **Benefit:** 75% = $135.00 85% = $153.00 |
| 72859 | A second opinion, provided in a written report, where the opinion and report together require more than 30 minutes to complete, on a patient specimen, requested by a treating practitioner, where further information is needed for accurate diagnosis and appropriate patient management.  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $370.00 **Benefit:** 75% = $277.50 85% = $314.50 |
| 72860 | Retrieval and review of one or more archived formalin fixed paraffin embedded blocks to determine the appropriate samples for the purpose of conducting genetic testing, other than:  (a) a service associated with a service to which item 72858 or 72859 applies; or  (b) a service associated with, and rendered in the same patient episode as, a service to which an item in Group P5, P6, P10 or P11 applies  Applicable not more than once in a patient episode    (See para PR.5.1 of explanatory notes to this Category)  **Fee:** $85.00 **Benefit:** 75% = $63.75 85% = $72.25 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P6. CYTOLOGY** |  | | |
|  | Group P6. Cytology |
| 73043 | Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes  1 or more tests  **Fee:** $22.85 **Benefit:** 75% = $17.15 85% = $19.45 |
| 73045 | Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73076); and including any Group P5 service, if performed on:  (a)    specimens resulting from washings or brushings from sites not specified in item 73043; or  (b)    a single specimen of sputum or urine; or  (c)    1 or more specimens of other body fluids;  1 or more tests  **Fee:** $48.60 **Benefit:** 75% = $36.45 85% = $41.35 |
| 73047 | Cytology of a series of 3 sputum or urine specimens for malignant cells  **Fee:** $94.70 **Benefit:** 75% = $71.05 85% = $80.50 |
| 73049 | Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue or tissues - 1 identified site  **Fee:** $68.15 **Benefit:** 75% = $51.15 85% = $57.95 |
| 73051 | Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue or tissues if a recognized pathologist:  (a)    performs the aspiration; or  (b)    attends the aspiration and performs cytological examination during the attendance  **Fee:** $170.35 **Benefit:** 75% = $127.80 85% = $144.80 |
| 73059 | Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 antibodies except those listed in 73061  (Item is subject to rule 13)  **Fee:** $43.00 **Benefit:** 75% = $32.25 85% = $36.55 |
| 73060 | Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067  for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 4 to 6  antibodies  (Item is subject to rule 13)  **Fee:** $57.35 **Benefit:** 75% = $43.05 85% = $48.75 |
| 73061 | Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 1 to 3 of the following antibodies - oestrogen, progesterone and c-erb-B2 (HER2)  (Item is subject to rule 13)  **Fee:** $51.20 **Benefit:** 75% = $38.40 85% = $43.55 |
| 73062 | Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue or tissues - 2 or more separately identified sites.  **Fee:** $89.00 **Benefit:** 75% = $66.75 85% = $75.65 |
| 73063 | Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy  **Fee:** $99.35 **Benefit:** 75% = $74.55 85% = $84.45 |
| 73064 | Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 7 to 10 antibodies  (Item is subject to rule 13)  **Fee:** $71.70 **Benefit:** 75% = $53.80 85% = $60.95 |
| 73065 | Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062, 73063, 73066 and 73067 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen - 11 or more antibodies  (Item is subject to rule 13)  **Fee:** $86.00 **Benefit:** 75% = $64.50 85% = $73.10 |
| 73066 | Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if a recognized pathologist:  (a)    performs the aspiration; or  (b)   attends the aspiration and performs cytological examination during the attendance  **Fee:** $221.45 **Benefit:** 75% = $166.10 85% = $188.25 |
| 73067 | Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue or tissues if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy  **Fee:** $129.15 **Benefit:** 75% = $96.90 85% = $109.80 |
| 73070 | 73070  A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer:  (a) performed on a liquid based cervical specimen; and  (b) for an asymptomatic patient who is at least 24 years and 9 months of age  For any particular patient, once only in a 57 month period  (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $35.00 **Benefit:** 75% = $26.25 85% = $29.75 |
| 73071 | A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre‑cancer or cancer, if performed:  (a) on a self‑collected vaginal specimen; and  (b) for an asymptomatic patient who is at least 24 years and 9 months of age  For any particular patient, applicable once in 57 months    (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $35.00 **Benefit:** 75% = $26.25 85% = $29.75 |
| 73072 | A test, including partial genotyping, for oncogenic human papillomavirus:  (a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre‑cancer or cancer; or  (b) for the follow‑up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre‑cancer or cancer; or  (c) for the investigation of a patient with symptoms suggestive of cervical cancer; or  (d) for the follow‑up management of a patient after treatment of high grade squamous intraepithelial lesions or adenocarcinoma in situ of the cervix; or  (e) for the follow‑up management of a patient with glandular abnormalities; or  (f) for the follow‑up management of a patient exposed to diethylstilboestrol in utero; or  (g) for a patient previously treated for a genital tract malignancy when performed as a co-test for both human papillomavirus (HPV) and liquid-based cytology (LBC).  (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $35.00 **Benefit:** 75% = $26.25 85% = $29.75 |
| 73074 | A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy.    (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $35.00 **Benefit:** 75% = $26.25 85% = $29.75 |
| 73075 | A test, including partial genotyping, for oncogenic human papillomavirus, if:  (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and  (b) the specimen collected for the previous test is unsatisfactory  (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $35.00 **Benefit:** 75% = $26.25 85% = $29.75 |
| 73076 | Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if:  (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by:  (i) a test to which item 73070, 73071, 73074 or 73075 applies; or  (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or  (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or  (c) the cytology is associated with a test to which item 73074 applies; or  (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or  (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma  (See para PN.0.22 of explanatory notes to this Category)  **Fee:** $46.00 **Benefit:** 75% = $34.50 85% = $39.10 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P7. GENETICS** |  | | |
|  | Group P7. Genetics |
| 73287 | The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests  (See para PR.7.3 of explanatory notes to this Category)  **Fee:** $394.55 **Benefit:** 75% = $295.95 85% = $335.40 |
| 73289 | The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests  **Fee:** $358.95 **Benefit:** 75% = $269.25 85% = $305.15 |
| 73290 | The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests.  (See para PR.7.2 of explanatory notes to this Category)  **Fee:** $394.55 **Benefit:** 75% = $295.95 85% = $335.40 |
| 73291 | Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in  a)    diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or  b)    studies of a relative for an abnormality previously identified in such an affected person.  - 1 or more tests.  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| 73292 | Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed)  - 1 or more tests.  **Fee:** $589.90 **Benefit:** 75% = $442.45 85% = $501.45 |
| 73293 | Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination.  - 1 or more tests.  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| 73294 | Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as:  a)    diagnostic studies of an affected person; or  b)    studies of a relative for an abnormality previously identified in an affected person  - 1 or more tests.  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| **Amend**  73295 | Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS), in a patient with:  (a)    advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or  (b)    triple negative early breast cancer; or  (c)    hormone receptor positive, HER2-negative, early breast cancer with one or more high-risk characteristics.  Applicable once per lifetime.  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73296 | Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician:  (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least:  (i) BRCA1 and BRCA 2 genes; and  (ii) one or more STK11, PTEN, CDH1, PALB2 and TP53 genes; and  (b) in a patient:  (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and  (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer  Once per cancer diagnosis  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73297 | Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician:  (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes:  (i) BRCA1 or BRCA2;  (ii) STK11, PTEN, CDH1, PALB2 and TP53; and  (b) in a patient:  (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); or  (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies  Once per variant  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73298 | Characterisation of germline gene variants in the following genes:  (a)  COL4A3; and  (b)  COL4A4; and  (c)  COL4A5;  in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome.  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73299 | Characterisation of germline gene variants:  (a)      in the following genes:                        (i)   COL4A3; and                        (ii)   COL4A4; and                        (iii)  COL4A5;  (b)          in a patient who:                        (i)    is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and                        (ii)   has not previously received a service which item 73298 applies; requested by a specialist or consultant physician.  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73300 | Detection of mutation of the FMR1 gene where:  (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or  (b) the patient has a relative with a FMR1 mutation  1 or more tests  (See para PN.0.23, PN.7.16 of explanatory notes to this Category)  **Fee:** $101.30 **Benefit:** 75% = $76.00 85% = $86.15 |
| 73301 | A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS)   Applicable once per primary tumour diagnosis  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73302 | Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician.    Applicable once per primary tumour diagnosis  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73303 | A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to olaparib under the Pharmaceutical Benefits Scheme.  Applicable once per primary tumour diagnosis  **Fee:** $1,000.00 **Benefit:** 75% = $750.00 85% = $901.30 |
| 73304 | Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme.  Applicable once per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $1,000.00 **Benefit:** 75% = $750.00 85% = $901.30 |
| 73305 | Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive  (See para PN.0.23, PN.7.16 of explanatory notes to this Category)  **Fee:** $202.65 **Benefit:** 75% = $152.00 85% = $172.30 |
| 73306 | Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if:  (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and  (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and  (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and  (d) the sample has no evidence of distal metastasis; and  (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics:  (i) histopathological grade 2 or 3;  (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and  (f) the service is not administered for the purpose of altering treatment decisions  Applicable once per new primary breast cancer diagnosis for any particular patient  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73307 | A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:  (a)    to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and  (b)    including a service described in item 73301  Applicable once per primary tumour diagnosis  **Fee:** $3,000.00 **Benefit:** 75% = $2250.00 85% = $2901.30 |
| 73308 | Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| 73309 | A test described in item 73308, if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| 73310 | Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist    (See para PN.0.35 of explanatory notes to this Category)  **Fee:** $1,550.00 **Benefit:** 75% = $1162.50 85% = $1451.30 |
| 73311 | Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| 73312 | A test described in item 73311, if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| **New**  73313 | Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist  Applicable once per patient per episode of disease or per relapse  (See para PN.7.20 of explanatory notes to this Category)  **Fee:** $3,000.00 **Benefit:** 75% = $2250.00 85% = $2901.30 |
| 73314 | Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of:  (a)    acute myeloid leukaemia; or  (b)    acute promyelocytic leukaemia; or  (c)    acute lymphoid leukaemia; or  (d)    chronic myeloid leukaemia;  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| 73315 | A test described in item 73314, if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18)  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| **New**  73316 | Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies  (See para PN.7.20 of explanatory notes to this Category)  **Fee:** $780.00 **Benefit:** 75% = $585.00 85% = $681.30 |
| 73317 | Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:  (a)    the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or  (b)    the patient has a first degree relative with haemochromatosis; or  (c)    the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis  (Item is subject to rule 20)  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| 73318 | A test described in item 73317, if rendered by a receiving APP - 1 or more tests  (Item is subject to rule 18 and 20)  **Fee:** $36.45 **Benefit:** 75% = $27.35 85% = $31.00 |
| 73320 | Detection of HLA-B27 by nucleic acid amplification  includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service.  (Item is subject to rule 27)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 73321 | A test described in item 73320, if rendered by a receiving APP - 1 or more tests.  (Item is subject to rule 18 and 27)  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 73323 | Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.  **Fee:** $40.55 **Benefit:** 75% = $30.45 85% = $34.50 |
| 73324 | A test described in item 73323 if rendered by a receiving APP  1 or more tests  (Item is subject to Rule 18)  **Fee:** $40.95 **Benefit:** 75% = $30.75 85% = $34.85 |
| 73325 | Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm  **Fee:** $90.00 **Benefit:** 75% = $67.50 85% = $76.50 |
| 73326 | Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of:  a)  mast cell disease; or  b)  idiopathic hypereosinophilic syndrome; or  c)  chronic eosinophilic leukaemia;.  1 or more tests  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| 73327 | Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075.    1 or more tests  **Fee:** $51.95 **Benefit:** 75% = $39.00 85% = $44.20 |
| 73332 | An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.  **Fee:** $315.40 **Benefit:** 75% = $236.55 85% = $268.10 |
| 73333 | Detection of germline mutations of the von Hippel‑Lindau (VHL) gene:  (a) in a patient who has a clinical diagnosis of VHL syndrome and:  (i) a family history of VHL syndrome and one of the following:  (A) haemangioblastoma (retinal or central nervous system);  (B) phaeochromocytoma;  (C) renal cell carcinoma; or  (ii) 2 or more haemangioblastomas; or  (iii) one haemangioblastoma and a tumour or a cyst of:  (A) the adrenal gland; or  (B) the kidney; or  (C) the pancreas; or  (D) the epididymis; or  (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or  (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:  (i) haemangiblastomas of the brain, spinal cord, or retina;  (ii) phaeochromocytoma;  (iii) functional extra‑adrenal paraganglioma  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $600.00 **Benefit:** 75% = $450.00 85% = $510.00 |
| 73334 | Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73335 | Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with:      (a)    2 or more tumours comprising:          (i)    2 or more haemangioblastomas, or          (ii)    one haemangioblastoma and a tumour of:              (A)    the adrenal gland; or              (B)    the kidney; or              (C)    the pancreas; or              (D)    the epididymis; and          (b)    no germline mutations of the VHL gene identified by genetic testing  **Fee:** $470.00 **Benefit:** 75% = $352.50 85% = $399.50 |
| 73336 | A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.  **Fee:** $230.95 **Benefit:** 75% = $173.25 85% = $196.35 |
| 73337 | A test of tumour tissue from a patient with a new diagnosis of non‑small cell lung cancer, shown to have non-squamous histology or histology not otherwise specified, requested by, or on behalf of, a specialist or consultant physician, if the test is:  (a)   to determine if requirements relating to epidermal growth factor receptor (EGFR) gene status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled; and  (b)   not associated with a service to which item 73437 or 73438 applies  (See para PN.7.15 of explanatory notes to this Category)  **Fee:** $397.35 **Benefit:** 75% = $298.05 85% = $337.75 |
| 73338 | A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:  (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:   1. the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or 2. a clinically-relevant RAS variant is detected;   and, in cases where no RAS variant is detected  (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.  (See para PN.0.26 of explanatory notes to this Category)  **Fee:** $362.60 **Benefit:** 75% = $271.95 85% = $308.25 |
| 73339 | Detection of germline mutations in the RET gene in patients with a suspected clinical diagnosis of multiple endocrine neoplasia type 2 (MEN2) requested by a specialist or consultant physician who manages the treatment of the patient.  One test.  (Item is  subject to rule 25)  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73340 | Detection of a known mutation in the RET gene in an asymptomatic relative of a patient with a documented pathogenic germline RET mutation requested by a specialist or consultant physician who manages the treatment of the patient.  One test.  (Item is subject to rule 25)  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $200.00 **Benefit:** 75% = $150.00 85% = $170.00 |
| 73341 | Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician, if the test is:  (a)   to determine if requirements relating to ALK gene rearrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled; and  (b)   not associated with a service to which item 73437 or 73439 applies  (See para PN.7.15 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73342 | An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (*HER2*) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to *HER2* gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.  (See para PN.1.2 of explanatory notes to this Category)  **Fee:** $315.40 **Benefit:** 75% = $236.55 85% = $268.10 |
| 73343 | Detection of 17p chromosomal deletions by fluorescence in situ hybridisation or genome wide micro‑array, in a patient with chronic lymphocytic leukaemia or small lymphocytic lymphoma, on a peripheral blood, bone marrow or lymph node sample, requested by a specialist or consultant physician  For any particular patient:  (a) at initial diagnosis; or  (b) at disease relapse; or  (c) on disease progression;  but only where initiation of, or change in, therapy is anticipated  **Fee:** $589.90 **Benefit:** 75% = $442.45 85% = $501.45 |
| 73344 | Fluorescence in situ hybridization (FISH) test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of ROS proto-oncogene 1 (ROS1) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+; and with documented absence of both activating mutations of the epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) immunoreactivity by IHC, requested by a specialist or consultant physician, if the test is:  (a)   to determine if requirements relating to ROS1 gene arrangement status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled: and  (b)   not associated with a service to which item 73437 or 73439 applies  (See para PN.1.2, PN.7.15 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73345 | Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of investigating, making or excluding a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73347, 73348, or 73349 applies.  The patient must have clinical or laboratory findings suggesting there is a high probability suggestive of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder.  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73346 | Testing of a pregnant patient whose carrier status for pathogenic cystic fibrosis transmembrane conductance regulator variants, as well as their reproductive partner carrier status is unknown, for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus, in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73350 applies.  The fetus must have ultrasonic findings of echogenic gut, with unknown familial cystic fibrosis transmembrane conductance regulator variants.  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73347 | Testing of a prospective parent for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the risk of their fetus having pathogenic cystic fibrosis transmembrane conductance regulator variants. This is indicated when the fetus has ultrasonic evidence of echogenic gut when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73348, or 73349 applies.  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73348 | Testing of a patient with a laboratory-established family history of pathogenic cystic fibrosis transmembrane conductance regulator variants, for the purpose of determining whether the patient is an asymptomatic genetic carrier of the pathogenic cystic fibrosis transmembrane conductance regulator variants that have been laboratory established in the family history, not being a service associated with a service to which item 73345, 73347, or 73349 applies.  The patient must have a positive family history, confirmed by laboratory findings of pathogenic cystic fibrosis transmembrane conductance regulator variants, with a personal risk of being a heterozygous genetic carrier of at least 6%. (This includes family relatedness of: parents, children, full-siblings, half-siblings, grand-parents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships).  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $250.00 **Benefit:** 75% = $187.50 85% = $212.50 |
| 73349 | Testing of a patient for pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining the reproductive risk of the patient with their reproductive partner because their reproductive partner is already known to have pathogenic cystic fibrosis transmembrane conductance regulator variants requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73345, 73347, or 73348 applies.  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73350 | Testing of a pregnant patient, where one or both prospective parents are known to be a genetic carrier of pathogenic cystic fibrosis transmembrane conductance regulator variants for the purpose of determining whether pathogenic cystic fibrosis transmembrane conductance regulator variants are present in the fetus in order to make or exclude a diagnosis of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder in the fetus, when requested by a specialist or consultant physician who manages the treatment of the patient, not being a service associated with a service to which item 73346 applies.  The fetus must be at 25% or more risk of cystic fibrosis or a cystic fibrosis transmembrane conductance regulator related disorder because of known familial cystic fibrosis transmembrane conductance regulator variants.  (See para PN.7.3, PN.7.16 of explanatory notes to this Category)  **Fee:** $250.00 **Benefit:** 75% = $187.50 85% = $212.50 |
| 73351 | A test of tumour tissue that is derived from a new sample from a patient with locally advanced (Stage IIIb) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), who has progressed on or after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). The test is to be requested by a specialist or consultant physician, to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under the Pharmaceutical Benefits Scheme are fulfilled.    **Fee:** $397.35 **Benefit:** 75% = $298.05 85% = $337.75 |
| 73352 | Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes), requested by a specialist or consultant physician, for a patient:  (a) for whom no familial mutation has been identified; and  (b) who has any of the following:  (i) a Dutch Lipid Clinic Network score of at least 6;  (ii) an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes;  (iii) an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis  Applicable only once per lifetime  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73353 | Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73354 | Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for:  (a) a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; or  (b) a patient:  (i) who has endometrial cancer; and  (ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73355 | Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient:  (a) who has adenomatous polyposis; and  (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria:  (i) familial adenomatous polyposis;  (ii) MUTYH-associated polyposis  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73356 | Characterisation of germline gene variants, including copy number variation, in the SMAD4, BMPR1A, STK11 and GREM1 genes, requested by a specialist or consultant physician, for a patient:  (a) who has non-adenomatous polyposis; and  (b) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having any of the following, on the basis of clinical and family history criteria:  (i) juvenile polyposis syndrome;  (ii) Peutz-Jeghers syndrome;  (iii) hereditary mixed polyposis syndrome  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73357 | Characterisation of germline gene variants, including copy number variation, in the genes mentioned in item 73354, 73355 or 73356, requested by a specialist or consultant physician, for a patient:  (a) who has a biological relative with a pathogenic mutation identified in one or more of those genes; and  (b) who has not previously received a service to which any of items 73354, 73355 and 73356 apply  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73358 | Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if:  (a) the characterisation is:  (i) requested by a consultant physician practising as a clinical geneticist; or  (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and  (b) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of:  (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or  (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and  (c) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and  (d) the characterisation is not performed in conjunction with a service to which item 73359 applies  Applicable only once per lifetime    (See para PN.7.4 of explanatory notes to this Category)  **Fee:** $2,100.00 **Benefit:** 75% = $1575.00 85% = $2001.30 |
| 73359 | Characterisation, via whole exome or genome sequencing and analysis, of germline variants known to cause monogenic disorders, if:  (a) the characterisation is:  (i) requested by a consultant physician practising as a clinical geneticist; or  (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and  (b) the request for the characterisation states that singleton testing is inappropriate; and  (c) the patient is aged 10 years or younger and is strongly suspected of having a monogenic condition, based on the presence of:  (i) dysmorphic facial appearance and one or more major structural congenital anomalies; or  (ii) intellectual disability or global developmental delay of at least moderate severity, as determined by a specialist paediatrician; and  (d) the characterisation is performed following the performance for the patient of a service to which item 73292 applies for which the results were non-informative; and  (e) the characterisation is performed using a sample from the patient and a sample from each of the patient’s biological parents; and  (f) the characterisation is not performed in conjunction with a service to which item 73358 applies  Applicable only once per lifetime    (See para PN.7.4 of explanatory notes to this Category)  **Fee:** $2,900.00 **Benefit:** 75% = $2175.00 85% = $2801.30 |
| 73360 | Re-analysis of whole exome or genome data obtained in performing a service to which item 73358 or 73359 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if:  (a) the re-analysis is:  (i) requested by a consultant physician practising as a clinical geneticist; or  (ii) requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and  (b) the patient is aged 15 years or younger and is strongly suspected of having a monogenic condition; and  (c) the re-analysis is performed at least 18 months after:  (i) a service to which item 73358 or 73359 applies; or  (ii) a service to which this item applies  Applicable only twice per lifetime    **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73361 | Testing of a person (the person tested) for the detection of a single gene variant for diagnostic purposes, if:   1. the person tested has a biological sibling (the sibling) with a known monogenic condition; and 2. a service described in item 73358, 73359 or 73360 has identified the causative variant for the sibling’s condition; and 3. the results of the testing performed for the sibling are made available for the purpose of providing the detection for the person tested; and 4. the detection is:    1. requested by a consultant physician practising as a clinical geneticist; or    2. requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and 5. the detection is not performed in conjunction with a service to which item 73362 or 73363 applies   Applicable only once per variant per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73362 | Testing of a person (the person tested) for the detection of a single gene variant for the purpose of reproductive decision making, if:   1. the person tested has a first‑degree relative (the relative) with a known monogenic condition; and 2. a service described in item 73358, 73359 or 73360 has identified the causative variant for the relative’s condition; and 3. the results of the testing performed for the relative are made available for the purpose of providing the detection for the person tested; and 4. the detection is requested by a consultant physician or specialist; and 5. the detection is not performed in conjunction with item 73359, 73361 or 73363   Applicable only once per variant per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73363 | Testing of a person (the person tested) for the detection of a single gene variant for segregation analysis in relation to another person (the patient), if:   1. the patient has a known phenotype of a suspected monogenic condition; and 2. a service described in item 73358 or 73360 has identified a potentially causative variant for the patient; and 3. the person tested is a biological parent or other biological relative of the patient; and 4. a sample from the person tested has not previously been tested in relation to the patient for a service to which item 73359 applies; and 5. the results of the testing of the person tested for this service are made available for the purpose of providing the detection for the patient; and 6. the detection is:    1. requested by a consultant physician practising as a clinical geneticist; or    2. requested by a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist; and 7. the detection is not performed in conjunction with item 73361 or 73362   Applicable only once per variant per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73364 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for:  (i) the characterisation of MYC gene rearrangement; and  (ii) if the results of the characterisation mentioned in subparagraph (i) are positive—the characterisation of either or both of BCL2 gene rearrangement and BCL6 gene rearrangement; and  (b) is for a patient:  (i) for whom MYC immunohistochemistry is non-negative; and  (ii) with clinical or laboratory evidence, including morphological features, of diffuse large B-cell lymphoma or high grade B-cell lymphoma; and  (c) is not performed in conjunction with item 73365  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73365 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of MYC gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of Burkitt lymphoma; and  (c) is not performed in conjunction with item 73364  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73366 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of either or both of the following:  (i) CCND1 gene rearrangement;  (ii) CCND2 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of mantle cell lymphoma  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73367 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the presence of isochromosome 7q; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of hepatosplenic T‑cell lymphoma  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73368 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of either or both of the following:  (i) DUSP22 gene rearrangement;  (ii) TP63 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of ALK negative anaplastic large cell lymphoma  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73369 | Analysis of blood or bone marrow, requested by a specialist or consultant physician, that:  (a) is for the characterisation of either or both of the following:  (i) TCL1A gene rearrangement;  (ii) MTCP1 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of T‑cell prolymphocytic leukaemia  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73370 | Analysis of blood or bone marrow, requested by a specialist or consultant physician, that:  (a) is for the characterisation of the following:  (i) chromosome translocations t(4;14), t(14;16), t(14;20);  (ii) 1q gain;  (iii) 17p deletion; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of plasma cell myeloma  Applicable only once per lifetime  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73371 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the detection of chromosome 1p/19q co‑deletion; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of glial neoplasm with probable oligodendroglial component  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73372 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the identification of IDH1/2 pathological variant status; and  (b) is for a patient with:  (i) negative IDH1 (R132H) immunohistochemistry; and  (ii) clinical or laboratory evidence, including morphological features, of glial neoplasm  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73373 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of MGMT promoter methylation status; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of glioblastoma  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73374 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes in one of the following genes:  (i) MDM2 CNV;  (ii) FUS;  (iii) DDIT3;  (iv) EWSR1;  (v) ETV6;  (vi) NTRK1;  (vii) NTRK3;  (viii) COL1A1;  (ix) PDGFB;  (x) STAT6;  (xi) PAX3;  (xii) PAX7;  (xiii) SS18;  (xiv) BCOR;  (xv) CIC;  (xvi) HEY1;  (xvii) ALK;  (xviii) USP6;  (xix) NR4A3;  (xx) NCOA2;  (xxi) FOXO1; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73375 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes, in 2 or 3 of the genes mentioned in item 73374; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73376 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of copy number changes, gene rearrangements, or other molecular changes, in 4 or more of the genes mentioned in item 73374; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of sarcoma  Applicable only once per lifetime  **Fee:** $800.00 **Benefit:** 75% = $600.00 85% = $701.30 |
| 73377 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the detection of FOXL2.402C>G status; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of granulosa cell ovarian tumour  Applicable only once per lifetime  **Fee:** $250.00 **Benefit:** 75% = $187.50 85% = $212.50 |
| 73378 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of NUTM1 gene status at 15q14; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of midline NUT carcinoma  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73379 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of secretory carcinoma of the breast  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73380 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of MAML2 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of mucoepidermoid carcinoma  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73381 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of ETV6‑NTRK3 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73382 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of EWSR1 gene rearrangement, with or without PLAG1 gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of hyalinising clear cell carcinoma of the salivary gland  Applicable only once per lifetime  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73383 | Analysis of tumour tissue, requested by a specialist or consultant physician, that:  (a) is for the characterisation of either or both of the following:  (i) TFE3 gene rearrangement;  (ii) TFEB gene rearrangement; and  (b) is for a patient with clinical or laboratory evidence, including morphological features, of renal cell carcinoma  Applicable only once per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73384 | Genetic analysis, for a patient who is eligible for this service under clause 2.7.3A of the pathology services table (see PR.7.1), of samples from the patient and (if relevant) the patient’s reproductive partner, for the purpose of providing an assay for pre‑implantation genetic testing, requested by a specialist or consultant physician  Applicable not more than once per patient episode per disorder (of a kind described in clause 2.7.3A (PR.7.1)) per reproductive relationship  (See para PR.7.1, TN.1.4 of explanatory notes to this Category)  **Fee:** $1,736.00 **Benefit:** 75% = $1302.00 85% = $1637.30 |
| 73385 | Genetic analysis, for a patient who is eligible for this service under clause 2.7.3A of the Pathology Services Table (see PR.7.1), of embryonic tissue from a sample from one embryo, if:  (a) the analysis is:  (i) requested by a specialist or consultant physician; and  (ii) for the purpose of providing a pre‑implantation genetic test; and  (iii) performed on an embryo that was produced in a single assisted reproductive treatment cycle; and  (b) the service is not a service to which item 73386 or 73387 applies for the same assisted reproductive treatment cycle  Applicable not more than once per embryo  (See para PR.7.1, TN.1.4 of explanatory notes to this Category)  **Fee:** $635.00 **Benefit:** 75% = $476.25 85% = $539.75 |
| 73386 | Genetic analysis, for a patient who is eligible for this service under clause 2.7.3A of the Pathology Services Table (see PR.7.1), of embryonic tissue from samples from 2 embryos, if:  (a) the analysis is:  (i) requested by a specialist or consultant physician; and  (ii) for the purpose of providing a pre‑implantation genetic test; and  (iii) performed on embryos that were produced in a single assisted reproductive treatment cycle; and  (b) the service is not a service to which item 73385 or 73387 applies for the same assisted reproductive treatment cycle  Applicable not more than once per assisted reproductive treatment cycle for the 2 embryos tested  (See para PR.7.1, TN.1.4 of explanatory notes to this Category)  **Fee:** $1,270.00 **Benefit:** 75% = $952.50 85% = $1171.30 |
| 73387 | Genetic analysis, for a patient who is eligible for this service under clause 2.7.3A of the Pathology Services Table (see PR.7.1), of embryonic tissue from samples from 3 or more embryos, if:  (a) the analysis is:  (i) requested by a specialist or consultant physician; and  (ii) for the purpose of providing a pre‑implantation genetic test; and  (iii) performed on embryos that were produced in a single assisted reproductive treatment cycle; and  (b) the service is not a service to which item 73385 or 73386 applies for the same assisted reproductive treatment cycle  Applicable not more than once per assisted reproductive treatment cycle for the 3 or more embryos tested  (See para PR.7.1, TN.1.4 of explanatory notes to this Category)  **Fee:** $1,905.00 **Benefit:** 75% = $1428.75 85% = $1806.30 |
| 73388 | Analysis of chromosomes by genome‑wide microarray, of a sample from amniocentesis or chorionic villus sampling, including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a fetus, if   1. one or more major fetal structural abnormalities have been detected on ultrasound; or 2. nuchal translucency was greater than 3.5 mm   Applicable only once per fetus    (See para PR.7.3 of explanatory notes to this Category)  **Fee:** $589.90 **Benefit:** 75% = $442.45 85% = $501.45 |
| 73389 | Analysis of products of conception from a patient with suspected hydatidiform mole for the characterisation of ploidy status  Applicable once per pregnancy  (See para PN.1.2 of explanatory notes to this Category)  **Fee:** $340.00 **Benefit:** 75% = $255.00 85% = $289.00 |
| 73391 | Analysis of chromosomes by genome‑wide microarray in diagnostic studies of a patient with multiple myeloma  Applicable once per lifetime    (See para PR.7.2 of explanatory notes to this Category)  **Fee:** $589.90 **Benefit:** 75% = $442.45 85% = $501.45 |
| 73392 | Characterisation of pathogenic or likely pathogenic germline gene variants, requested by a specialist or consultant physician:  (a) in at least the following genes:  (i) MYBPC3;  (ii) MYH7;  (iii) TNNI3;  (iv) TNNT2;  (v) TPM1;  (vi) ACTC1;  (vii) MYL2;  (viii) MYL3;  (ix) PRKAG2;  (x) LAMP2;  (xi) GLA;  (xii) LMNA;  (xiii) SCN5A;  (xiv) TTN;  (xv) RBM20;  (xvi) PLN;  (xvii) DSP;  (xviii) DSC2;  (xix) DSG2;  (xx) JUP;  (xxi) PKP2;  (xxii) TMEM43; and  (b) for a patient for whom clinical history, family history or laboratory findings suggest there is a high probability of one or more of the following heritable cardiomyopathies in the patient:  (i) hypertrophic cardiomyopathy;  (ii) dilated cardiomyopathy;  (iii) arrhythmogenic cardiomyopathy  Applicable once per lifetime  (See para PN.0.27, PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73393 | Characterisation of one or more pathogenic or likely pathogenic germline gene variants, requested by a specialist or consultant physician, if:  (a) a service described in item 73392 has not previously been performed for the patient; and  (b) the patient is a first-degree biological relative (or a second-degree biological relative if a first-degree biological relative is unavailable) of a person who has a pathogenic or likely pathogenic germline gene variant that is confirmed by laboratory findings; and  (c) the service is performed for the purpose of assessing present or future risk of any of the following heritable cardiomyopathies in the patient:  (i) hypertrophic cardiomyopathy;  (ii) dilated cardiomyopathy;  (iii) arrhythmogenic cardiomyopathy  Applicable once per variant per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73394 | Characterisation of one or more recessive pathogenic or likely pathogenic germline genes, requested by a specialist or consultant physician, for the purpose of determining the reproductive risk of heritable cardiomyopathy in a patient:  (a) who is a reproductive partner of a known carrier of a pathogenic or likely pathogenic germline gene that is confirmed by laboratory findings ; and  (b) for whom carrier status of a pathogenic or likely pathogenic germline gene is unknown; and  (c) who has a clinical history, family history or laboratory findings suggesting there is a low probability of heritable cardiomyopathy  Applicable once per gene per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73395 | Re‑analysis of whole exome or genome data that is obtained in performing a service to which item 73392 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if:  (a) the re-analysis is requested by a consultant physician practising as a clinical geneticist or a cardiologist; and  (b) the patient is strongly suspected of having a heritable cardiomyopathy; and  (c) the re-analysis is performed at least 18 months after a service to which item 73392 or this item applies is performed for the patient  Applicable twice per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73396 | Characterisation of variants in the JAK2 exon 12 in the diagnostic work‑up of a patient with clinical and laboratory evidence of polycythaemia vera, requested by a specialist or consultant physician  **Fee:** $90.00 **Benefit:** 75% = $67.50 85% = $76.50 |
| 73397 | Characterisation of variants in both the CALR and MPL genes in the diagnostic work‑up of a patient with clinical and laboratory evidence of essential thrombocythaemia or primary myelofibrosis, requested by a specialist or consultant physician  **Fee:** $200.00 **Benefit:** 75% = $150.00 85% = $170.00 |
| 73398 | Characterisation of variants in at least 8 genes, which must include all of the following genes:  (a) JAK2 (including exons 12 and 14);  (b) CALR;  (c) MPL;  in the diagnostic work‑up of a patient with clinical and laboratory evidence of polycythaemia vera or essential thrombocythaemia, requested by a specialist or consultant physician  Applicable to one test per diagnostic episode  **Fee:** $420.00 **Benefit:** 75% = $315.00 85% = $357.00 |
| 73399 | Characterisation of variants in at least 20 genes, which must include all of the following genes:  (a) JAK2 (including exons 12 and 14);  (b) CALR;  (c) MPL;  in the diagnostic work‑up of a patient, with clinical and laboratory evidence of primary myelofibrosis, who is eligible for a stem cell transplant, requested by a specialist or consultant physician  Applicable to one test per diagnostic episode  **Fee:** $700.00 **Benefit:** 75% = $525.00 85% = $601.30 |
| 73401 | Characterisation, by whole exome or genome sequencing and analysis, of germline gene variants in one or more of the genes implicated in heritable cystic kidney disease, if:  (a) the service is requested by a consultant physician practising as:  (i) a clinical geneticist; or  (ii) a specialist nephrologist; and  (b) the patient has a renal abnormality and is strongly suspected of having a monogenic condition  Applicable once per lifetime  **Fee:** $2,100.00 **Benefit:** 75% = $1575.00 85% = $2001.30 |
| 73402 | Characterisation, by whole exome or genome sequencing and analysis, of germline gene variants in one or more of the genes implicated in heritable kidney disease, if:  (a) the service is requested by a consultant physician practising as:  (i) a clinical geneticist; or  (ii) a specialist nephrologist; and  (b) the patient has chronic kidney disease (other than cystic disease or Alport syndrome) and is strongly suspected of having a monogenic condition  Applicable once per lifetime  **Fee:** $2,100.00 **Benefit:** 75% = $1575.00 85% = $2001.30 |
| 73403 | Re‑analysis of genetic data obtained in performing a service to which item 73401 or 73402 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if:  (a) the re-analysis is requested by a consultant physician practising as a clinical geneticist or a specialist paediatrician; and  (b) the patient has a strong clinical suspicion of a monogenic condition; and  (c) a service to which item 73401, 73402 or this item applies has not been performed for the patient in the previous 18 months  Applicable twice per lifetime  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73404 | Detection of a single gene variant in a patient, if:  (a) the service is requested by:  (i) a clinical geneticist; or  (ii) a specialist or consultant physician providing professional genetic counselling services; and  (b) the patient has a first-degree relative with a known monogenic cause of kidney disease; and  (c) a service described in item 73401, 73402, or 73403 has identified the causative variant for the disease for the relative  Applicable once per variant per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73405 | Detection of one or more variants of a single gene known to cause heritable kidney disease, for the purpose of reproductive decision making, if:  (a) the detection is requested by a consultant physician practising as:  (i) a clinical geneticist; or  (ii) a specialist nephrologist; and  (b) the patient is the reproductive partner of an individual known to be a carrier of a pathogenic variant that causes heritable kidney disease that has a recessive mode of inheritance; and  (c) a service described in item 73401, 73402, 73403 or 73404 has identified the causative gene for the patient’s partner; and  (d) the detection test methodology has sufficient diagnostic range and sensitivity to detect at least 95% of pathogenic variants likely to be present in the patient  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73406 | Testing of a pregnant patient, for the purpose of determining whether monogenic variants are present in the fetus, if:  (a) the service is requested by a consultant physician practising as:  (i) a clinical geneticist; or  (ii) a specialist nephrologist; and  (b) the patient or the patient’s reproductive partner (or both) are known to be affected by, or are carriers of, a known pathogenic variant that causes heritable kidney disease; and  (c) the fetus is at risk, of at least 25%, of inheriting a monogenic variant known to cause kidney disease  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| **Amend**  73410 | Deletion testing of HBA1 and HBA2 for:  (a) the diagnosis of alpha thalassaemia in a patient of reproductive age:  (i) who has abnormal red cell indices; and  (ii) for whom thalassaemia screening was suggestive of thalassaemia; and  (iii) who does not have a concurrent iron deficiency (or who, irrespective of iron status, is pregnant); and  (iv) who has no historic normal cell indices; or  (b) the determination of carrier status in a person:  (i) who is a reproductive partner of a person with alpha thalassaemia; and  (ii) who has abnormal red cell indices; and  (iii) who does not have a concurrent iron deficiency; or  (c) the determination of carrier status in a person:  (i) who is a reproductive partner of a person with alpha thalassaemia and heterozygous 2‑gene deletion; and  (ii) who has normal red cell indices  (See para PN.7.5 of explanatory notes to this Category)  **Fee:** $100.00 **Benefit:** 75% = $75.00 85% = $85.00 |
| **Amend**  73411 | Sequencing of HBA1 or HBA2, if the results of deletion testing described in item 73410 were inconclusive and a less common or rare variant is suspected, either:  (a) for the diagnosis of alpha thalassaemia in a patient of reproductive age; or  (b) for the determination of carrier status in a reproductive partner of a person with alpha thalassaemia  Applicable once per gene per lifetime  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| **Amend**  73412 | Deletion testing of HBA1 and HBA2, if the results of deletion testing described in item 73410 were inconclusive and a large deletion variant is suspected, either:  (a) for the diagnosis of alpha thalassaemia in a patient of reproductive age; or  (b) for the determination of carrier status in a reproductive partner of a person with alpha thalassaemia  **Fee:** $250.00 **Benefit:** 75% = $187.50 85% = $212.50 |
| **Amend**  73413 | Non‑deletion testing of HBA1 and HBA2 using techniques other than sequencing, if the results of deletion testing described in item 73410 were inconclusive, either:  (a) for the diagnosis of alpha thalassaemia in a patient of reproductive age ; or  (b) for the determination of carrier status in a reproductive partner of a person with alpha thalassaemia  **Fee:** $250.00 **Benefit:** 75% = $187.50 85% = $212.50 |
| 73416 | Detection of germline gene variants, including copy number variation, requested by a specialist or consultant physician:  (a) in at least the following genes:  (i) KCNQ1;  (ii) KCNH2;  (iii) SCN5A;  (iv) KCNE1;  (v) KCNE2;  (vi) KCNJ2;  (vii) CACNA1C;  (viii) RYR2;  (ix) CASQ2;  (x) CAV3;  (xi) SCN4B;  (xii) AKAP9;  (xiii) SNTA1;  (xiv) KCNJ5;  (xv) ALG10;  (xvi) CALM1;  (xvii) CALM2;  (xviii) ANK2;  (xix) TECRL;  (xx) TRDN; and  (b) for a patient for whom clinical or family history criteria is suggestive of inherited cardiac arrhythmias or channelopathies that place the patient at greater than 10% risk of having a pathogenic variant  Applicable once per lifetime  (See para PN.0.27, PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73417 | Characterisation of one or more pathogenic or likely pathogenic germline gene variants, requested by a specialist or consultant physician, if:  (a) the patient is a first-degree or second‑degree biological relative of a person with a pathogenic or likely pathogenic germline gene variant that is confirmed by laboratory findings; and  (b) the service is performed for the purpose of assessing present or future risk of a cardiac arrhythmia or channelopathy; and  (c) a service to which item 73416 applies has not previously been performed for the patient  Applicable once per variant per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73418 | Characterisation of one or more recessive pathogenic or likely pathogenic germline genes, requested by a specialist or consultant physician, for the purpose of determining the reproductive risk of cardiac arrhythmia or channelopathy in a patient:  (a) who is a reproductive partner of a person who is a known carrier of a pathogenic or likely pathogenic germline gene variant of a gene confirmed by laboratory findings; and  (b) for whom a service to which item 73416 applies has not previously been performed; and  (c) for whom carrier status of a pathogenic or likely pathogenic germline gene variant is unknown; and  (d) who has a clinical history, family history or laboratory findings suggesting there is a low probability of cardiac arrhythmia or channelopathy  Applicable once per gene per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73419 | Re‑analysis of whole exome or genome data that was obtained in performing a service to which item 73416 applies, for characterisation of previously unreported germline gene variants related to the clinical phenotype, if:  (a) the re-analysis is requested by a consultant physician practising as a clinical geneticist or a cardiologist; and  (b) the patient is strongly suspected of having inheritable cardiac arrhythmia or channelopathies; and  (c) the service is performed at least 18 months after a service to which item 73416 or this item applies was performed for the patient  Applicable twice per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73420 | Non‑invasive prenatal testing of blood from an RhD negative pregnant patient for the detection of the RHD gene from fetal DNA circulating in maternal blood  **Fee:** $56.00 **Benefit:** 75% = $42.00 85% = $47.60 |
| 73421 | Non‑invasive prenatal testing of blood from an RhD negative pregnant patient (in a singleton pregnancy) for the detection of the RHD gene from fetal DNA circulating in maternal blood, if the patient is alloimmunised with immune Anti-D  **Fee:** $550.00 **Benefit:** 75% = $412.50 85% = $467.50 |
| 73422 | Characterisation of a gene variant or gene variants using a gene panel, in a patient presenting with clinical signs and symptoms suggestive of a genetic neuromuscular disorder (other than signs and symptoms associated with variants that are not detected by massively parallel sequencing), if the service is requested:  (a) by a specialist or consultant physician; and  (b) after exclusion of non‑genetic causes  Applicable once per lifetime    (See para PN.7.6 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73423 | Detection of a single identified gene variant, in a biological relative of a person with a germline gene variant for a neuromuscular disorder identified by a service described in item 73422, 73425 or 73426, if the service is requested by a specialist or consultant physician  Applicable once per variant  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73424 | Prenatal detection of an actionable pathogenic familial gene variant or gene variants (including maternal cell contamination assessment), requested by a specialist or consultant physician, for a genetic neuromuscular disorder previously identified in an index person in the patient’s family as a result of a service described in item 73422  Applicable once per pregnancy  **Fee:** $1,600.00 **Benefit:** 75% = $1200.00 85% = $1501.30 |
| 73425 | Prenatal detection of unknown gene variants (including maternal cell contamination assessment) using a gene panel, if:  (a) the service is requested:  (i) by a specialist or consultant physician, for a suspected genetic neuromuscular disorder; and  (ii) after exclusion of non‑genetic causes; and  (b) the service is performed using a sample from the fetus; and  (c) the service is not performed in conjunction with a service to which item 73426 applies  Applicable once per pregnancy  **Fee:** $1,800.00 **Benefit:** 75% = $1350.00 85% = $1701.30 |
| 73426 | Prenatal detection of unknown gene variants (including maternal cell contamination assessment) using a gene panel, if:  (a) the service is requested:  (i) by a specialist or consultant physician; and  (ii) for a suspected genetic neuromuscular disorder; and  (iii) after exclusion of non‑genetic causes; and  (b) the request states that singleton testing is inappropriate; and  (c) the service is performed using a sample from the fetus and a sample from each of the fetus’s biological parents; and  (d) the service is not performed in conjunction with a service to which item 73425 applies  Applicable once per pregnancy  **Fee:** $2,400.00 **Benefit:** 75% = $1800.00 85% = $2301.30 |
| 73427 | Single gene testing for the characterisation of a germline gene variant or germline gene variants:  (a) if requested by a specialist or consultant physician; and  (b) within the same gene in which the patient’s reproductive partner has a documented pathogenic germline recessive gene variant for a neuromuscular disorder identified by a service described in:  (i) item 73422, 73425 or 73426; or  (ii) item 73434, if the patient has been provided a service described in item 73434 and that service has not identified a relevant variant  Applicable once per gene  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73428 | Re‑analysis of whole genome or exome data obtained in performing a service described in item 73422, 73425 or 73426, for characterisation of previously unreported gene variants related to the clinical phenotype, if the re‑analysis is requested by:  (a) a consultant physician practicing as a clinical geneticist; or  (b) a consultant physician practising as a specialist paediatrician, following consultation with a clinical geneticist  Applicable twice per lifetime    (See para PN.7.7 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73429 | Genetic testing (including characterisation of single nucleotide variants, structural variants, fusions and copy number alterations) in a single gene panel, requested by a specialist or consultant physician, for a patient with clinical or laboratory evidence of a glioma, glioneuronal tumour or glioblastoma, to aid diagnosis and classification of the relevant tumour, including assessments of at least the following kinds:  (a) IDH1, IDH2—variant testing;  (b) 1p/19q—co‑deletion assessment;  (c) H3F3A—variant status;  (d) TERT—promoter variant status;  (e) EGFR—amplification;  (f) CDKN2A/B—deletion;  (g) BRAF—variants  Applicable to one test per diagnostic episode    (See para PN.7.10 of explanatory notes to this Category)  **Fee:** $887.90 **Benefit:** 75% = $665.95 85% = $789.20 |
| 73430 | Fluorescence in-situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic solid tumour, if:  (a)     the tumour is at risk of being caused by a neurotrophic receptor tyrosine kinase (NTRK) gene fusion as determined by either:                     (i)        occurring in a child less than 18 years of age; or                     (ii)        being mammary analogue secretory carcinoma of the salivary gland; or                     (iii)        being secretory breast carcinoma; and  (b)    the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled  This item cannot be claimed if item 73433 has been claimed for the same patient during the same cancer diagnosis  Applicable only once per cancer diagnosis  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73431 | Two tests described in item 73430  **Fee:** $533.00 **Benefit:** 75% = $399.75 85% = $453.05 |
| 73432 | Three or more tests described in item 73430  **Fee:** $667.00 **Benefit:** 75% = $500.25 85% = $568.30 |
| 73433 | Next generation sequencing (NGS) test for neurotrophic receptor tyrosine kinase (NTRK1, NTRK2, NTRK3) fusions by RNA or DNA in tumour tissue from a patient with locally advanced or metastatic solid tumour, if:  (a)     the tumour is at risk of being caused by an NTRK gene fusion as determined by either:                     (i)        occurring in a child less than 18 years of age; or                     (ii)        being mammary analogue secretory carcinoma of the salivary gland; or                     (iii)        being secretory breast carcinoma;  (b)    the test is requested by a specialist or consultant physician to determine if requirements relating to NTRK gene fusion status for access to a tropomyosin receptor kinase (Trk) inhibitor under the Pharmaceutical Benefits Scheme are fulfilled  This item cannot be claimed if item 73430 has been claimed for the same patient during the same cancer diagnosis  Applicable only once per cancer diagnosis  **Fee:** $1,000.00 **Benefit:** 75% = $750.00 85% = $901.30 |
| 73434 | Detection of pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, for any of the following:  (a) a patient with a suspected neuromuscular disorder;  (b) a relative of a patient with a pathogenic or likely pathogenic germline gene variant associated with a neuromuscular disorder (confirmed by laboratory findings);  (c) the reproductive partner of a patient with a recessive pathogenic or likely pathogenic germline gene variant associated with a neuromuscular disorder (confirmed by laboratory findings)  Applicable once per gene per lifetime  (See para PN.7.11, PN.7.12 of explanatory notes to this Category)  **Fee:** $392.00 **Benefit:** 75% = $294.00 85% = $333.20 |
| 73435 | Detection of pathogenic or likely pathogenic DUX4 gene variants, requested by a specialist or consultant physician, for:  (a) a patient with a suspected neuromuscular disorder; or  (b) a relative of a patient with a pathogenic or likely pathogenic germline gene variant associated with a neuromuscular disorder (confirmed by laboratory findings)  Applicable once per gene per lifetime  **Fee:** $1,000.00 **Benefit:** 75% = $750.00 85% = $901.30 |
| 73436 | A test of tumour tissue from a patient with a new diagnosis of locally advanced or metastatic non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:  (a)   to determine if the requirements relating to MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk) status for access to an immunotherapy listed under the Pharmaceutical Benefits Scheme (PBS) are fulfilled: and  (b)   not associated with a service to which item 73437 or 73438 applies  (See para PN.1.2, PN.7.15 of explanatory notes to this Category)  **Fee:** $397.35 **Benefit:** 75% = $298.05 85% = $337.75 |
| 73437 | A nucleic acid-based multi-gene panel test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:  (a)  to detect variants in at least EGFR, BRAF, KRAS and MET exon 14 to determine access to specific therapies relevant to these variants listed on the Pharmaceutical Benefits Scheme (PBS); and  (b)  to detect the fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3; and            (i)   to determine access to specific therapies relevant to these variants listed on the PBS; or           (ii)   determine if the requirements relating to EGFR, ALK and ROS1 status for access immunotherapies listed on the PBS are fulfilled; and  (c)  not associated with a service to which item 73438, 73439, 73337, 73341, 73344, 73436 or 73351 applies  (See para PN.7.15 of explanatory notes to this Category)  **Fee:** $1,247.00 **Benefit:** 75% = $935.25 85% = $1148.30 |
| 73438 | A DNA-based multi-gene panel test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is:  (a)   to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and  (b)   to determine access to specific therapies relevant to these variants listed on the Pharmaceutical Benefits Scheme (PBS); or  (c)   to determine if the requirements relating to EGFR status for access to immunotherapies listed on the PBS are fulfilled; and  (d)   not associated with a service to which item 73437, 73337, 73436 or 73351 applies  (See para PN.7.15 of explanatory notes to this Category)  **Fee:** $682.35 **Benefit:** 75% = $511.80 85% = $583.65 |
| 73439 | A nucleic acid-based multi-gene panel test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer and with documented absence of activating variants of the EGFR gene, KRAS, BRAF and MET exon14, requested by, or on behalf of, a specialist or consultant physician, if the test is:  (a)   to determine the fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 to determine access to specific therapies relevant to these variants listed on the Pharmaceutical Benefits Scheme (PBS) are fulfilled; or  (b)   to determine if the requirements relating to ALK and ROS1 status for access to immunotherapies listed on the PBS are fulfilled; and  (c)   not associated with a service to which item 73437, 73341, 73344 or 73351 applies  (See para PN.7.15 of explanatory notes to this Category)  **Fee:** $682.35 **Benefit:** 75% = $511.80 85% = $583.65 |
| 73440 | Genomic testing and copy number variant analysis of genes known to be causative or likely causative of childhood hearing loss in a patient, if: (a) the testing and analysis is requested by a specialist or consultant physician; and (b) the patient has congenital or childhood onset hearing loss that presented before the patient was 18 years of age and is permanent moderate, severe, or profound (>40 dB in the worst ear over 3 frequencies) and classified as sensorineural, auditory neuropathy or mixed; and (c) the patient is not eligible for a service to which item 73358 or 73359 applies; and (d) the testing and analysis is not associated with a service to which item 73441 applies  Applicable once per lifetime  (See para PN.0.23, PN.7.13 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73441 | Genomic testing and copy number variant analysis of relevant genes known to be causative or likely causative of childhood hearing loss in a patient, if: (a) the testing and analysis is requested by a specialist or consultant physician; and (b) the patient has congenital or childhood onset hearing loss that presented before the patient was 18 years of age and is permanent bilateral moderate, severe, or profound (>40 dB in the worst ear over 3 frequencies) and classified as sensorineural, auditory neuropathy or mixed; and (c) the testing and analysis is performed using a sample from the patient and a sample from each of the patient’s biological parents; and (d) the patient is not eligible for a service to which item 73358 or 73359 applies; and (e) the testing and analysis is not associated with a service to which item 73440 applies  Applicable once per lifetime  (See para PN.0.23, PN.7.13 of explanatory notes to this Category)  **Fee:** $2,100.00 **Benefit:** 75% = $1575.00 85% = $2001.30 |
| 73442 | Re-analysis of whole exome or genome data obtained under a service to which item 73440 or 73441 applies, for characterisation of previously unreported germline gene variants for childhood hearing loss in a patient, if: (a) the re-analysis is requested by a specialist or consultant physician; and (b) the re-analysis is performed at least 24 months after: (i) the service to which items 73440 or 73441 applies has been provided to the patient; or (ii) a service to which this item applies is performed for the patient  Applicable twice per lifetime  (See para PN.0.23 of explanatory notes to this Category)  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73443 | Characterisation of one or more familial germline gene variants known to be causative or likely causative of childhood hearing loss in a person, if: (a) the person tested is a biological relative of a patient with a germline gene variant known to be causative or likely causative of hearing loss confirmed by laboratory findings; and (b) the result of a previous proband testing is made available to the laboratory undertaking the characterisation  (See para PN.0.23, PN.7.13 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73444 | Characterisation of all germline variants in one or more genes known to cause hearing loss in a person, if: (a) the characterisation is requested by a specialist or consultant physician; and (b) the characterisation is for the reproductive partner of a patient with a pathogenic or likely pathogenic recessive germline gene variant known to cause hearing loss confirmed by laboratory findings; and (c) the result of the patient’s previous testing is made available to the laboratory undertaking the characterisation  (See para PN.0.23, PN.7.13 of explanatory notes to this Category)  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73445 | Characterisation of a variant or variants in a panel of at least 25 genes using DNA and RNA, requested by a specialist or consultant physician, to determine the diagnosis, prognosis and/or management of a patient presenting with a clinically suspected haematological malignancy of myeloid origin  Applicable once per diagnostic episode, at diagnosis, disease progression or relapse  (See para PN.7.14 of explanatory notes to this Category)  **Fee:** $1,100.00 **Benefit:** 75% = $825.00 85% = $1001.30 |
| 73446 | Characterisation of a variant or variants in a panel of at least 25 genes using DNA and RNA, requested by a specialist or consultant physician, to determine the diagnosis, prognosis and/or management of a patient presenting with a clinically suspected haematological malignancy of lymphoid origin  Applicable once per diagnostic episode, at diagnosis, disease progression or relapse  (See para PN.7.14 of explanatory notes to this Category)  **Fee:** $1,100.00 **Benefit:** 75% = $825.00 85% = $1001.30 |
| 73447 | Characterisation of a variant or variants in a panel of at least 25 genes using DNA, requested by a specialist or consultant physician, to determine the diagnosis, prognosis and/or management of a patient presenting with a clinically suspected haematological malignancy of myeloid origin  Applicable once per diagnostic episode, at diagnosis, disease progression or relapse  (See para PN.7.14 of explanatory notes to this Category)  **Fee:** $927.90 **Benefit:** 75% = $695.95 85% = $829.20 |
| 73448 | Characterisation of a variant or variants in a panel of at least 25 genes using DNA, requested by a specialist or consultant physician, to determine the diagnosis, prognosis and/or management of a patient presenting with a clinically suspected haematological malignancy of lymphoid origin  Applicable once per diagnostic episode, at diagnosis, disease progression or relapse  (See para PN.7.14 of explanatory notes to this Category)  **Fee:** $927.90 **Benefit:** 75% = $695.95 85% = $829.20 |
| 73451 | Testing of a patient who is pregnant, or planning pregnancy, to identify carrier status for pathogenic or likely pathogenic variants in the following genes, for the purpose of determining reproductive risk of cystic fibrosis, spinal muscular atrophy or fragile X syndrome:   1. CFTR; 2. SMN1; 3. FMR1   One test per lifetime.  (See para PN.7.16 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73452 | Testing of the reproductive partner of a patient who has been found to be a carrier of a pathogenic or likely pathogenic variant in the CFTR or SMN1 gene identified by testing under item 73451, for the purpose of determining the couple’s reproductive risk of cystic fibrosis or spinal muscular atrophy  One test per condition per lifetime  (See para PN.7.16 of explanatory notes to this Category)  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |
| 73453 | Characterisation of germline pathogenic or likely pathogenic gene variants:   (a) in at least the following genes:           (i) ASPA;           (ii) BLM;           (iii) CFTR;           (iv) ELP1;           (v) FANCA;           (vi) FANCC;           (vii) FANCG;           (viii) FMR1;           (ix) G6PC1;           (x) GBA1;           (xi) HEXA;           (xii) MCOLN1;           (xiii) SLC37A4;           (xiv) SMN1;           (xv) SMPD1; and   (b) in a patient of reproductive age who is of Ashkenazi Jewish descent for the purpose of ascertaining the patient’s carrier status for the following:           (i) Bloom syndrome           (ii) Canavan disease           (iii) Cystic fibrosis           (iv) Familial dysautonomia           (v) Fanconi anaemia type C           (vi) Fragile-X syndrome           (vii) Gaucher disease           (viii) Glycogen storage disease type I           (ix) Mucolipidosis type IV           (x) Niemann-Pick disease type A 7           (xi) Spinal muscular atrophy           (xii) Tay-Sachs disease  Applicable once per lifetime    (See para PN.7.18 of explanatory notes to this Category)  **Fee:** $425.00 **Benefit:** 75% = $318.75 85% = $361.25 |
| 73454 | Whole gene sequencing of a gene or genes described in item 73453, in a patient who is the reproductive partner of an individual who is affected by, or is a known genetic carrier of, one or more conditions described in item 73453 (other than cystic fibrosis, fragile‑X syndrome or spinal muscular atrophy), for the purpose of determining the couple’s combined reproductive risk of the conditions, if:  (a) the patient is not eligible for a service to which item 73453 applies; and  (b) the patient has not received a service to which item 73453 applies; and  (c) the patient has not received a service to which this item applies for the purpose of determining the patient’s reproductive risk with the patient’s current reproductive partner  Applicable once per couple per lifetime  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73455 | Testing of a pregnant patient, if at least one prospective parent is known to be affected by, or is a genetic carrier of, one or more conditions described in item 73453, for the purpose of determining whether a familial variant or variants are present in the fetus, if:  (a) the testing is requested by a specialist or consultant physician; and  (b) there is at least a 25% risk of the fetus inheriting a condition described in paragraph (b) of item 73453  **Fee:** $1,600.00 **Benefit:** 75% = $1200.00 85% = $1501.30 |
| 73456 | Characterisation by whole genome sequencing, or by either or both whole exome sequencing and mitochondrial DNA sequencing, of germline variants present in nuclear DNA and in mitochondrial DNA of a patient with a strong suspicion of a mitochondrial disease, if:  (a) the characterisation is requested by a specialist or consultant physician; and  (b) the characterisation is requested because of the onset of one or more clinical features indicative of mitochondrial disease, including at least one or more of the following:              (i) meeting the clinical criteria of a probable indicator of                   mitochondrial disease on a relevant scoring system;              (ii) evident mitochondrial dysfunction or decompensation;              (iii) unexplained hypotonia or weakness, profound hypoglycaemia                    or “failure to thrive” in the presence of a metabolic acidosis;              (iv) unexplained single or multi-organ dysfunction or fulminant                    failure (including, but not limited to, neuropathies,                    myopathies, hepatopathy, pancreatic and/or bone marrow                    failure);              (v) refractory or atypical seizures, developmental delays or cognitive                    regression, or progressive encephalopathy or progressive                    encephalomyopathy;              (vi) cardiomyopathy and/or cardiac arrythmias;              (vii) rapid hearing or painless visual loss or ptosis;              (viii) stroke-like episodes or nonvasculitic strokes;              (ix) ataxia, encephalopathy, seizures, muscle fatigue or weakness;              (x) external ophthalmoplegia;              (xi) hearing loss, diabetes, unexplained short stature, or                     endocrinopathy;              (xii) family history of mitochondrial disease, or any of the above;                     and  (c) the service is not a service associated with a service to which item 73358, 73359 or 73457 applies  Applicable only once per lifetime  **Fee:** $2,100.00 **Benefit:** 75% = $1575.00 85% = $2001.30 |
| 73457 | Characterisation by whole genome sequencing, or either or both whole exome sequencing and mitochondrial DNA sequencing, of germline variants present in nuclear DNA and in mitochondrial DNA, of a patient with a strong suspicion of a mitochondrial disease, if:  (a) the characterisation is performed using a sample from the patient and a sample from each of the patient’s biological parents; and  (b) the request for the characterisation states that singleton testing is inappropriate; and  (c) the characterisation is requested by a specialist or consultant physician; and  (d) the characterisation is requested because of the onset of one or more clinical features indicative of mitochondrial disease, including at least one or more of the following:  (i) meeting the clinical criteria of a probable indicator of mitochondrial disease on a relevant scoring system;  (ii) evident mitochondrial dysfunction or decompensation;  (iii) unexplained hypotonia or weakness, profound hypoglycaemia or “failure to thrive” in the presence of a metabolic acidosis;  (iv) unexplained single or multi-organ dysfunction or fulminant failure (including, but not limited to, neuropathies, myopathies, hepatopathy, pancreatic and/or bone marrow failure);  (v) refractory or atypical seizures, developmental delays or cognitive regression, or progressive encephalopathy or progressive encephalomyopathy;  (vi) cardiomyopathy and/or cardiac arrythmias;  (vii) rapid hearing or painless visual loss or ptosis;  (viii) stroke-like episodes or nonvasculitic strokes;  (ix) ataxia, encephalopathy, seizures, muscle fatigue or weakness;  (x) external ophthalmoplegia;  (xi) hearing loss, diabetes, unexplained short stature, or endocrinopathy;  (xii) family history of mitochondrial disease; and  (e) the service is not a service associated with a service to which item 73358, 73359 or 73456 applies  Applicable only once per lifetime  **Fee:** $3,300.00 **Benefit:** 75% = $2475.00 85% = $3201.30 |
| 73458 | Re-analysis of whole genome or whole exome or mitochondrial DNA data obtained in performing a service to which item 73456 or 73457 applies, for characterisation of previously unreported germline variants related to the clinical phenotype, if:  (a) the re-analysis is requested by a specialist or consultant physician; and  (b) the patient is strongly suspected of having a monogenic mitochondrial disease; and  (c) the re-analysis is performed at least 24 months after:          (i) the service to which item 73456 or 73457 applies; or          (ii) a service to which this item applies  Applicable twice per lifetime  **Fee:** $500.00 **Benefit:** 75% = $375.00 85% = $425.00 |
| 73459 | Testing for diagnostic purposes of a pregnant patient, for detection in the fetus of a gene variant or variants present in the parents, if:  (a) the gene variant or variants are:  (i) a variant or variants in the mitochondrial genome identified in the oocyte donating parent; or  (ii) autosomal recessive variants identified in both biological parents within the same gene; or  (iii) an autosomal dominant or X-linked variant identified in either biological parent; or  (iv) identified in a biological sibling of the fetus; and  (b) the causative variant or variants for the condition of the fetus’ first-degree relative have been confirmed by laboratory findings; and  (c) the detection is requested by a specialist or consultant physician; and  (d) the service is not a service associated with a service to which item 73361, 73362, 73363 or 73462 applies  **Fee:** $1,600.00 **Benefit:** 75% = $1200.00 85% = $1501.30 |
| 73460 | Characterisation of mitochondrial DNA deletion or variant for diagnostic purposes in a patient suspected to have mitochondrial disease, if:  (a) the characterisation is requested by the specialist or consultant physician managing the patient’s treatment; and  (b) the patient displays onset of one or more clinical features indicative of mitochondrial disease, including at least one or more of the following:  (i) meeting the clinical criteria of a probable indicator of mitochondrial disease on a relevant scoring system;  (ii) evident mitochondrial dysfunction or decompensation;  (iii) unexplained hypotonia or weakness, profound hypoglycaemia or ‘failure to thrive’ in the presence of a metabolic acidosis;  (iv) unexplained single or multi-organ dysfunction or fulminant failure (including, but not limited to, neuropathies, myopathies, hepatopathy, pancreatic and/or bone marrow failure);  (v) refractory or atypical seizures, developmental delays or cognitive regression, or progressive encephalopathy or progressive encephalomyopathy;  (vi) cardiomyopathy and/or cardiac arrythmias;  (vii) rapid hearing or painless visual loss or ptosis;  (viii) stroke-like episodes or nonvasculitic strokes;  (ix) ataxia, encephalopathy, seizures, muscle fatigue or weakness;  (x) external ophthalmoplegia;  (xi) hearing loss, diabetes, unexplained short stature, or endocrinopathy;  (xii) family history of mitochondrial disease; and  (c) the service is performed following a service to which items 73292, 73358, 73359, 73456 or 73457 applies for the same patient if the results were non-informative Applicable 3 times per lifetime  **Fee:** $450.00 **Benefit:** 75% = $337.50 85% = $382.50 |
| 73461 | Whole gene testing of a person for the characterisation of all germline gene variants within the same gene in which the person’s reproductive partner has a pathogenic or likely pathogenic germline recessive gene variant for mitochondrial disease, if:  (a) the partner’s germline recessive gene variant is confirmed by laboratory findings; and  (b) the characterisation is requested by a specialist or consultant physician  **Fee:** $1,200.00 **Benefit:** 75% = $900.00 85% = $1101.30 |
| 73462 | Testing of a person for the detection of a single gene variant, if:  (a) the person tested has a biological relative with a known pathogenic or likely pathogenic mitochondrial disease variant confirmed by laboratory findings; and  (b) the testing is requested by a specialist or consultant physician; and  (c) the service is not a service associated with a service to which item 73361, 73362 or 73363 applies  **Fee:** $400.00 **Benefit:** 75% = $300.00 85% = $340.00 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P8. INFERTILITY AND PREGNANCY TESTS** |  | | |
|  | Group P8. Infertility And Pregnancy Tests |
| 73521 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner's test)  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $9.70 **Benefit:** 75% = $7.30 85% = $8.25 |
| 73523 | Semen examination (other than post-vasectomy semen examination), including:  (a)        measurement of volume, sperm count and motility; and  (b)        examination of stained preparations; and  (c)        morphology; and (if performed)  (d)        differential count and 1 or more chemical tests;  (Item is subject to rule 25)  **Fee:** $41.75 **Benefit:** 75% = $31.35 85% = $35.50 |
| 73525 | Sperm antibodies - sperm-penetrating ability - 1 or more tests  (See para TN.1.4 of explanatory notes to this Category)  **Fee:** $28.35 **Benefit:** 75% = $21.30 85% = $24.10 |
| 73527 | Human chorionic gonadotrophin (HCG) - detection in serum or urine by 1 or more methods for diagnosis of pregnancy - 1 or more tests  **Fee:** $10.00 **Benefit:** 75% = $7.50 85% = $8.50 |
| 73529 | Human chorionic gonadotrophin (HCG), quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527 - 1 test  (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $28.65 **Benefit:** 75% = $21.50 85% = $24.40 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P9. SIMPLE BASIC PATHOLOGY TESTS** |  | | |
|  | Group P9. Simple Basic Pathology Tests |
| 73801 | Semen examination for presence of spermatozoa  **Fee:** $6.90 **Benefit:** 75% = $5.20 85% = $5.90 |
| 73802 | Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count - 1 test  **Fee:** $4.55 **Benefit:** 75% = $3.45 85% = $3.90 |
| 73803 | 2 tests described in item 73802  **Fee:** $6.35 **Benefit:** 75% = $4.80 85% = $5.40 |
| 73804 | 3 or more tests described in item 73802  **Fee:** $8.15 **Benefit:** 75% = $6.15 85% = $6.95 |
| 73805 | Microscopy of urine, excluding dipstick testing.  **Fee:** $4.55 **Benefit:** 75% = $3.45 85% = $3.90 |
| 73806 | Pregnancy test by 1 or more immunochemical methods  **Fee:** $10.15 **Benefit:** 75% = $7.65 85% = $8.65 |
| 73807 | Microscopy for wet film other than urine, including any relevant stain  **Fee:** $6.90 **Benefit:** 75% = $5.20 85% = $5.90 |
| 73808 | Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807  **Fee:** $8.65 **Benefit:** 75% = $6.50 85% = $7.40 |
| 73809 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method  **Fee:** $2.35 **Benefit:** 75% = $1.80 85% = $2.00 |
| 73810 | Microscopy for fungi in skin, hair or nails - 1 or more sites  **Fee:** $6.90 **Benefit:** 75% = $5.20 85% = $5.90 |
| 73811 | Mantoux test  **Fee:** $11.20 **Benefit:** 75% = $8.40 85% = $9.55 |
| 73812 | Quantitation of glycated haemoglobin (HbA1c) performed in the management of established diabetes, if performed:  (a) as a point‑of‑care test; and  (b) by or on behalf of a medical practitioner who works in a general practice that is accredited to the Royal Australian College of General Practitioners Standards for point‑of-care testing under the National General Practice Accreditation Scheme; and  (c) using a method certified by the National Glycohemoglobin Standardization Program (NGSP), if the instrumentation used has a total coefficient variation less than 3.0% at 48 mmol/mol (6.5%)  Applicable not more than 3 times per 12 months per patient  (See para PR.9.4 of explanatory notes to this Category)  **Fee:** $11.80 **Benefit:** 75% = $8.85 85% = $10.05 |
| 73826 | Quantitation of glycated haemoglobin (HbA1c) performed by a participating nurse practitioner in the management of established diabetes when performed:     (a)  as a point‑of‑care test;     (b)  by a nurse practitioner who works in a general practice that is accredited to the Royal Australian College of General Practitioners Standards for point-of-care testing under the National General Practice Accreditation Scheme; and     (c)  using a method and instrument certified by the National Glycohemoglobin Standardization Program (NGSP), if the instrument has a total coefficient variation less than 3.0% at 48 mmol/mol (6.5%)  Applicable not more than 3 times per 12 months per patient    (See para PR.9.3 of explanatory notes to this Category)  **Fee:** $11.80 **Benefit:** 75% = $8.85 85% = $10.05 |
| 73828 | Semen examination for presence of spermatozoa by a participating nurse practitioner  **Fee:** $6.90 **Benefit:** 85% = $5.90 |
| 73829 | Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count by a participating nurse practitioner  - 1 test  **Fee:** $4.55 **Benefit:** 85% = $3.90 |
| 73830 | 2 tests described in item 73829 by a participating nurse practitioner  **Fee:** $6.35 **Benefit:** 85% = $5.40 |
| 73831 | 3 or more tests described in item 73829 by a participating nurse practitioner  **Fee:** $8.15 **Benefit:** 85% = $6.95 |
| 73832 | Microscopy of urine, excluding dipstick testing by a participating nurse practitioner.  **Fee:** $4.55 **Benefit:** 85% = $3.90 |
| 73833 | Pregnancy test by 1 or more immunochemical methods by a participating nurse practitioner  **Fee:** $10.15 **Benefit:** 85% = $8.65 |
| 73834 | Microscopy for wet film other than urine, including any relevant stain by a participating nurse practitioner  **Fee:** $6.90 **Benefit:** 85% = $5.90 |
| 73835 | Microscopy of Gram-stained film, including (if performed) a service described in item 73832 or 73834 by a participating nurse practitioner  **Fee:** $8.65 **Benefit:** 85% = $7.40 |
| 73836 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method by a participating nurse practitioner  **Fee:** $2.35 **Benefit:** 85% = $2.00 |
| 73837 | Microscopy for fungi in skin, hair or nails by a participating nurse practitioner  - 1 or more sites  **Fee:** $6.90 **Benefit:** 85% = $5.90 |
| 73839 | Quantitation of HbA1c (glycated haemoglobin) performed for the diagnosis of diabetes in asymptomatic patients at high risk - not more than once in a 12 month period.  (Item is subject to restrictions in rule PR.9.1 of explanatory notes to this category)  (See para PR.9.1 of explanatory notes to this Category)  **Fee:** $16.80 **Benefit:** 75% = $12.60 85% = $14.30 |
| 73840 | Quantitation of glycosylated haemoglobin performed in the management of established diabetes – each test to a maximum of 4 tests in a 12 month period.  (Item is subject to restrictions in rule PR.9.1 of explanatory notes to this category)  (See para PR.9.1 of explanatory notes to this Category)  **Fee:** $17.00 **Benefit:** 75% = $12.75 85% = $14.45 |
| 73844 | Quantitation of urinary albumin/creatine ratio in urine on a random spot collection in the management of patients with established diabetes or patients at risk of microalbuminuria.  (See para PR.9.1 of explanatory notes to this Category)  **Fee:** $20.35 **Benefit:** 75% = $15.30 85% = $17.30 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P10. PATIENT EPISODE INITIATION** |  | | |
|  | Group P10. Patient Episode Initiation |
| 73899 | Initiation of a patient episode that consists of a service described in item 72858 or 72859 in circumstances other than those mentioned in item 73900  **Fee:** $5.95 **Benefit:** 75% = $4.50 85% = $5.10 |
| 73900 | Initiation of a patient episode that consists of a service described in item 72858 or 72859 if the service is rendered in a prescribed laboratory.  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73920 | Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected in an approved collection centre that the APA operates in the same premises as it operates a category GX or GY pathology laboratory  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73922 | Initiation of a patient episode that consists of a service described in item 73070, 73071, 73072, 73074, 73075 or 73076 (in circumstances other than those described in item 73923)  **Fee:** $8.20 **Benefit:** 75% = $6.15 85% = $7.00 |
| 73923 | Initiation of a patient episode that consists of a service described in items 73070, 73071, 73072, 73074, 73075 or 73076 if:  (a) the person is a private patient in a recognised hospital; or  (b) the person receives the service from a prescribed laboratory  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73924 | Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73925) from a person who is an in-patient of a hospital.  **Fee:** $14.65 **Benefit:** 75% = $11.00 85% = $12.50 |
| 73925 | Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 if the person is:  (a)    a private patient of a recognised hospital;  or  (b) a private patient of a hospital who receives the service or services from a prescribed laboratory.  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73926 | Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73927) from a person who is not a patient of a hospital.  **Fee:** $8.20 **Benefit:** 75% = $6.15 85% = $7.00 |
| 73927 | Initiation of a patient episode by a prescribed laboratory that consists of 1 or more services described in items, 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 from a person who is not a patient of a hospital.  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73928 | Initiation of a patient episode by collection of a specimen for 1 or more  services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected in an approved collection centre. Unless item 73920 or 73929 applies  **Fee:** $5.95 **Benefit:** 75% = $4.50 85% = $5.10 |
| 73929 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, if the specimen is collected in an approved pathology collection centre  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73930 | Initiation of a patient episode by collection of a specimen for a service for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital. Unless item 73931 applies  **Fee:** $5.95 **Benefit:** 75% = $4.50 85% = $5.10 |
| 73931 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926) if:  ()    the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person who is a private patient in a hospital or  ()     the person is a private patient in a recognised hospital and the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73932 | Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing. Unless item 73933 applies  **Fee:** $10.25 **Benefit:** 75% = $7.70 85% = $8.75 |
| 73933 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner for a prescribed laboratory or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person in the place where the person is residing  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73934 | Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 and 73926) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a residential aged care home or institution. Unless 73935 applies  **Fee:** $17.60 **Benefit:** 75% = $13.20 85% = $15.00 |
| 73935 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by an approved pathology practitioner or by an employee of an approved pathology authority, who conducts a prescribed laboratory, from a person in a residential aged care home or institution  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73936 | Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected from the person by the person.  **Fee:** $5.95 **Benefit:** 75% = $4.50 85% = $5.10 |
| 73937 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926), if the specimen is collected from the person by the person and if:  ()    the service is performed in a prescribed laboratory or  ()    the person is a private patient in a recognised hospital  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |
| 73938 | Initiation of a patient episode by collection of a specimen for 1 or more services (other than those services described in items 73922, 73924 or 73926) if the specimen is collected by or on behalf of the treating practitioner. Unless item 73939 applies  **Fee:** $7.95 **Benefit:** 75% = $6.00 85% = $6.80 |
| 73939 | Initiation of a patient episode by collection of a specimen for 1 or more services  (other than those services described in items 73922, 73924 or 73926), if the specimen is collected by or on behalf of the treating practitioner and if:  ()    the service is performed in a prescribed laboratory or  ()    the person is a private patient in a recognised hospital  **Fee:** $2.40 **Benefit:** 75% = $1.80 85% = $2.05 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P11. SPECIMEN REFERRED** |  | | |
|  | Group P11. Specimen Referred |
| 73940 | Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of another approved pathology authority      (See para PN.0.33 of explanatory notes to this Category)  **Fee:** $10.25 **Benefit:** 75% = $7.70 85% = $8.75 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P12. MANAGEMENT OF BULK-BILLED SERVICES** |  | | |
|  | Group P12. Management Of Bulk-Billed Services |
| **Fee**  74990 | A pathology service to which an item in this table (other than this item or item 74991, 75861, 75862, 75863 or 75864) applies if:  (a)    the service is an unreferred service; and  (b)    the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder;    and  (c)    the person is not an admitted patient of a hospital; and  (d)    the service is bulk-billed in respect of the fees for:      (i)    this item; and      (ii)    the other item in this table applying to the service  (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $7.85 **Benefit:** 85% = $6.70 |
| **Fee**  74991 | A pathology service to which an item in this table (other than this item or items 74990, 75861, 75862, 75863 or 75864) applies if:  (a)    the service is an unreferred service; and  (b)    the service is provided to a person who is under the age of 16 or is a Commonwealth concession card holder; and  (c)    the person is not an admitted patient of a hospital; and  (d)    the service is bulk-billed in respect of the fees for:      (i)    this item; and      (ii)    the other item in this table applying to the service; and  (e) the service is provided at, or from, a practice location in a Modified Monash 2 area.  (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $11.90 **Benefit:** 85% = $10.15 |
| **Fee**  75861 | A pathology service to which an item in this table (other than this item or item 74990, 74991, 75862, 75863 or 75864) applies if:  (a) the service is an unreferred service; and  (b) the service is rendered to a person who is under the age of 16 or is a concessional beneficiary; and  (c) the person is not an admitted patient of a hospital; and  (d) the service is bulk-billed in respect of the fees for:       (i)    this item; and       (ii)   the other item in this Schedule applying to the service; and  (e) the service is rendered at, or from, a practice location in:        (i)   a Modified Monash 3 area; or        (ii) a Modified Monash 4 area  (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $12.65 **Benefit:** 85% = $10.80 |
| **Fee**  75862 | A pathology service to which an item in this Schedule (other than this item or item 74990, 74991, 75861, 75863, or 75864) applies if:  (a) the service is an unreferred service; and  (b) the service is rendered to a person who is under the age of 16 or is a concessional beneficiary; and  (c) the person is not an admitted patient of a hospital; and  (d) the service is bulk-billed in relation to the fees for:       (i)    this item; and       (ii)    the other item in this Schedule applying to the service; and  (e)  the service is rendered at, or from, a practice location in a Modified Monash 5 area  (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $13.40 **Benefit:** 85% = $11.40 |
| **Fee**  75863 | A pathology service to which an item in this Schedule (other than this item or item 74990, 74991, 75861, 75862 or 75864) applies if:  (a) the service is an unreferred service; and  (b) the service is rendered to a person who is under the age of 16 or is a concessional beneficiary; and  (c) the person is not an admitted patient of a hospital; and  (d) the service is bulk-billed in respect of the fees for:       (i)    this item; and       (ii)   the other item in this Schedule applying to the service; and  (e) the service is rendered at, or from, a practice location in a Modified Monash 6 area  (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $14.25 **Benefit:** 85% = $12.15 |
| **Fee**  75864 | A pathology service to which an item in this Schedule (other than this item or item 74990, 74991, 75861, 75862 or 75863) applies if:  (a) the service is an unreferred service; and  (b) the service is rendered to a person who is under the age of 16 or is a concessional beneficiary; and  (c) the person is not an admitted patient of a hospital; and  (d) the service is bulk-billed in relation to the fees for:       (i)   this item; and       (ii)  the other item in this Schedule applying to the service; and  (e) the service is rendered at, or from, a practice location in a Modified Monash 7 area    (See para PN.0.24, PN.0.33 of explanatory notes to this Category)  **Fee:** $15.60 **Benefit:** 85% = $13.30 |

|  |  |  |  |
| --- | --- | --- | --- |
| |  |  | | --- | --- | | **P13. BULK-BILLING INCENTIVE** |  | | |
|  | Group P13. Bulk-Billing Incentive |
| 74992 | A payment when the episode is bulk billed and includes item 73920.  **Fee:** $1.60 **Benefit:** 75% = $1.20 85% = $1.40 |
| 74993 | A payment when the episode is bulk billed and includes item 73922 or 73926.  **Fee:** $3.75 **Benefit:** 75% = $2.85 85% = $3.20 |
| 74994 | A payment when the episode is bulk billed and includes item 73924.  **Fee:** $3.25 **Benefit:** 75% = $2.45 85% = $2.80 |
| 74995 | A payment when the episode is bulk billed and includes item 73899, 73900, 73928, 73930 or 73936.  **Fee:** $4.00 **Benefit:** 75% = $3.00 85% = $3.40 |
| 74996 | A payment when the episode is bulk billed and includes item 73932 or 73940.  **Fee:** $3.70 **Benefit:** 75% = $2.80 85% = $3.15 |
| 74997 | A payment when the episode is bulk billed and includes item 73934.  **Fee:** $3.30 **Benefit:** 75% = $2.50 85% = $2.85 |
| 74998 | A payment when the episode is bulk billed and includes item 73938.  **Fee:** $2.00 **Benefit:** 75% = $1.50 85% = $1.70 |
| 74999 | A payment when the episode is bulk billed and includes item 73923, 73925, 73927, 73929, 73931, 73933, 73935, 73937 or 73939.  **Fee:** $1.60 **Benefit:** 75% = $1.20 85% = $1.40 |

## COMPLEXITY LEVELS FOR HISTOPATHOLOGY ITEMS

| **Specimen Type** | **Complexity level** |
| --- | --- |
| Adrenal resection, neoplasm | 5 |
| Adrenal resection, not neoplasm | 4 |
| Anus, all specimens not otherwise specified | 3 |
| Anus, neoplasm, biopsy | 4 |
| Anus, neoplasm, radical resection | 6 |
| Anus, submucosal resection – neoplasm | 5 |
| Appendix | 3 |
| Artery, all specimens not otherwise specified | 3 |
| Artery, biopsy | 4 |
| Bartholin's gland - cyst | 3 |
| Bile duct, resection - all specimens | 6 |
| Bone, biopsy, curettings or fragments - lesion | 5 |
| Bone, biopsy or curettings quantitation - metabolic disease | 6 |
| Bone, femoral head | 4 |
| Bone, resection, neoplasm - all sites and types | 6 |
| Bone marrow, biopsy | 4 |
| Bone - all specimens not otherwise specified | 4 |
| Brain neoplasm, resection - cerebello-pontine angle | 4 |
| Brain or meninges, biopsy - all lesions | 5 |
| Brain or meninges, not neoplasm - temporal lobe | 6 |
| Brain or meninges, resection - neoplasm (intracranial) | 5 |
| Brain or meninges, resection - not neoplasm | 4 |
| Branchial cleft, cyst | 4 |
| Breast, excision biopsy, guidewire localisation - non-palpable lesion | 6 |
| Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease - all specimen types | 6 |
| Breast, incision biopsy or needle biopsy, malignant neoplasm - all specimen types | 4 |
| Breast – microdochectomy | 6 |
| Breast, orientated wide local excision for carcinoma, with margin assessment | 7 |
| Breast tissue - all specimens not otherwise specified | 4 |
| Bronchus, biopsy | 4 |
| Carotid body - neoplasm | 5 |
| Cholesteatoma | 3 |
| Digits, amputation - not traumatic | 4 |
| Digits, amputation - traumatic | 2 |
| Ear, middle and inner - not cholesteatoma | 4 |
| Endocrine neoplasm - not otherwise specified | 5 |
| Extremity, amputation or disarticulation – neoplasm | 6 |
| Extremity, amputation - not otherwise specified | 4 |
| Eye, conjunctiva - biopsy or pterygium | 3 |
| Eye, cornea | 4 |
| Eye, enucleation or exenteration - all lesions | 6 |
| Eye - not otherwise specified | 4 |
| Fallopian tube, biopsy | 4 |
| Fallopian tube, ectopic pregnancy | 4 |
| Fallopian tube, sterilization | 2 |
| Fetus with dissection | 6 |
| Foreskin - new born | 2 |
| Foreskin - not new born | 3 |
| Gallbladder | 3 |
| Gallbladder and porta hepatis-radical resection | 6 |
| Ganglion cyst, all sites | 3 |
| Gum or oral mucosa, biopsy | 4 |
| Heart valve | 4 |
| Heart - not otherwise specified | 5 |
| Hernia sac | 2 |
| Hydrocele sac | 2 |
| Jaw, upper or lower, including bone, radical resection for neoplasm | 6 |
| Joint and periarticular tissue, without bone - all specimens | 3 |
| Joint tissue, including bone - all specimens | 4 |
| Kidney, biopsy including transplant | 5 |
| Kidney, nephrectomy transplant | 5 |
| Kidney, partial or total nephrectomy or nephroureterectomy - neoplasm | 6 |
| Kidney, partial or total nephrectomy - not neoplasm | 4 |
| Large bowel (including rectum), biopsy - all sites | 4 |
| Large bowel, colostomy - stoma | 3 |
| Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung’s Disease | 5 |
| Large bowel (including rectum), polyp | 4 |
| Large bowel, segmental resection - colon, not neoplasm | 5 |
| Large bowel (including rectum), segmental resection, neoplasm | 6 |
| Large bowel (including rectum), submucosal resection – neoplasm | 5 |
| Larynx, biopsy | 4 |
| Larynx, partial or total resection | 5 |
| Larynx, resection with nodes or pharynx or both | 6 |
| Lip, biopsy - all specimens not otherwise specified | 3 |
| Lip, wedge resection or local excision with orientation | 4 |
| Liver, hydatid cyst or resection for trauma | 4 |
| Liver, total or subtotal hepatectomy - neoplasm | 6 |
| Liver - all specimens not otherwise specified | 5 |
| Lung, needle or transbronchial biopsy | 4 |
| Lung, resection - neoplasm | 6 |
| Lung, wedge biopsy | 5 |
| Lung segment, lobar or total resection | 6 |
| Lymph node, biopsy - all sites | 4 |
| Lymph node, biopsy – for lymphoma or lymphoproliferative disorder | 5 |
| Lymph nodes, regional resection - all sites | 5 |
| Mediastinum mass | 5 |
| Muscle, biopsy | 6 |
| Nasopharynx or oropharynx, biopsy | 4 |
| Nerve, biopsy neuropathy | 5 |
| Nerve, neurectomy or removal of neoplasm | 4 |
| Nerve - not otherwise specified | 3 |
| Nose, mucosal biopsy | 4 |
| Nose or sinuses, polyps | 3 |
| Odontogenic neoplasm | 5 |
| Odontogenic or dental cyst | 4 |
| Oesophagus, biopsy | 4 |
| Oesophagus, diverticulum | 3 |
| Oesophagus, partial or total resection | 6 |
| Oesophagus, submucosal resection – neoplasm | 5 |
| Omentum, biopsy | 4 |
| Ovary with or without tube - neoplasm | 5 |
| Ovary with or without tube - not neoplasm | 4 |
| Pancreas, biopsy | 5 |
| Pancreas, cyst | 4 |
| Pancreas, subtotal or total with or without splenectomy | 6 |
| Parathyroid gland(s) | 4 |
| Penisectomy with node dissection | 5 |
| Penisectomy - simple | 4 |
| Peritoneum, biopsy | 4 |
| Pituitary neoplasm | 4 |
| Placenta - not third trimester | 4 |
| Placenta - third trimester, abnormal pregnancy or delivery | 4 |
| Pleura or pericardium, biopsy or tissue | 4 |
| Products of conception, spontaneous or missed abortion | 4 |
| Products of conception, termination of pregnancy | 3 |
| Prostate, radical prostatectomy or cystoprostatectomy for carcinoma | 7 |
| Prostate, radical resection | 6 |
| Prostate - all types of specimen not otherwise specified | 4 |
| Retroperitoneum, neoplasm | 5 |
| Salivary gland, Mucocele | 3 |
| Salivary gland, neoplasm - all sites | 5 |
| Salivary gland - all specimens not otherwise specified | 4 |
| Sinus, paranasal, biopsy | 4 |
| Sinus, paranasal, resection - neoplasm | 6 |
| Skin, biopsy - blistering skin diseases | 4 |
| Skin biopsy - for investigation of alopecia other than for male pattern baldness, where serial horizontal sections are taken | 5 |
| Skin, biopsy - for investigation of lymphoproliferative disorder | 5 |
| Skin, biopsy - inflammatory dermatosis | 4 |
| Skin, eyelid, wedge resection | 4 |
| Skin, local resection - orientation | 4 |
| Skin, resection of malignant melanoma or melanoma in-situ | 5 |
| Skin - all specimens not otherwise specified including all neoplasms and cysts | 3 |
| Small bowel - biopsy, all sites | 4 |
| Small bowel, diverticulum | 3 |
| Small bowel, resection - neoplasm | 6 |
| Small bowel – resection, all specimens | 5 |
| Small bowel, submucosal resection – neoplasm | 5 |
| Soft tissue, infiltrative lesion, extensive resections at least 5cm in maximal dimension | 6 |
| Soft tissue, lipoma and variants | 3 |
| Soft tissue, neoplasm, not lipoma - all specimens | 5 |
| Soft tissue - not otherwise specified | 4 |
| Spleen | 5 |
| Stomach, endoscopic biopsy or endoscopic polypectomy | 4 |
| Stomach, resection, neoplasm - all specimens | 6 |
| Stomach, submucosal resection – neoplasm | 5 |
| Stomach - all specimens not otherwise specified | 4 |
| Tendon or tendon sheath, giant cell neoplasm | 4 |
| Tendon or tendon sheath - not otherwise specified | 3 |
| Testis, biopsy | 5 |
| Testis and adjacent structures, castration | 2 |
| Testis and adjacent structures, neoplasm with or without nodes | 5 |
| Testis and adjacent structures, vas deferens sterilization | 2 |
| Testis and adjacent structures - not otherwise specified | 3 |
| Thymus - not otherwise specified | 5 |
| Thyroglossal duct - all lesions | 4 |
| Thyroid - all specimens | 5 |
| Tissue or organ not otherwise specified, abscess | 3 |
| Tissue or organ not otherwise specified, haematoma | 3 |
| Tissue or organ not otherwise specified, malignant neoplasm with regional nodes | 6 |
| Tissue or organ not otherwise specified, neoplasm local | 4 |
| Tissue or organ not otherwise specified, pilonidal cyst or sinus | 3 |
| Tissue or organ not otherwise specified, thrombus or embolus | 3 |
| Tissue or organ not otherwise specified, veins varicosity | 3 |
| Tissue or organ - all specimens not otherwise specified | 3 |
| Tongue, biopsy | 4 |
| Tongue or tonsil, neoplasm local | 5 |
| Tongue or tonsil, neoplasm with nodes | 6 |
| Tonsil, biopsy - excluding resection of whole organ | 4 |
| Tonsil or adenoids or both | 2 |
| Trachea, biopsy | 4 |
| Ureter, biopsy | 4 |
| Ureter, resection | 5 |
| Urethra, biopsy | 4 |
| Urethra, resection | 5 |
| Urinary bladder, partial or total with or without prostatectomy | 6 |
| Urinary bladder, transurethral resection of neoplasm | 5 |
| Urinary bladder - all specimens not otherwise specified | 4 |
| Uterus, cervix, curettings or biopsy | 4 |
| Uterus, cervix cone, biopsy (including LLETZ or LEEP biopsy) | 5 |
| Uterus, endocervix, polyp | 3 |
| Uterus, endometrium, polyp | 3 |
| Uterus with or without adnexa, malignant neoplasm - all specimen types not otherwise specified | 6 |
| Uterus with or without adnexa, neoplasm, Wertheim's or pelvic clearance | 6 |
| Uterus and/or cervix - all specimens not otherwise specified | 4 |
| Vagina, biopsy | 4 |
| Vagina, radical resection | 6 |
| Vaginal mucosa, incidental | 3 |
| Vulva or labia, biopsy | 4 |
| Vulval, subtotal or total with or without nodes | 6 |